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Thesis Abstract 
Introduction 
Despite the well-documented association between potentially inappropriate 
prescribing (PIP) and adverse outcomes for hospitalised older adults, the 
prevalence of PIP remains unacceptably high. Recommendations to improve 
medication appropriateness in hospital often come from sources external to the 
attending prescribing team, such as pharmacists and computerised system alerts. 
However, these recommendations to minimise PIP are not always implemented by 
prescribers, meaning that PIP can continue, thereby increasing the risk of adverse 
drug reactions (ADRs), rehospitalisation, and higher healthcare costs. 
Interventions with sufficiently high rates of adherence to medication 
appropriateness recommendations among prescribers are more likely to result in 
significantly improved patient outcomes in comparison to those interventions with 
lower implementation rates, which often show non-significant effects on key 
outcomes. Thus, it is imperative that prescribing optimisation interventions achieve 
sufficiently high prescriber implementation rates for these recommendations to be 
clinically effective. However, it is not always clear which specific intervention 
components are essential to high implementation rates of prescribing 
recommendations.  
Therefore, the overarching aim of this thesis was to identify the key factors 
affecting prescriber implementation of recommendations to improve medication 
2 
 
appropriateness in hospitalised older adults, focusing on the factors affecting 
implementation of i) computer-generated recommendations and ii) pharmacist 
recommendations. 
Methods 
Initially, a systematic review and meta-analysis were undertaken to ascertain the 
effectiveness of computerised interventions in minimising PIP in hospitalised older 
adults. Secondly, a semi-structured qualitative interview study was conducted 
alongside the Software ENgine for the Assessment & optimization of drug and non-
drug Therapy in Older peRsons (SENATOR) trial to determine the key factors 
affecting prescriber implementation of the SENATOR software-generated 
recommendations, which aimed to reduce PIP and ADRs in hospitalised older 
adults. Based on these qualitative findings, an evaluation of the clinical relevance of 
SENATOR’s computer-generated recommendations based on Screening Tool of 
Older People's Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment 
(START) criteria (version 2) was performed. Subsequently, the association between 
the clinical relevance of the recommendations and their implementation by 
prescribers was assessed. Thereafter, the prescriber implementation rates of 
STOPP/START recommendations from a physician approach and a pharmacist 
approach were compared. Finally, a further semi-structured qualitative interview 
study was conducted to identify the key factors affecting physician prescriber 
implementation of pharmacist recommendations aimed at optimising medication 




The systematic review and meta-analysis showed that computerised interventions 
can significantly reduce PIP in hospitalised older adults (p < 0.05). Of the nine 
included studies, five reported prescriber implementation rates for the computer-
generated recommendations, ranging from 22.5% – 95%, but none of the included 
studies comprehensively explored the underlying reasons for non-implementation. 
The qualitative study conducted alongside the SENATOR trial identified four key 
factors affecting prescriber implementation of the computer-generated 
recommendations:  
i) Computerised output: the clinical relevance and method of provision for the 
recommendations. 
ii) Acute hospital environment: the timing and location of recommendations in 
a busy and often pressurised clinical setting.   
iii) Prescriber role and identity: the responsibility, experience, and specialty of 
prescribers, as well as their attitude towards research studies. 
iv) Patient-specific details: knowing the patient, patient preferences, and their 
acutely ill status in hospital. 
The study evaluating the clinical relevance of the computer-generated SENATOR 
recommendations showed that nearly three quarters of the 925 computer-
generated STOPP/START recommendations generated were judged to be clinically 
relevant (73.6%), whilst the remainder were judged to be of ‘no clinical relevance’ 
(21.5%) or of potential ‘adverse significance’ if implemented (4.9%). 
Recommendations judged to be of higher clinical relevance were significantly more 
4 
 
likely to be implemented than those of lower clinical relevance (p < 0.05), 
substantiating the findings from the preceding qualitative study that clinical 
relevance was a key factor affecting implementation. 
In the study comparing the implementation of pharmacist-provided and physician-
provided STOPP/START recommendations, prescribers implemented a significantly 
greater proportion of physician recommendations in comparison to pharmacist 
recommendations (83.4% versus 37.8%; p < 0.0001). The final qualitative interview 
study found that the key factors affecting prescriber implementation of 
pharmacists' medication appropriateness recommendations for hospitalised older 
adults were: 
i) Clinical relevance and complexity of the recommendation. 
ii) Interprofessional communication. 
iii) Prescriber role and identity. 
iv) Knowing each other and developing trusting relationships. 
v) Hospital environment.  
Conclusion 
This thesis has made a significant contribution to the understanding of the key 
factors affecting prescriber implementation of recommendations to improve 
medication appropriateness in hospitalised older adults. Prescriber non-
implementation of these recommendations is not attributable to one easily 
identifiable cause, and it is likely that a multi-faceted approach will be required in 
future interventions. The novel studies conducted in this thesis will facilitate the 
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development of theoretically-informed interventions that result in enhanced 
prescriber implementation of these recommendations, ultimately with the aims of 

















Chapter 1: Introduction 
 
 
1.1 Chapter description 
This chapter provides an overview of the literature which informed my research. I 
begin by discussing the increasingly ageing population and the complexity 
associated with prescribing in older adults. Secondly, I define what is meant by 
‘potentially inappropriate prescribing’ (PIP) in this older patient group, its 
prevalence, and the associated consequences for patients and healthcare systems. 
Following this, I describe the common types of interventions that have been 
conducted in hospital settings to reduce PIP in older adults. Thereafter, I focus on 
prescriber implementation of recommendations to optimise prescribing in older 
adults, and explain how this behaviour can be targeted in future interventions. 
Finally, I present the hypothesis underpinning my research and an outline of the 











1.2 The ageing population 
Healthier lifestyles, improving socioeconomic conditions, advances in medicine, and 
greater access to healthcare have contributed to significant gains in life expectancy 
over time [1]. Within the 36 member countries of the Organisation for Economic 
Co-operation and Development (OECD), the average life expectancy at birth is now 
80.6 years, ten years higher than it was in 1970 [2]. Rising life expectancy in both 
sexes and decreasing fertility rates mean that older adults comprise an ever-
expanding proportion of the global population. The percentage of people aged ≥ 65 
years in OECD countries has grown from 10% in 1970 to 17% in 2015, and is 
predicted to reach 28% by 2050 [3]. Older adults (≥ 65 years) have much higher 
rates of medication consumption and health services utilisation than their younger 
counterparts [4]. Thus, healthcare systems worldwide face significant challenges to 
meet the needs of this increasingly ageing population.   
At present, the growing proportion of older adults is placing a substantial burden 
on already-strained resources in all areas of healthcare. With an ageing population 
and associated increased workload, general practitioners (GPs), often find that they 
have increasingly limited time to thoroughly review older patients’ healthcare 
needs and complex medication regimens [5, 6]. In secondary care, older adults now 
occupy over half of acute hospital bed days in the United Kingdom (UK) and 
Republic of Ireland [7, 8]. Discharging these patients from acute care beds is often 
complicated further by a lack of bed availability in step-down facilities and long-
term care facilities, where older adults occupy the majority of beds [9].   
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However, the challenge facing health services in most developed countries is not 
simply a matter of increased numbers of older adults. These patients often have 
multimorbidity, defined by the World Health Organisation (WHO) as the 
“coexistence of two or more chronic conditions in the same individual” [10], which is 
increasingly more common with advancing age and complicates their healthcare 
[11, 12]. A systematic review reported that the prevalence of multimorbidity in 
older adults ranged from 55% to 98% [13]. Thus, although a 65-year-old in the 
OECD population could today expect to live an additional 19.5 years on average, 
only 9 of these are likely to be ‘healthy years’ [14]. 
Multimorbidity is associated with increased functional decline, cognitive decline, 
poorer quality of life, greater morbidity, and mortality [15-18]. Not surprisingly, 
multimorbidity significantly contributes to increased primary care consultations, 
hospital visits, hospital admissions, as well as escalating the need for specialised 
care [11, 19-22]. In fact, healthcare utilisation increases significantly with each 
additional chronic condition in older adults [11, 23]. Moreover, the presence of 
multimorbidity increases the requirement for multiple medications concomitantly. 
Medications are the most common form of healthcare intervention worldwide, but 
despite their many benefits in reducing the progression of chronic diseases in 
patients by treating and preventing illness, they are also the most common cause of 
iatrogenic harm [24]. Polypharmacy, most commonly defined as the concurrent use 
of five or more regular medications [25], is highly prevalent in multimorbid older 
adults and is associated with negative health outcomes, mostly arising from adverse 
drug reactions (ADRs) [26, 27]. Older adults are particularly vulnerable to these 
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medication-related harms due to physiological changes and altered 
pharmacokinetics and pharmacodynamics associated with advancing age [28]. 
Therefore, the safe prescribing of medications in older adults presents unique 
challenges not encountered when prescribing for younger patient populations [29]. 
  
1.3 The complexity of prescribing in older adults 
Prescribers commonly find a greater degree of heterogeneity amongst our aged 
population than in the younger adult population, with a spectrum ranging from 
those who are fit and healthy to those who are frail and multimorbid [30]. 
Interindividual variability in health, disease, and pharmacotherapy increases 
significantly with ageing, which adds to the complexity of prescribing and makes it 
difficult to predict how older adults will respond to different medications.    
1.3.1 Age-related changes in pharmacokinetics and 
pharmacodynamics 
With advancing age, the body undergoes several physiological changes which can 
affect pharmacokinetics and pharmacodynamics. Age-related alterations in 
pharmacokinetics mean that older adults often have changes in the absorption, 
distribution, metabolism, and excretion of drugs – which can affect the onset of 
action, peak concentration, and duration of effect of medications [28, 31]. 
Moreover, age-related pharmacodynamic changes result in altered drug sensitivity, 
and can affect older adults’ response to drugs that work at certain receptors or 




The oral absorption of drugs may be affected by age-related changes in the 
gastrointestinal tract, including reduced gastric acid secretion, delayed gastric 
emptying, decreased splanchnic blood flow, as well as prolonged intestinal transit 
time [32]. However, these changes may more commonly affect the rate of oral drug 
absorption rather than the extent of absorption [28, 33].  
Age-related changes in body composition have a substantial effect on drug 
distribution. Total body water is reduced by 10% – 15% from age 20 years to age 80 
years [34]. Therefore, the volume of distribution for hydrophilic drugs (such as 
aspirin, lithium, and digoxin) decreases in older adults, leading to higher plasma 
concentrations, and increasing the risk of toxicity [35]. The decrease in total body 
water coincides with a reduction in lean body mass, mostly skeletal muscle. This 
decline in lean body mass contributes to a proportional increase in total body fat. 
This means that lipophilic drugs have a greater volume of distribution in older 
adults, and are eliminated more slowly due to their accumulation in adipose tissue. 
Consequently, lipophilic drugs such as benzodiazepines have prolonged half-lives in 
older patients, protracting the risk for unwanted side effects, including confusion, 
drowsiness, and falls. Furthermore, weight loss and frailty may commonly occur in 
very old individuals, contributing to a decrease in the proportion of body fat. This, 
in turn, lowers the volume of distribution of lipophilic drugs and results in increased 
serum drug concentrations [36].  
The most clinically significant age-related pharmacokinetic changes involve drug 
elimination, i.e. primarily through hepatic metabolism and/or renal excretion [37, 
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38]. In older adults, the liver mass is generally reduced by 20% – 30%, resulting in a 
decrease in the total number of drug-metabolising enzymes [39]. Thus, hepatic drug 
metabolism is reduced in advanced age and drug-drug interactions may be more 
clinically significant. Furthermore, a concomitant reduction in hepatic blood flow by 
approximately 20% – 50% in older adults means that drugs are presented to the 
liver at a much slower rate [40, 41]. This is particularly significant for drugs that are 
extensively extracted from the blood by the liver (e.g. propranolol, morphine, 
amitriptyline, verapamil); as their metabolism is ‘blood-flow limited’, lower doses 
are often required in older patients [42].   
In addition to a decline in hepatic metabolism, ageing is associated with a reduction 
in the excretory capacity of the kidney [43]. Renal mass decreases by approximately 
25% – 30%, with a 1% reduction in renal blood flow annually in adults from age 50 
years and over [39]. Furthermore, the glomerular filtration rate (GFR) declines by an 
estimated 0.75 ml/minute/year on average in patients between the age of 30 and 
90 years [44]. However, longitudinal studies have shown that there may be no 
significant decrease in GFR in approximately one third of older patients; thus, 
individual patient comorbidities are key factors affecting renal function with 
advancing age [44, 45]. 
Reduced renal clearance in older adults results in elevated drug plasma levels and 
prolongs the drug’s half-life, thus increasing the risk of ADRs [46]. For example, age-
related reductions in renal function and water volume make older adults more 
susceptible to toxicity from water-soluble drugs, particularly those with a narrow 
therapeutic index, such as aminoglycosides, lithium, and digoxin [47-49]. However, 
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in contrast to hepatic elimination, altered drug levels due to age-related changes in 
renal function can be more easily predicted by calculating GFR [50]. Accordingly, it 
would be prudent to monitor GFR with the use of renally excreted drugs in older 
adults, with dose adjustment where appropriate. 
1.3.1.2 Pharmacodynamics 
In addition to these pharmacokinetic changes, ageing also has an impact on the 
body’s response to drugs, i.e. pharmacodynamics. At the receptor level, ageing may 
lead to changes in the number of receptor sites, drug affinity for receptors, or in 
signal transduction mechanisms. For example, the abundance of dopaminergic 
receptors in older adults is reduced causing greater blockade with standard doses 
of metoclopramide at dopamine D2 receptors when compared with younger adults, 
and increases the risk for parkinsonian side effects [35]. Older adults generally have 
increased pharmacodynamic sensitivity to drugs, particularly those that act on the 
central nervous system. For example, increased sensitivity to benzodiazepines, 
tricyclic antidepressants (TCAs), and antipsychotics can result in increased sedation 
and augment the risk of falls. Conversely, older adults may have decreased 
sensitivity to other drug classes; for example, reduced drug binding affinity at β-
adrenergic receptors in older adults may lead to a decrease in the sensitivity and 
clinical response to β-agonists and β-blockers [51, 52]. 
At an organ system level, older adults may experience accentuated 
pharmacodynamic responses due to age-related changes in homeostatic 
mechanisms [53]. An example of this may be seen with volume-depleting drugs 
such as diuretics, whereby insufficient responses to hypovolaemia are mainly due 
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to age-related impairments of cardiovascular reflex function. Therefore, this 
increased pharmacodynamic sensitivity is not due to an increased drug-receptor 
effect, but rather an exaggerated reaction to the drug’s effect on volume depletion, 
which may result in orthostatic hypotension and falls in older adults [34]. 
Furthermore, these patients may be more sensitive to the troublesome 
anticholinergic effects of some drugs such as dry mouth, constipation, and urinary 
retention; however, the underlying reason for older adults’ increased sensitivity to 
some ADRs, such as those mentioned, is not always clear [54].  
1.3.2 Guidelines 
Best practice would advocate prescribers to comply with evidence-based guidelines 
when initiating or optimising medications for patients. However, despite being the 
main users of medications, older adults are often underrepresented in guidelines 
and in the clinical trials on which the guidelines are based [55]. These trials include 
patients that are usually selected by strict criteria, often comprising narrow subsets 
of the population which do not represent the typical patient with the condition 
[56]. In fact, older adults are commonly excluded from these clinical trials, 
especially those with multimorbidity [57]. 
This means that existing clinical practice guidelines are largely focused on single 
diseases, and many do not consider multimorbidity, despite its high prevalence. 
However, it should be noted that recent guidelines for some chronic conditions, 
such as heart failure, chronic obstructive pulmonary disease (COPD), and diabetes 
mellitus, have attempted to incorporate advice on likely comorbidities [58-60], but 
these guidelines often only consider one comorbid condition at a time [61]. 
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Therefore, indiscriminate application of prescribing guidelines based on data 
extrapolated from younger populations may not be justified when prescribing for 
older adults [26, 62]. Consequently, this often results in healthcare professionals 
prescribing medications for older patients without a clear evidence base or denying 
them a treatment they may possibly benefit from [63]. 
1.3.3 Multimorbidity and multiple healthcare providers 
Older patients with complex multimorbidity often attend several different 
healthcare providers working across multiple sites [64]. With multiple clinicians 
providing care to older patients with numerous chronic diseases, the number of 
prescribed medications can accumulate dangerously, particularly as many clinicians 
may be hesitant to discontinue medications started by fellow prescribers [65]. 
Furthermore, various prescribers treating the same patient may have different 
treatment priorities, and commonly a holistic approach to older patient care may 
be lacking, with each prescriber focusing solely on their area of expertise. This 
increases the possibility for drug-drug interactions as well as drug-disease 
interactions, whereby beneficial medications for one condition may be harmful for 
another (e.g. pioglitazone for diabetes mellitus can exacerbate heart failure) [66]. 
This emphasises that older patients under the care of multiple prescribers are at a 
heightened risk of both inappropriate prescribing and ADRs, with each additional 
prescriber’s influence on a patient’s pharmacotherapy reported to increase the ADR 
risk by 30% [67, 68]. 
These negative patient outcomes are frequently due to suboptimal communication 
between prescribers [69]. This is particularly problematic on transitions of care, but 
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may also exist between prescribers practising in the same setting [70]. The 
incomplete transfer of important patient information between prescribers can 
result in inaccurate patient records, which hinder informed decision-making and 
predisposes to potentially inappropriate prescribing (PIP). For example, the 
prescription of duplicate therapies or counter-acting drugs can occur when 
prescribers are not aware of their peers’ therapeutic plans [71].  
This lack of information sharing between prescribers adds to the intricacy of 
prescribing for older patients. The GP is often consigned the responsibility of 
managing the patient’s pharmacotherapy and liaising with the various prescribers 
involved in the patient’s care. However, due to the evolving nature of general 
practice, older patients may often see more than one GP. This is becoming 
increasingly more common with a trend towards larger, multi-partner practices 
[72]. Having multiple prescribers in primary care may impact on continuity of care 
and prescriber familiarity with individual patient cases [73]. Greater continuity of 
care is associated with reduced rates of hospitalisation, emergency department 
(ED) visits, disease complications, as well as lower healthcare costs [74]. Continuity 
of care and familiarity with individual cases have also been shown to be important 
in the community pharmacy setting. While most older adults obtain all their 
prescriptions from one pharmacy, studies have shown that those who use more 
than one pharmacy are at an increased risk of drug-drug interactions and non-
adherence with their medications [75]. However, the issue of multiple healthcare 
providers is much more problematic in the hospital setting, whereby clinicians with 
different expertise and varying levels of experience in dealing with multimorbid 
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older patients are often challenged with complex pharmacotherapy decisions that 
may be outside of their specialist area for multimorbid older patients that they are 
not familiar with [76].  
1.3.4 Polypharmacy 
The presence of multiple prescribers involved in the care of multimorbid older 
adults has made polypharmacy, and even hyperpolypharmacy (the use of 10 or 
more regular medications concomitantly), increasingly more prevalent in older 
adult populations [77-79]. Polypharmacy increases the likelihood of both adverse 
drug-drug and drug-disease interactions, adding both to the complexity of 
prescribing and the risk of adverse clinical outcomes in older patients [80]. 
Despite these potential dangers, polypharmacy is often clinically appropriate when 
treating older patients with several chronic conditions. Multiple medications are 
often required in combination to treat, delay the progression of, or ameliorate the 
symptoms of disease [81], with evidence-based practice guidelines often 
recommending the use of more than one medication as first-line therapy in some 
chronic conditions (e.g. heart failure) [58]. Furthermore, the use of appropriate 
polypharmacy to manage chronic disease can extend patients’ life expectancy, 
improve their quality of life, and prevent complications such as disability and 
unnecessary hospitalisations [81, 82]. Given the possibility of both positive and 
negative outcomes in older adults, it is no surprise that polypharmacy has been 
termed a ‘necessary evil’ [82]. Balancing the risks and benefits of using a multitude 
of medications concomitantly remains a significant challenge for prescribers caring 
for older patients in all care settings.  
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In summary, reduced drug elimination, coupled with a typically increased sensitivity 
to medications, renders older adults more susceptible to ADRs. These patients 
often require lower doses than younger populations, but it is difficult to predict 
medication response due to interindividual variability in older adults’ drug handling. 
The paucity of prescribing guidelines for multimorbid older adults with 
polypharmacy means that increased caution is necessary when initiating 
medications, along with close monitoring of drug response to ensure both 
therapeutic efficacy and to prevent PIP and medication-related harm. 
  
1.4 Potentially inappropriate prescribing (PIP) in older adults 
1.4.1 Defining PIP 
PIP is a term which describes a wide range of suboptimal prescribing practices 
encompassing, but not limited to, the following: 
 Misprescribing, i.e. erroneously prescribing a drug that is needed. This may 
include prescribing the wrong drug (e.g. because of drug-drug or drug-
disease interactions), selecting an inappropriate formulation or route of 
administration, or the use of drugs lacking cost-effectiveness where equally 
efficacious cheaper alternatives exist [83-85]. 
 Overprescribing, i.e. the prescription of medications at a dosage, frequency, 
or duration in excess of what is clinically needed, or for which no clear 
clinical indication exists [70, 85]. 
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 Underprescribing, i.e. the prescription of too low a dose to be effective or 
the failure to prescribe appropriate drug therapy when it may be of benefit 
to the patient [70, 86]. 
PIP can often result in the appearance of potentially inappropriate medications 
(PIMs) in older adults’ pharmacotherapy, where the associated risks may outweigh 
the benefits, and can often predispose patients to an unacceptably increased risk of 
ADRs [70]. It is widely acknowledged that certain medications should be used with 
caution or completely avoided in older adults, particularly when there may be an 
effective safer alternative [4, 87]. Common examples of PIMs in older adults include 
the following: 
 long-term prescription of benzodiazepines or neuroleptics in patients who 
are at an increased risk of fall [88], or  
 metoclopramide in patients with Parkinson’s disease [88], or  
 anticholinergics in patients with delirium or dementia [88]. 
However, PIP does not only comprise the prescription of PIMs, but also includes 
potential prescribing omissions (PPOs), i.e. non-prescription of certain medications 
that older patients may benefit from [89]. PPOs are often highly prevalent in 
patients with common conditions such as hypertension, heart failure, atrial 
fibrillation, and osteoporosis [89, 90]. Whilst some PPOs may be unintentionally 
overlooked by prescribers due to lack of knowledge around evidence-based 
secondary preventative therapies (e.g. the absence of a bisphosphonate in a patient 
with osteoporosis), others may be intentionally and inappropriately withheld due to 
ageist attitudes or other unjustifiable reasons such as therapeutic nihilism or 
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ignorance of medication benefit  to older people in certain circumstances (e.g. the 
omission of anticoagulation to prevent a cardio-embolic stroke in a patient with 
known atrial fibrillation) [91].  
Polypharmacy is intimately linked with PIP and is one of the principal risk factors for 
PIM prescription in older adults [92]. Studies have shown an increased likelihood of 
PIMs with each additional medication prescribed [67, 93]. Furthermore, 
polypharmacy can exacerbate the risk of a so-called ‘prescribing cascade’ 
developing, whereby an ADR or side effect of one medication is inadvertently 
misinterpreted as a new condition, and consequently results in the unnecessary 
prescription of a new medication to treat it, rather than discontinuation of the 
causative agent [94]. For example, a patient who develops ankle oedema as a side 
effect to a calcium channel blocker for hypertension is subsequently prescribed a 
loop diuretic to manage the oedema, rather than switching to an alternative 
antihypertensive.  
Paradoxically, patients with polypharmacy may also be more susceptible to 
underprescribing compared to those receiving fewer medications [95]. The negative 
connotations associated with the term ‘polypharmacy’ may be a causative factor for 
the underutilisation of potentially beneficial, clinically indicated medications [96]. 
Prescribers may be reluctant to add to patients’ drug burden for fear of adverse 
events; however, underprescribing itself is associated with adverse health 
outcomes [97]. Therefore, it is crucial for prescribers to focus not just on the 
number of medications prescribed alone, but to distinguish between appropriate 
polypharmacy and inappropriate polypharmacy in order to facilitate the 
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deprescribing of PIMs and the optimal utilisation of appropriate medications 
through detection of PPOs [25]. 
1.4.2 Prevalence of PIP 
Despite increased awareness about PIP, it remains highly prevalent in older adults 
globally [98-100]. PIP prevalence can vary between different healthcare settings, 
but usually rises steadily from primary care through secondary care and further into 
long-term care settings [89, 92, 101-108]. The median PIP prevalence of 
community-dwelling older adults across Europe was found to be 22.6% in a 
systematic review by Tommelein et al. [103]. Moreover, a study from six hospitals 
in six European countries showed an overall PIM prevalence of 51.3% and an overall 
PPO prevalence of 59.4% in hospitalised older adults [92]. Furthermore, in older 
people in the long-term care setting, a recent systematic review comprised of 
mostly European studies reported a median PIM prevalence of 61.1% and a median 
PPO prevalence of 48.6% [108]. Examples of reported PIM and PPO prevalence 
from studies conducted in different healthcare settings in Ireland are illustrated in 











Table 1.1: Prevalence of potentially inappropriate prescribing (PIP) in older adults 
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It must be acknowledged that the rates of PIP are dependent on the PIP assessment 
tool utilised to detect prevalence. More recent versions of these tools may be 
capable of identifying additional instances of PIP in older adults; therefore, the true 
prevalence rates may be higher than reported [109].  
PIP is usually more prevalent in community-dwelling older adults when they are in 
the hospital setting compared to when they are being managed in primary care. 
This hospitalised patient cohort are particularly at risk of PIP as they are often 
acutely unwell, have a wide range of comorbidities, and are often assessed and 
medicated by multiple prescribers. Furthermore, these patients are especially 
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susceptible to PIP at points of care transition [76]. However, admission to hospital 
may provide an opportunity to review older patients’ pharmacotherapy – this is 
particularly vital when the cause of admission may be medication-related. Laroche 
et al. observed that hospitalisation in an acute geriatric unit resulted in a significant 
reduction in PIP from admission to discharge [110]. However, the acute hospital 
environment is not always conducive to pharmacotherapy optimisation [111]. 
Moreover, older patients can often be exposed to new and possibly unnecessary 
medications during hospitalisation [67, 76]. Studies have shown that the prevalence 
of PIP in older adults may be higher or remain unchanged after hospitalisation in 
comparison to pre-admission, potentially exposing these patients to an increased 
risk of medication-related harm [112, 113].  
1.4.3 Consequences of PIP 
The high prevalence of PIP in older adults is a major public health concern 
worldwide. In 2017, the WHO launched its third Global Patient Safety Challenge: 
‘Medication Without Harm’, aiming to reduce severe avoidable medication-related 
harm by 50% within 5 years [114]. PIP in older adults can contribute to a wide range 
of adverse patient outcomes and increased healthcare utilisation. PIP is associated 
with increased ED visits and unplanned hospitalisations [104, 115-118], prolonged 
hospital stays [119, 120], as well as increased morbidity and mortality [121, 122]. 
Many of these adverse outcomes in older adults are related to ADRs, and studies 
have shown that PIP is one of the main risk factors for ADRs [105, 123].  
As well as effects on morbidity and mortality, ADRs can result in exorbitant 
healthcare costs. In 2002, a study calculated that approximately 76,800 older 
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people experience an avoidable hospital admission in the Netherlands each year 
resulting from preventable ADRs, at an average cost of €2,128 per drug-related 
admission [124]. In addition, it has been reported that ADRs extend hospitalisation 
by an additional 2 to 4 days on average [125], with the average cost of an in-
hospital ADR estimated at €2,250 [126]. Furthermore, PIP in older adults results in 
superfluous medication costs. Cahir et al. reported the annual cost of PIMs in 
Ireland to be €45 million, equating to 9% of the total expenditure on 
pharmaceuticals in those aged ≥ 70 years [127].  
Ultimately, PIP results in significant morbidity in older adults and increased 
healthcare costs, both in terms of greater medication usage and healthcare 
utilisation requirements to manage negative health consequences. However, 
certain adverse patient outcomes associated with PIP are potentially preventable. 
For example, approximately 70% of ADRs may be avoidable, most of which are also 
predictable [105, 128]. Not all risk factors for ADRs in older adults are amenable to 
intervention (e.g. age-related changes in pharmacokinetics and 
pharmacodynamics); however, PIP is one such risk factor that can be identified and 
targeted by interventions. Therefore, it is not surprising that PIP reduction has been 
the focus of many hospital-based interventions to prevent ADRs and other 





1.5 Interventions to reduce PIP in hospitalised older adults 
Hospitalisation may provide an opportunity to review the appropriateness of 
prescribing in a high-risk older adult population. However, without clear evidence 
of adverse outcomes such as ADRs, it can be difficult to prospectively determine 
prescribing that is truly inappropriate for older adults [129]. The term ‘PIP’ includes 
the word ‘potentially’ to emphasise that some PIP instances may not be truly 
inappropriate in all patient cases, and any pharmacotherapy review should also 
consider the individual patient’s preferences, goals of care, and life expectancy 
[130]. This ambiguity can make PIP more difficult to identify in hospitalised older 
patients, and even more difficult to intervene.  
Whilst educational interventions have been a common approach taken to improve 
prescribing appropriateness in older adults in other healthcare settings [131-142], 
there are limited studies of this nature in hospitals [143-145]. Henceforth, 
interventions commonly employed with a more direct approach to minimising PIP 
in hospitalised older adults, and their associated outcomes, are outlined in the 
following section.  
1.5.1 Prescribing assessment tools 
Prescribing assessment tools are used to identify PIP instances in older adults, and 
are commonly employed in intervention studies to reduce PIP [146-148]. These 
approaches employ the use of explicit (rule-based) or implicit (judgment-based) 
criteria, or a combination of both. In 2013, a systematic review by Kaufmann et al. 
found 46 assessment tools to identify PIP, 28 (61%) of which were explicit, 8 (17%) 
were implicit, and 10 (22%) used a combined approach. Thirty-six (78%) of these 
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tools were aimed towards older people, with the remainder not specifying the 
target age group [149].  
1.5.1.1 Explicit criteria 
Explicit criteria are clearly defined statements that highlight instances of PIP, 
typically developed based on published evidence and expert opinions using 
consensus techniques [70]. These criteria are usually focused on drugs that should 
be avoided or used with caution in older adults in general or in certain disease 
states. Whilst they can be applied with little or no judgment, they often do not 
consider factors such as patient preferences, comorbidities, life expectancy, and 
quality of life [85].  
Explicit criteria have high reliability and reproducibility, and can be readily applied 
in a structured manner to large cohorts of older patients; therefore, they are 
commonly deployed in intervention strategies to reduce PIP in hospitalised older 
adults [83]. A broad spectrum of explicit criterion-based tools has been developed 
worldwide [87, 88, 150-158]. However, lack of transferability outside the country of 
origin is a common drawback with many explicit PIM lists [70]. Most significantly, 
very few of these criteria have been proven to be more effective than standard 
pharmaceutical care when applied to older patients’ prescriptions in randomised 
controlled trial (RCT) settings [62].  
The explicit PIP tools most commonly utilised and cited in the literature are Beers 
criteria, Screening Tool of Older People's Prescriptions (STOPP) criteria, and 
Screening Tool to Alert to Right Treatment (START) criteria [87, 88]. Beers criteria, 
first published in 1991, were originally developed to identify PIM use in nursing 
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home residents [159]. Updated most recently in 2019, and now on their sixth 
iteration, Beers criteria currently include 30 criteria highlighting medications or 
medication classes to avoid in older adults, and 16 criteria specifying over 40 
medication or medication classes to use with caution or to avoid in certain diseases 
or conditions [87]. Like many of the other explicit tools, Beers criteria do not assess 
for underprescribing. Furthermore, there are no RCTs demonstrating that 
application of Beers criteria to older patients’ prescriptions results in improved 
clinical outcomes.  
The STOPP and START criteria were first published together in 2008 as an explicit 
screening tool to enable healthcare professionals to appraise older patients’ 
pharmacotherapy in the context of their concurrent diagnoses [160]. The most 
recent iteration – STOPP/START version 2 – contains 114 criteria, of which 3 are 
implicit prescribing rules (Appendix 1) [88]. STOPP criteria identify PIMs and START 
criteria identify PPOs, and they have been used in tandem as a successful 
intervention in RCTs to significantly reduce PIP, medication costs, and ADRs in 
hospitalised older adults [146, 148]. To date, the only other set of explicit 
prescribing criteria that have been shown in an RCT setting to improve clinical 
endpoints are the Fit fOR The Aged (FORTA) criteria [161]. In this RCT, Wehling et al. 
showed that application of FORTA criteria produced significant reductions in 
overprescribing, underprescribing, ADRs, as well as significant improvements in 
activities of daily living. The most recent iteration of the FORTA criteria contains 264 
medications or medication classes organised into 26 main indication groups, 
whereby the prescriber is guided to the safest/most effective medications for each 
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of the common clinical conditions listed, including hypertension, atrial fibrillation, 
COPD, diabetes mellitus, and dementia [158].  
PIP instances identified by explicit criteria-based tools may not always be truly 
inappropriate. These criteria were developed to complement good clinical 
judgment, not to replace it. Occasionally, instances of so-called ‘PIP’, as defined by 
explicit criteria, may be clinically justified, e.g. the use of propranolol to treat 
benign essential tremor, or the use of amitriptyline to treat severe postherpetic 
neuralgia (propranolol and amitriptyline being identified as drugs to be avoided at 
all times in Beers criteria). Patient-specific information is often required to identify 
true instances of PIP. A recent systematic review has shown that trials deploying 
criteria requiring detailed patient information, such as STOPP/START and FORTA 
criteria, are more likely to have a positive impact on clinical endpoints than criteria 
which are primarily drug-oriented, such as Beers criteria [162]. However, time 
constraints, particularly in the busy acute hospital setting, may be an obstacle to 
systematically applying an extensive set of criteria to multimorbid older adults with 
complex polypharmacy. Digitalisation of such criteria for the purpose of automated 
rapid deployment may be key in facilitating their routine application in clinical 
practice [88].  
1.5.1.2 Implicit criteria 
In contrast to the explicit criteria described above, implicit criteria consist of quality 
indicators of prescribing that are focused on the patient rather than on particular 
drugs or disease states. The user employs patient-specific information, published 
evidence, and one’s own pharmaceutical knowledge to make judgments about 
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appropriateness [76]. Whilst there are several implicit tools in the literature to 
evaluate prescribing in older adults [163], the most commonly used is the 
Medication Appropriateness Index (MAI) [164].  This tool contains ten criteria which 
are used to rate the appropriateness of each medication the patient is prescribed, 
posing questions such as: 
 “Is there an indication for the drug?”  
 “Is the medication effective for the condition?”  
 “Is the duration of therapy acceptable?” 
The sum of all the ratings for each criterion produces a measure of the overall 
appropriateness for that medication. This procedure is then repeated for each 
medication. However, the MAI does not assess for underprescribing. Instead, the 
Assessment of Underutilization of Medication (AOU) tool can be used to implicitly 
identify PPOs [165], and has been used to complement the application of MAI in 
measuring prescribing appropriateness [146].  
Some implicit criteria-based tools have been deployed as an intervention in primary 
care, long-term care, and community pharmacy settings [166-168]. In the hospital 
setting, implicit criteria have primarily been employed to assess prescribing 
appropriateness as an outcome measure rather than as the sole intervention 
component [163, 169, 170]. However, the Assessing Care of Vulnerable Elders 
(ACOVE) criteria – which contain a broad set of quality indicators in caring for older 
adults, of which 24 (6%) are related to medication [171] – have been applied in the 
form of an intervention checklist to improve the appropriateness of prescribing 
thromboprophylaxis in hospitalised older adults [172].  
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The main advantage of implicit criteria-based tools is that they can focus more on 
the needs of individual patients. They have been shown to have good inter-rater 
agreement [163, 164], but successful deployment depends on the users’ levels of 
knowledge and experience. However, the most significant limitation in applying 
implicit criteria is their highly time-consuming nature. Thus, their employment has 
been primarily within the realm of research, with limited applicability to 
interventions in routine clinical practice. 
1.5.2 Geriatrician-based assessments 
Given the complexity of prescribing for older adults, it would seem logical that a 
pharmacotherapy review by a physician specialised in geriatric medicine would be 
valuable in improving the appropriateness of prescribing in hospitalised older 
adults. Patients under the care of geriatricians are less likely to have instances of 
PIP compared to those without specialist geriatrician care [173]. In the hospital 
setting, it is common for other specialist physicians to ask for a geriatrician’s expert 
review of older patients’ pharmacotherapy, particularly those with complicated 
medication regimens relating to complex comorbidity and geriatric syndromes. 
Studies have shown that recommendations provided by physicians specialised in 
geriatric medicine can significantly decrease PIP in hospitalised older patients, with 
reductions in PIMs, PPOs, and ADRs [146, 148, 174]. 
A comprehensive geriatric assessment (CGA) is a geriatrician-based intervention 
that enables pharmacotherapy optimisation as part of a more global evaluation of 
older patients’ healthcare problems, including assessment of their cognitive and 
physical functional status, quality of life, and life expectancy [175]. CGA 
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encompasses a thorough and holistic review of an older patient’s healthcare needs 
by a multidisciplinary team comprising a geriatrician and a number of other 
healthcare professionals, e.g. nurses, physiotherapists, occupational therapists, 
nutritionists, and pharmacists [70, 85]. This holistic approach provides an 
opportunity to utilise the knowledge and expertise of each multidisciplinary team 
member to make informed decisions in devising comprehensive treatment 
strategies specifically tailored for individual patients [176].  
Several RCTs have proven that CGA in the inpatient hospital setting can be effective 
in improving prescribing appropriateness [177-179]. Owens et al. reported a 
significant reduction in ‘inappropriate medication choices’ after CGA compared to 
usual care in a single-centre RCT [177]. Similarly, a Norwegian study found a 
significant decrease in anticholinergic drugs, antipsychotics, and drug-drug 
interactions in the CGA intervention group compared to usual care [178]. 
Furthermore, Schmader et al. conducted a multi-centre RCT which showed that 
CGA significantly reduced the prevalence of inpatient PIMs and PPOs compared to 
usual care; however, there was no significant difference in ADRs between these 
groups [179]. A recent systematic review and meta-analysis has shown that older 
adults who receive CGA are more likely to be alive and in their own homes at 
follow-up than older people who do not receive CGA, but CGA may result in 
increased costs [180]. Furthermore, no CGA studies to date have shown significant 
improvements in clinical outcomes directly related to prescribing optimisation in 
hospitalised older patients (such as reducing ADRs). 
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Pharmacotherapy review as part of a CGA allows for a multidimensional 
interdisciplinary approach but may be time-consuming and resource-intensive. 
With an increasingly ageing population and a limited number of geriatricians, a 
medication review by a geriatrician as part of a CGA is not a feasible option for all 
hospitalised older adults, and perhaps is most suitable for those older patients with 
complex multimorbidity, frailty, or other geriatric syndromes [181].  
1.5.3 Pharmacist interventions 
With their training and expertise in pharmacotherapy, hospital pharmacists are well 
positioned to recognise and resolve instances of PIP in older adults, either 
independently or as part of a multidisciplinary team [169, 182]. Pharmacist 
initiatives to improve the appropriateness of prescribing in older adults may include 
practices such as: 
i) medication review, 
ii) participation in multidisciplinary team meetings and/or ward rounds, 
iii) delivery of education sessions, and  
iv) provision of patient counselling.  
Pharmacist interventions of this nature usually involve a standardised assessment 
of older patients’ prescriptions, followed by provision of recommendations to the 
prescriber to optimise pharmacotherapy. These recommendations may be in the 
form of written communication, verbal communication, or through a combination 
of approaches. Face-to-face discussion with the prescriber, usually a physician, is 
highlighted in the literature as the preferred method of communication by 
pharmacists to resolve pharmacotherapy issues [183]. 
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In previous studies, pharmacist interventions have achieved significant 
improvements in medication appropriateness in hospitalised older adults [169, 184-
186]. Furthermore, a number of RCTs have also illustrated that pharmacist 
interventions can have a significantly positive impact on patient outcomes. Gillespie 
et al. showed that pharmacist interventions in hospitalised patients aged 80 years 
and older resulted in a 16% reduction in all hospital visits, a 47% reduction in ED 
visits, and an 80% reduction in drug-related readmissions compared to standard 
care (i.e. without direct involvement of ward-based pharmacists) [187]. O’Sullivan 
et al. showed that a structured pharmacist review of medication significantly 
decreased the proportion of older patients experiencing incident ADRs in hospital 
compared to patients receiving usual hospital pharmaceutical care (13.9% versus 
20.7%; p = 0.02) [147]. Furthermore, the interventions described in both RCTs were 
shown to be cost-effective [147, 187]. In fact, most clinical pharmacist interventions 
have been shown to be cost-effective as implementation costs are generally offset 
by cost savings associated with the reduction in PIP and ADRs [188-190]. 
However, not all pharmacists have expertise in geriatric pharmacotherapy. 
Therefore, intervention delivery and success may depend on the training and 
experience of the individual pharmacist. The specialisation of hospital pharmacists 
with further expanded roles may prove beneficial in achieving enhanced patient 
medication-related outcomes. The advent of pharmacist prescribing in some 
countries – either as collaborative, supplementary, or independent prescribers – 
has transformed the manner in which some pharmacists make interventions to 
improve older patients’ pharmacotherapy. For example, pharmacists making 
33 
 
prescription changes as part of a collaborative prescribing initiative in an Irish 
hospital has been shown to significantly improve medication appropriateness in 
older adults [191]. A recent systematic review has provided evidence that hospital 
pharmacists can prescribe to the same standards as doctors [192]. However, there 
is limited evidence to date to show that pharmacist prescribing interventions 
improve both medication appropriateness and clinical outcomes in hospitalised 
older adults.  
1.5.4 Computerised interventions 
Most computerised interventions aiming to improve prescribing appropriateness 
include either computer-based alerts or clinical decision support systems (CDSSs), 
usually embedded within computerised provider order entry (CPOE) systems to 
facilitate safer electronic prescribing. CDSSs are software applications designed to 
assist prescribers regarding drug choice, dosage, monitoring, potential interactions, 
as well as highlighting instances of PIP.  
A fundamental component to the success of these computerised interventions is 
that they are integrated with patients’ electronic prescription records (EPRs) or 
electronic health records (EHRs), which may include an EPR as well as clinical data 
on the patients’ comorbidities and laboratory results. By linking these electronic 
records to computerised algorithms based on explicit prescribing rules, such as 
Beers criteria or STOPP/START criteria, detection of PIP and decision support at the 
point of prescribing can be provided, often in the form of an electronic alert. 
However, creating computerised algorithms to incorporate the complexity of 
prescribing for older adults can be profoundly challenging, especially given the 
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degree and wide range of multimorbidity and polypharmacy that often accompany 
the age-related changes in pharmacokinetics and pharmacodynamics in older 
people [193]. If the quality of the computerised algorithms is suboptimal, this can 
result in the generation of alerts that are of low relevance or the production of too 
many alerts. This predisposes to the phenomenon of ‘alert fatigue’, whereby 
clinicians may be overloaded with alerts and clinically important information may 
be ignored, increasing the risk of patient harm [194]. 
Despite the increasing deployment of these computerised interventions in hospitals 
in developed countries [195], their routine use in developing countries is often 
constrained by limited resources, and thus significant investment would be 
required [196]. However, once implemented, studies have proven that these 
interventions can be cost-effective by preventing medication errors, adverse drug 
events (ADEs), and reducing patients’ hospital length of stay [197].  
Reviews have shown that computerised interventions can be successful in 
improving prescribing appropriateness for older adults in different healthcare 
settings [198, 199]. Two controlled studies have shown improved health-related 
outcomes with significant reductions in ADEs and inpatient falls respectively arising 
from application of such computerised interventions [200, 201]. However, most of 
the interventions in the literature are single-centre studies and do not routinely 
show improvements in patients’ health-related outcomes. Two European multi-
centre RCTs have recently been completed which deployed the STOPP/START 
criteria (version 2) in computerised interventions – Software ENgine for the 
Assessment & optimization of drug and non-drug Therapy in Older peRsons 
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(SENATOR) and OPtimising ThERapy to prevent Avoidable hospital admissions in the 
Multimorbid elderly (OPERAM) [202, 203]. The SENATOR RCT’s primary aim was to 
reduce in-hospital ADRs, and the primary aim of the OPERAM RCT to reduce drug-
related rehospitalisations. The results from both RCTs have not been published yet, 
but future interventions of this kind must demonstrate improved patient outcomes 
if they are to be utilised routinely in clinical practice. 
1.5.5 Multiple component interventions 
Given the complexity associated with optimising prescribing for older adults in an 
acute hospital environment, many research groups have conducted multiple 
component interventions which incorporate one or more of the elements described 
in the interventions above. Two studies have shown that a pharmacist medication 
review in combination with applying STOPP/START criteria or an adjusted STOPP 
tool have resulted in significant reductions in PIP, ADRs, ED visits without 
subsequent hospitalisation, as well as a significant improvement in patient quality 
of life [147, 185]. In addition, collaborative approaches between pharmacists and 
physicians have been shown to significantly improve the appropriateness of 
prescribing in hospitalised older patients, with significant reductions in ED visits 
[182, 187, 204]. Furthermore, some research groups have utilised computerised 
interventions in combination with other components to reduce PIP in this older 
patient group. Stevens et al. showed that combining a CDSS intervention with 
education and individual provider feedback can significantly reduce the number of 
PIMs in older adults in the ED [205]. Similarly, Cossette et al. have shown that 
pharmacist review of alerts from a computerised system in combination with CGA 
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and education can also significantly decrease PIM use [206]. However, when 
multiple component interventions are successful in reducing PIP, it is not always 
clear which elements were effective, thus making replication problematic.  
In summary, many of the interventions described throughout this section have 
shown significant reductions in PIP, but few studies produce significant 
improvements in clinical outcomes for hospitalised older patients. Even with the 
success of some initiatives, many of these interventions have been conducted in 
single centres or in a specific context that may not be transferable to other settings. 
Furthermore, few studies have demonstrated sustainable reductions in PIP, and 
therefore PIP prevalence remains unacceptably high. It has been hypothesised that 
low prescriber implementation rates of recommendations to improve 
appropriateness of prescribing may be maintaining this high prevalence of PIP, and 
potentially contributing to avoidable ADRs [147, 187]. Given the clear link between 
PIP, adverse patient outcomes, and increased healthcare costs, it is surprising that 
these low rates of prescriber implementation have not been extensively 








1.6 Prescriber implementation of recommendations: a target 
for behaviour change interventions 
1.6.1 Prescriber implementation rates of medication appropriateness 
recommendations 
From the interventions described above, it is clear that many of the 
recommendations to improve the appropriateness of prescribing in older adults 
come from sources external to the prescribing team, for example: from 
geriatricians, pharmacists, and computerised systems (e.g. CDSSs or computerised 
alerts). Most geriatrician reviews of this nature are requested by other specialist 
physicians, and therefore their pharmacotherapy recommendations are highly likely 
to be implemented. However, recommendations from other external sources that 
have not been specifically requested by the prescribing team are less likely to be 
followed. The implementation rates of recommendations from pharmacist-based 
and computerised interventions to improve prescribing appropriateness in 
hospitalised older adults generally range from 39% – 69% [169, 186, 187, 207-209] 
and 29.3% – 95% [200, 201, 210, 211] respectively. If these pharmacotherapy 
recommendations are not implemented, it means that the high prevalence of PIP 
continues in these older patients, augmenting the risk of ADRs, rehospitalisation, 
and increased healthcare costs. 
Pharmacist interventions with higher prescriber implementation rates for 
medication appropriateness recommendations [186, 187] are more likely to result 
in significantly improved patient outcomes in comparison to those with lower 
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implementation rates, which often show non-significant patient outcomes [207, 
208]. However, O’Sullivan et al. showed that a structured pharmacist intervention 
in 361 patients with only 38.5% of medication appropriateness recommendations 
implemented can still result in a clinically significant 6.8% absolute risk reduction in 
patients with ADRs compared with standard pharmaceutical care (p = 0.02) [147, 
169]. Moreover, as the authors suggested, an enhanced implementation rate may 
have generated a further reduction in ADRs. 
A narrative review on computerised interventions in various healthcare settings has 
suggested that computer-generated recommendations can be successful in 
improving prescribing appropriateness in older adults, but there is limited evidence 
showing how their implementation affects important patient outcomes such as 
hospital length of stay, rehospitalisation, and mortality [198]. Nevertheless, studies 
have shown significant reductions in both in-hospital falls and ADEs with relatively 
low implementation rates of 31% and 29% respectively [200, 201]. Further research 
is clearly required to assess the effectiveness, implementation rates, and patient 
outcomes specifically associated with computer-generated recommendations to 
improve the appropriateness of prescribing in hospitalised older adults. 
In studies with pharmacist and computer-generated recommendations, the 
reported implementation rate is merely a quantitative measure of the 
intervention’s success. Many of these studies do not provide sufficient information 
on how the recommendations were communicated, how the intervention 
integrated into practice, or any specific barriers encountered. Therefore, it is 
important that quantitative and qualitative research be used in tandem to inform 
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the design of future intervention strategies targeting medication appropriateness in 
older adults. 
1.6.2 Identifying behavioural components affecting implementation 
Interventions based on medication appropriateness recommendations with high 
implementation rates are more likely to translate into improved clinical outcomes 
for hospitalised older patients compared to interventions with low implementation 
rates. Therefore, it would seem logical that future interventions should aim to 
attain high uptake rates for these recommendations. However, it is not always clear 
for researchers which specific intervention components contribute to achieving 
high implementation rates. Robust qualitative research is required to ascertain the 
key factors affecting prescriber behaviours concerning implementation of these 
recommendations. By identifying the pertinent barriers and facilitators, future 
interventions can be targeted towards changing practice to increase the 
implementation of recommendations.  
1.6.2.1 Behaviour change in healthcare interventions 
The UK Medical Research Council (MRC) framework advocates the incorporation of 
a theoretical basis into the development of complex interventions [212]. However, 
previous systematic reviews of interventions designed to change professional 
practice have shown that limited numbers of studies report using theory to inform 
intervention design [213, 214], even though the evidence from the literature 
demonstrates that theory-based behaviour change interventions are more effective 
than those without a theoretical base [215]. There are many different health 
psychology theories that could be utilised to inform and develop interventions 
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[216]. While the use of a single theory may be justified, it is preferable to utilise a 
more comprehensive approach to increase the likelihood of identifying all relevant 
factors underpinning a specific behaviour [217]. The Theoretical Domains 
Framework (TDF) is one such validated tool that has been synthesised using 33 
behaviour change theories [217]. The TDF, now on its second iteration, is comprised 
of 14 domains based on 84 theoretical constructs related to behaviour change 
(Appendix 2). This integrative framework makes behaviour change theory more 
accessible to healthcare researchers, particularly those without a background in 
health psychology [218]. As a result, the TDF has been widely used by healthcare 
researchers to explain practice implementation problems and to inform 
interventions [219-223].  
Whilst the TDF can be applied to quantitative data (e.g. from questionnaires), it is 
most commonly employed in qualitative studies (e.g. using interviews or focus 
groups). Even though no formal guidelines have been established on how to apply 
the TDF to qualitative interview studies, formulating topic guides based on the TDF 
is a well-established approach to ensure that intervention development is theory-
based [224]. This allows exploration of interviewees’ perceptions on how each 
domain may affect the target behaviour, which provides greater clarification on the 
TDF-related barriers and facilitators that could be targeted by an intervention [225]. 
Thereafter, the transcripts are usually coded into the theoretical domains, with the 
most relevant domains or overarching themes representing the factors that 
predominantly influence the target behaviour [224]. The TDF is commonly 
employed with the Behaviour Change Wheel (BCW) (Appendix 3) to inform the 
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design of future interventions [226]. Having identified the relevant theoretical 
domains, these can then be mapped to the BCW to identify intervention functions 
as well as several behaviour change techniques (BCTs) that may be appropriate in 
addressing the target behaviour [226, 227].  
1.6.2.2 Informing the development of interventions with enhanced prescriber 
implementation rates 
In developing behaviour change interventions to optimise prescribing, one must be 
clear on the behaviour(s) being targeted. Hence, it is important now to distinguish 
between the behaviours of ‘prescriber acceptance’ and ‘prescriber implementation’ 
of medication appropriateness recommendations. Whilst many prescribers may 
agree with these recommendations and accept that action may be required, issues 
such as forgetting (due to distraction in the busy clinical setting) or patient 
preference can be problematic and prevent their implementation. The term 
‘prescriber implementation’ demonstrates that the recommendation has been 
actively executed, and studies have shown large discrepancies between rates of 
prescriber acceptance and prescriber implementation of medication 
recommendations [228, 229]. Therefore, TDF-related qualitative studies in this 
research area should specifically explore the barriers and facilitators to successful 
implementation of medication recommendations provided to prescribers, and not 
just their acceptance of them.  
The TDF has been used previously to explore the influences on prescriber behaviour 
regarding appropriate prescribing for older adults in different healthcare settings, 
with the subsequent identification of possible intervention types that may be 
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suitable in future studies using the BCW [111, 230, 231]. Going beyond this, the TDF 
and BCW have been exploited successfully to develop interventions to improve 
prescribing. Cadogan et al. have shown that an intervention developed using the 
TDF to improve appropriate polypharmacy for older people in primary care is 
feasible and acceptable to stakeholders [232]. Furthermore, Elouafkaoui et al. have 
shown that a TDF-informed intervention can be successful in significantly improving 
antibiotic prescribing practices of dentists [233]. Therefore, it would seem 
reasonable to expect that the TDF could also be employed in a similar fashion i) to 
explore the behavioural determinants underpinning prescriber implementation of 
medication appropriateness recommendations for older adults in the hospital 
setting, and ii) to use these findings to inform the development of future 
interventions to improve prescribing. 
To date, the TDF has not been used to specifically assess factors affecting prescriber 
implementation of medication appropriateness recommendations from sources 
such as pharmacists and computer systems in the hospital setting. Therefore, these 
represent significant gaps in our knowledge and evidence base. By identifying the 
key barriers and facilitators to implementation of medication appropriateness 
recommendations from robust qualitative research methods, interventions can be 
tailored to address issues affecting prescriber implementation, and ultimately to 






PIP in older adults remains a significant healthcare problem worldwide. Despite the 
myriad of interventions that have been evaluated, there is still no widely accepted 
optimal strategy for reducing PIP in older hospitalised patients. Many interventions 
in hospital settings consist of recommendations from sources external to the 
prescribing team. However, these recommendations to improve the 
appropriateness of older patients’ pharmacotherapy are not always implemented 
by hospital prescribers, despite the abundant quantity of evidence highlighting the 
adverse outcomes that PIP may cause in this patient population.  
Rather than maintaining a continued focus on conducting further interventions that 
may not be evidence-based, a clear gap in the evidence base must be addressed 
first, i.e. the key underlying factors affecting prescriber implementation of these 
medication appropriateness recommendations in the hospital setting. In addressing 
this knowledge gap, future theoretically-informed interventions can be designed 
that tackle the issue of non-implementation, thus improving medication 






1.8 Hypothesis, aims, and objectives 
1.8.1 Hypothesis 
The basis of this research is the knowledge that prescriber non-implementation of 
prescribing recommendations to improve medication appropriateness results in PIP 
continuation in older adults, thereby increasing the risk for adverse clinical 
outcomes. Robust research is required to investigate the reasons behind non-
implementation of prescribing recommendations in order to inform the design of 
future interventions to effectively minimise PIP in hospitalised older adults.  
1.8.2 Thesis aim and objectives 
The overarching aim of this thesis is to identify the key factors affecting prescriber 
implementation of medication appropriateness recommendations in hospitalised 
older adults, focusing on the factors affecting implementation of i) computer-
generated recommendations and ii) pharmacist recommendations.  
Firstly, two definitive objectives were formed ab initio to achieve the aim of 
identifying the factors affecting prescriber implementation of these computer-
generated recommendations: 
1. To systematically review the literature in order to establish the effectiveness 
of computerised interventions designed to improve medication 
appropriateness in hospitalised older adults, the implementation rate of the 
computer-generated recommendations, and their associated clinical 
outcomes (Chapter 2).  
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2. To determine the key factors affecting prescriber implementation of 
computer-generated recommendations in the multi-centre SENATOR RCT 
using semi-structured interviews with physician prescribers and trial 
researchers (Chapter 3).  
Thereafter, based on the findings from Chapter 3, a third objective was defined in 
order to achieve this aim: 
3. To systematically evaluate the clinical relevance of the computer-generated 
recommendations in the SENATOR trial and to determine if the relevance of 
recommendations was associated with their rate of implementation 
(Chapter 4). 
Furthermore, two specific objectives were defined in order to achieve the aim of 
identifying the key factors affecting prescriber implementation of pharmacist 
recommendations to improve the appropriateness of prescribing in hospitalised 
older adults:  
1. To compare the prescriber implementation rates of STOPP/START 
recommendations between a pharmacist approach and a physician 
approach in the same hospital, and to identify components within the 
intervention approaches that may have affected the implementation rates 
(Chapter 5).  
2. To explore the key factors affecting prescriber implementation of 
pharmacist recommendations in the hospital setting using semi-structured 
interviews with physician prescribers and pharmacists (Chapter 6).  
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1.8.3 Thesis outline 
Each of the five objectives outlined above are associated with a specific study 
chapter (Chapters 2 – 6), which are then followed by an overarching discussion 
chapter (Chapter 7). Figure 1.1 illustrates how the individual studies undertaken as 
part of this doctoral research address the thesis aims and objectives and, when 
combined, these chapters provide a comprehensive investigation into the key 
factors affecting prescriber implementation of medication appropriateness 
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To compare prescriber 
implementation rates of 
STOPP/START 
recommendations 
between a physician 
intervention and a 
pharmacist intervention, 
and to identify the 
intervention components 
that may have affected 
implementation. 
Background and Hypothesis (Chapter 1): 
Prescriber non-implementation of recommendations to improve medication appropriateness in hospitalised older adults results in PIP continuation, and increases 
the risk for adverse clinical outcomes. Reasons underlying this non-implementation must be robustly identified in order to inform future intervention strategies.  
Discussion (Chapter 7): 
To synthesise the findings from each chapter which may be used in the future development of theoretically-informed 
interventions to sustainably minimise inappropriate prescribing in hospitalised older adults and improve patient outcomes.  
 
Aim i) 
- To identify the key factors affecting prescriber implementation of              
computer-generated recommendations.  
 
Aim ii) 
- To identify the key factors affecting prescriber 
implementation of pharmacist recommendations. 
 
Figure 1.1: Thesis Outline 47 
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Chapter 2: Computerised interventions designed 
to reduce potentially inappropriate prescribing in 




2.1 Chapter description 
In Chapter 1, I explained how hospitalised older adults are particularly vulnerable to 
PIP, and how computerised interventions may be effective in identifying PIP in this 
patient group. In this chapter, I conduct a systematic review and meta-analysis to 
examine the effectiveness of computerised interventions in minimising PIP in 
hospitalised older adults, with a secondary focus on the implementation rates of 
these computer-generated recommendations. An addendum is provided at the end 
of this chapter with a discussion of up-to-date search results.  
 
The work of this chapter has been published as: Dalton K, O’Brien G, O’Mahony D, 
Byrne S. Computerised interventions designed to reduce potentially inappropriate 
prescribing in hospitalised older adults: a systematic review and meta-analysis. Age 





Computerised interventions have been suggested as an effective strategy to reduce 
PIP for hospitalised older adults. This systematic review and meta-analysis 
examined the evidence for efficacy of computerised interventions designed to 
reduce PIP in this patient group. 
2.2.2 Methods 
An electronic literature search was conducted using eight databases up to October 
2017. Included studies were controlled trials of computerised interventions aiming 
to reduce PIP in hospitalised older adults (≥ 65 years). Risk of bias was assessed 
using Cochrane’s Effective Practice and Organisation of Care (EPOC) criteria.  
2.2.3 Results 
Of 653 records identified, eight studies were included - two randomised controlled 
trials, two interrupted time series analysis studies, and four before-after studies. 
Included studies were mostly at a low risk of bias. Overall, seven studies showed 
either a statistically significant reduction in the proportion of patients prescribed a 
PIM (absolute risk reduction 1.3% – 30.1%), or in PIMs ordered (absolute risk 
reduction 2% – 5.9%). It was only possible to include three studies in the meta-
analysis for one of the primary outcomes – which demonstrated that intervention 
patients were less likely to be prescribed a PIM (odds ratio 0.6; 95% confidence 
interval [CI] 0.38, 0.93). No computerised intervention targeting PPOs was 
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identified. There is insufficient evidence thus far to suggest that these interventions 
can routinely improve patient-related outcomes. 
2.2.4 Conclusion 
This systematic review concludes that computerised interventions are capable of 
statistically significantly reducing PIMs in hospitalised older adults. Future 
interventions should strive to target both PIMs and PPOs, ideally demonstrating 
















Prescribing medications for older adults is a challenging process due to age-related 
alterations in pharmacokinetics and pharmacodynamics, often coupled with 
multimorbidity and polypharmacy [13, 28, 77]. In the hospital setting, older patients 
are commonly exposed to new medications under the care of multiple prescribers 
in the management of acute illness; this increases the risk for drug-drug 
interactions, drug-disease interactions, PIP, and ADRs [76].  
Computerised interventions have been suggested as an effective strategy to 
support healthcare professionals’ decision-making and improve medication 
appropriateness for hospitalised older adults [85]. However, given the complexity 
associated with prescribing in this patient group, distinct challenges arise in 
designing software algorithms to generate patient-specific recommendations by 
factoring in all pertinent patient information [193], e.g. which may include a wide 
range of comorbidities, medications, and laboratory parameters. 
In hospital settings, electronic prescribing and CPOE systems have been shown to 
reduce prescribing errors and aid in the prevention of ADEs [234, 235]. However, no 
review has yet summarised the evidence regarding the impact of computerised 
interventions in hospital to reduce PIP specifically in older adults. Therefore, the 
primary aim of this study was to collect all currently available evidence of 
prospective controlled studies that have utilised computerised interventions 
capable of independently identifying PIP and which aimed to improve the 
appropriateness of prescribing in hospitalised older adults (≥ 65 years). Second, it 
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aimed to quantify the effect that these computerised interventions could have on 
reducing PIP in hospitalised older adults by conducting a parallel meta-analysis. 
 
2.4 Methods 
This systematic review and meta-analysis were reported in compliance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement [236], and the PRISMA checklist is provided in Appendix 4. The inclusion 
criteria, exclusion criteria, and methods for the analysis were established in 
advance and documented in a protocol, which was registered in the International 
Prospective Register of Systematic Reviews (PROSPERO) with the identification 
number CRD42017059795. 
A comprehensive electronic search of the literature was conducted using the 
following eight databases from inception up to and including October 2017: 
PubMed, EMBASE, Medline (via Ovid), Web of Science, CINAHL, Cochrane Central 
Register of Controlled Trials, PsycInfo and ClinicalTrials.gov. The search strategy was 
developed in PubMed using a combination of key words and Medical Subject 
Headings (as shown in Appendix 5). For each of the remaining databases, the 
search strategy was modified to suit their specific search capabilities if necessary. 
Additionally, the hand search involved scrutinising the bibliographies of i) any 
review papers that looked at computerised interventions in reducing PIP in older 
adults across different healthcare settings and ii) all papers that were included at 
the full text review stage to ensure no other relevant studies were missed. 
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2.4.1 Eligibility criteria 
Studies were eligible if they described a controlled intervention in which an 
objective was to reduce PIP in hospitalised older adults (≥ 65 years) using 
computer-generated recommendations. The primary outcomes of interest for this 
review were: reductions in PIP or patients with PIP. The secondary outcomes of 
interest were patient outcomes and implementation rates of recommendations. As 
determined a priori, studies involving a multifaceted intervention would be 
included only if the effect of the computerised intervention on reducing PIP could 
be clearly determined. No date or language restrictions were applied. 
2.4.2 Study selection 
For the first stage of study selection, one reviewer screened titles to eliminate 
papers that were clearly not relevant to the research question. Secondly, two 
reviewers independently screened titles and abstracts to identify potentially 
pertinent full texts. The last stage involved papers being read in full and their 
suitability for inclusion was determined independently by two reviewers. Two 
authors were contacted to supply any additional information required to decide on 
inclusion of the full texts [237, 238]. Consensus on inclusion was reached by 
discussion between reviewers, with arbitration by a senior supervisor if necessary. 
2.4.3 Data extraction 
Data extraction was performed by one reviewer and verified by another. A data 
extraction form was piloted on two papers and adjusted thereafter where 
necessary. All authors of the included papers were contacted to provide 
supplementary information where required. 
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2.4.4 Risk of bias assessments 
Two review authors independently assessed risk of bias for the included studies 
according to Cochrane’s Effective Practice and Organisation of Care (EPOC) risk of 
bias criteria [239]. Consensus on the assessments was reached by discussion, with 
advice from a senior supervisor if required. This tool was used to determine if any 
of the included studies were at a high risk of bias which may impact the findings 
from the narrative summary or meta-analysis. 
2.4.5 Data Synthesis 
Quantitative analysis was conducted if at least two studies had a common 
comparable primary outcome measure, and if pooling their results was deemed 
appropriate. Study heterogeneity was assessed qualitatively by reviewing the 
differences in the interventions and study design, whereas statistical heterogeneity 
was assessed using the I2 statistic. Review Manager 5.3 software was employed to 
determine the pooled estimate of effect and 95% confidence intervals (CIs), with    
p < 0.05 considered statistically significant. When it was not possible to combine 
primary outcome data due to the variability in results reporting across studies, or 
simply due to lack of data available, a narrative summary was provided.  
 
2.5 Results  
2.5.1 Search results 
A total of 653 studies were identified after duplicates were removed. After the 
exclusion of records based on their titles and abstracts, 20 full texts were assessed
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for eligibility. Eight papers were suitable for inclusion in the systematic review. A 
PRISMA flow diagram describes the flow of studies in the review [236] and details 




2.5.2 Characteristics of included studies 
The included studies’ characteristics and outcomes are provided in Table 2.1. A 
more detailed summary of each intervention is provided in Appendix 6. In four of 
Figure 2.1: PRISMA flow diagram of search strategy results 
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the studies, the intervention utilised clinical decision support within a CPOE system 
[200, 201, 210, 240]. In three other studies, the intervention consisted of alerts or 
reminders embedded into a CPOE system [211, 241, 242]. The remaining study 
involved the use of INTERcheck® software, a ‘computerised prescription support 
system’ which aimed to reduce PIMs, potentially severe drug-drug interactions, and 
anticholinergic burden [238]. The medications on admission were reviewed using 
the computerised tool and changed according to the INTERcheck® indication. This 
was the only included intervention not conducted at the point of PIM prescribing. In 
total, there were 18,507 control patients and 24,535 intervention patients across 6 
of the studies [201, 210, 211, 238, 240, 241]. One study did not report the total 
number of patients – primary author contacted: data no longer available [242]. The 
remaining study reported patient visits only [200]. 
Six of the eight included studies utilised computerised alerts or reminders 
incorporated into a CPOE system, which appeared in various forms to notify 
healthcare professionals of PIP instances at the time a PIM was ordered [200, 210, 
211, 240-242]. While some alerts simply provided information to the healthcare 
professional to guide prescribing [200, 242], others provided recommendations that 
required acceptance or rejection at the time of medication ordering [240]. Five of 
the six studies that utilised alerts or reminders suggested an alternative to PIM use 
[200, 210, 211, 240, 242]. The study by Lester et al. was the exception to this; they 
stated that the suggested alternative may also be inappropriate for certain older 
patients, thus forcing the prescriber to think for themselves regarding treatment 
options and the health status of individual patients [241]. 
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The authors state “a decline in the 
number of patients exposed to a 
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(0.07 versus 0.054)*. 
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Table 2.1: (continued) Characteristics of included studies 
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effectiveness of CDS in 
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Nine high-use and high impact PIMs, 
selected by an expert panel consisting 
of two doctors of pharmacy, two 
physician information technology 
experts, three geriatricians, and three 
emergency physicians. 
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There were significantly fewer 
patients prescribed PIMs by the 
intervention physicians compared 
with the control physicians (2.6% 
versus 3.9%)*.  
 
 
Lower proportion of 
inappropriate 
medications in the 
intervention group 




- Decision support was 
provided 114 times to 
physicians, who accepted 49 
(43%) of the 
recommendations. 
Table 2.1: (continued) Characteristics of included studies 
USA: United States of America, CPOE: Computerised physician order entry, C: Control, I: Intervention, CDSS: Computerised decision support system, PIM: Potentially inappropriate medication,  
DDI: Drug-drug interaction, CDS: Clinical decision support, PIP: Potentially inappropriate prescribing * Statistically significant difference, † No statistically significant difference. 
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2.5.3 Results of the risk of bias assessments 
The results of the risk of bias assessments are shown in Table 2.2. All of the 
included studies were found to be at a low risk of bias overall, with one exception 
where the risk of bias was deemed unclear [242]. Both RCTs recognise that they 
may have been at risk of contamination [210, 240]. However, the potential for 
contamination in these studies, if present, would tend to bias against finding an 
effect of the intervention.  
According to Cochrane’s EPOC criteria [239], the before-after studies must be 
deemed ‘high risk’ with regard to the two selection bias domains. Three of the four 
before-after studies did not provide enough information to confirm that the 
baseline characteristics and outcome measurements were similar [211, 241, 242], 
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Other risks of 
bias 
Overall risk of 
bias 
Griffey et al. [201] 
 
        
Peterson et al. [200] 
 
        
Judgments are categorised as ‘Low Risk’ of bias (+), ‘High Risk’ of bias (-) or ‘Unclear Risk’ of bias (?)           * RCTs: Randomised controlled trials         
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2.5.4 Reduction in patients with PIMs 
2.5.4.1 Quantitative analysis 
Three of the eight studies had data available on the exact number of patients that 
were prescribed PIMs as an outcome, and so were amenable to quantitative 
analysis [210, 211, 238]. In these three studies, there were a total of 29,791 
patients/patient visits (14,860 and 14,931 in the intervention and control arms 
respectively). Given the heterogeneous types of intervention and considerable 
statistical heterogeneity between the study results (I2 = 82%; p = 0.004), a random-
effects model was performed to provide a pooled estimate of effect. The meta-
analysis found that patients in the intervention group were less likely to be 
prescribed PIMs post-intervention (odds ratio 0.6; 95% CI: 0.38, 0.93) (Figure 2.2). 
These three studies were found to be at a low risk of bias, so one can be reasonably 









Figure 2.2: Forest plot for the odds ratio for the reduction in the proportion of 
patients prescribed PIMs post-intervention 
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2.5.4.2 Narrative summary 
Four of the included studies reported results on the effect the intervention had on 
the proportion of patients prescribed PIMs, all of which showed a statistically 
significant reduction (p < 0.05) for this outcome [210, 211, 238, 241]. Where it was 
possible to calculate, there was an absolute risk reduction of 1.3% – 30.1% [210, 
211, 238], and a relative risk reduction of 16.7% – 72.2% [210, 211, 238, 241] in 
patients prescribed PIMs across the studies. 
2.5.5 Reduction in PIMs prescribed 
Due to the variability in which the results were reported, a meta-analysis could not 
be performed for this primary outcome. Where it was possible to calculate, there 
was an absolute risk reduction of 2% – 5.9% [200, 210, 238], and a relative risk 
reduction of 14% – 77.6% [200, 210, 238, 242] in PIMs prescribed across the 
studies. Overall, six studies showed a reduction in the number of PIMs prescribed 
when comparing the intervention and control groups, with five studies 
demonstrating statistically significant reductions (p < 0.01) [200, 240, 242]. The only 
exception to this was the study by Boustani et al., whereby the intervention group 
still had a greater discontinuation rate in anticholinergic drug orders versus the 
control group, but the difference was not statistically significant (48.9% versus 
31.2%; p = 0.11) [240]. As previously mentioned, contamination may have been an 
issue in this study which may have reduced the difference found between the 
groups. Given the overall low risk of bias in these studies, one can be reasonably 
confident in the results provided. 
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2.5.6 Implementation rates of computer-generated recommendations 
Four of the included studies have data on implementation rates or levels of 





2.5.7 Reasons for not implementing recommendations 
Three studies identified reasons why prescribers did not accept or may have 
overridden the computerised recommendations [201, 210, 242]. A patient having 
previously tolerated a PIM was the most common reason for non-implementation 
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95% 95% of patients were successfully 
directed to a non-pharmacological 










Nine high-use and 
high impact PIMs 
43% Decision support was provided 114 
times to intervention physicians, 












31%; 7.5% Of initial medicine orders: 403/1283 
(31%) were consistent with the 
computerised recommendations for 
medication dosage/frequency. 7.5% 
of suggestions for alternatives were 
accepted (4/53). 
 









by expert panel 
29.3% 29.3% of prescriptions for 
psychotropics were in agreement 
with system recommendations. 
Table 2.3: Implementation rates of computer-generated recommendations 
PIM: Potentially inappropriate medication; NSAID: Non-steroidal anti-inflammatory drug.  
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most common in the remaining study after the reason that the prescriber felt that 
the regimen was clinically indicated [242]. This perhaps suggests a degree of inertia 
with regard to addressing PIP in the acute hospital setting. 
Some of the other reasons given in these three studies included:  
i) On the advice of a consultant, the medicine is not to be changed [201]. 
ii) No good substitute exists for the medication [210]. 
iii) The patient insists on the medication [210]. 
iv) Interaction noted, regimen clinically indicated, will closely monitor [242]. 
v) Warning noted, will use smaller dose and monitor for side effects [242]. 
2.5.8 Clinical outcomes 
Three of the included studies assessed clinical outcomes [200, 201, 240]. Griffey et 
al. demonstrated a statistically significant reduction in ADEs (3.4% versus 7.1%;       
p = 0.02) [201] and Peterson et al. showed a statistically significant reduction in 
inpatient falls (0.28 versus 0.64 falls per 100 patient-days; p = 0.001) [200]. 
However, there was no statistically significant difference in the remaining fifteen 
clinical outcomes identified, such as hospital length of stay, readmission rates, or 








Table 2.4: Studies which assessed clinical outcomes 
Author Description of Clinical Outcomes 
  
Boustani et al. 
[240] 
  
All clinical outcomes with no statistically significant difference (0/9) 
  
No statistically significant effects on health outcomes including:  
 the mean days of hospital stay (intervention: 7.7 days versus usual care: 6.8,    
p = 0.12),  
 30-day mortality rate (intervention: 6% versus usual care: 5.8%, p = 0.69),  
 home discharge (intervention: 43.2% versus usual care: 36.9%, p = 0.13),  
 30-day readmission rates (intervention: 18.6% versus usual care: 16.4%,           
p = 0.53),  
 hospital-acquired complications (intervention: 47.2% versus usual care: 44.9%,    
p = 0.94).  
  
The hospital-acquired complications included:  
 incidence of delirium (intervention: 33.7% versus usual care: 31.1%, p = 0.78),  
 the presence of ICD-9 codes of pressure ulcer at discharge (intervention: 12.1% 
versus usual care: 11.1%, p = 0.77),  
 the presence of ICD-9 code for fall or injury at discharge (intervention: 4.5% 
versus usual care: 4.9%, p = 0.88),  
 orders for physical restraints or patients observed to be physically restrained 
(intervention: 11.1% versus usual care: 7.6%, p = 0.54). 
  
Griffey et al.  
[201] 
One clinical outcome with statistically significant difference* (1/5) 
  
No significant differences were observed in: admission rate, reversal drug 
administration, number of 10-fold orders, or emergency department length of 
stay. 
  
*ADEs: There were 39 ADEs identified, distributed as 8/237 patients (3%; 95% CI: 
1% – 6%) during ON periods and 31/436 patients (7%; 95% CI 5% – 9%) during OFF 
periods (p = 0.02). 
  
Peterson et al. 
[200] 
One clinical outcome with statistically significant difference† (1/3) 
  
No difference between control and intervention for length of stay or altered 
mental status. 
  
†The rate of falls continued to be significantly less (0.28 versus 0.64 falls per 100 








This systematic review and meta-analysis showed that computerised interventions 
can reduce PIP in hospitalised older adults. Although seven of the eight included 
studies showed a statistically significant reduction in PIMs ordered or the 
proportion of patients prescribed PIMs, it is important to note that all of these were 
single-centre studies. Furthermore, all the included studies in this review were 
conducted in the United States of America (USA), except for one study conducted in 
Italy [238], and therefore this may impact on the generalisability of the review 
findings for other countries.  
The implementation rates of the computer-generated recommendations varied 
highly across the studies that measured this outcome (Table 2.3). These findings 
suggest that interventions that target a smaller number of PIP instances may have 
greater recommendation implementation rates than those targeting a wider range 
of PIP instances. One reason for this may be that prescribers could become 
overwhelmed by the complexity of information provided in broader interventions 
[243]. It is interesting to note that Agostini et al. achieved a 95% success rate in 
switching to a safer alternative to a PIM, whereas only 4/53 (7.5%) 
recommendations for alternatives were accepted in Griffey et al. [201, 211]. Thus, 
providing a recommendation for an alternative does not necessarily mean that 
prescribers will accept this and discontinue the PIM in question. Further qualitative 
research is required to identify factors affecting implementation of computer-
generated recommendations of this kind.  
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Autonomy is very important when encountering computerised interventions such 
as these; prescribers should be capable of bypassing recommendations where 
clinically appropriate [211]. While overrides are often justified, they can be 
associated with serious adverse events (or even death) if clinically significant 
information is unintentionally ignored [244]. A common reason for overrides may 
be due to ‘alert fatigue’, whereby prescribers may pay less attention if they are 
encountering repeated or inappropriate alerts, or are being inundated by a large 
quantity of alerts [241, 244]. Customisation of alerts for individual institutions may 
improve their specificity, and potentially reduce the occurrence of this 
phenomenon [245].  
The results of this systematic review are in keeping with that of previous reviews, 
which have shown that computerised interventions may be effective in improving 
the appropriateness of prescribing in older adults. One review assessed the use of 
electronic prescribing and other forms of technology in reducing PIP and 
polypharmacy in older adults [198], and an older review evaluated computer 
decision support to improve medication prescribing in older adults [199]; however, 
both studies broadly looked at interventions across different healthcare settings. 
This is the first systematic review to focus specifically on computerised 
interventions which aimed to reduce PIP for older adults in the hospital setting.  
It should be noted that only two of the included studies in this review were RCTs, 
which are considered the most robust way of identifying if a cause-effect 
relationship exists between an intervention and outcome [246]. The studies 
included in the meta-analysis were at a low risk of bias; however, the pooled 
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estimate of effects may have been biased as incomplete reporting in some papers 
meant that these were the only studies which allowed comparison of one of the 
primary outcomes (data retrieval bias) [247]. Even though the other studies that 
assessed this outcome showed a statistically significant reduction in the proportion 
of patients prescribed PIMs, the pooled estimate may not accurately represent the 
true effect that these computerised interventions can have on reducing PIP in 
hospitalised older adults, especially when you consider that the meta-analysis 
contained studies that were not RCTs. Despite these limitations, this review is 
valuable for healthcare professionals as it shows that computerised interventions 
can be implemented in hospital settings to reduce instances of PIP for older 
patients.  
This systematic review aimed to identify computerised interventions targeting PIMs 
and PPOs. However, the included studies in this review only targeted PIMs, and did 
not identify medication underuse, i.e. PPOs which older patients may benefit from. 
Despite the comprehensive search strategy, it is still possible that all relevant 
papers may not have been identified. A systematic review by Meid et al. 
recommended that future interventions targeting PIP should utilise explicit criteria, 
such as START, alone or in combination with implicit reasoning, to screen for 
medication underuse in older people [248]. Thus, if possible, computerised 
interventions should strive to target PPOs and not just PIMs.  
With the increasing prevalence of electronic prescribing and CPOE worldwide, it 
should be noted that implementing these systems does not always result in positive 
patient outcomes [249]. Hospital managers and other key stakeholders will have to 
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devise strategies to allow for successful integration with clinical workflows and with 
other technologies already in place. All but one of the interventions in this review 
were conducted at the point of prescribing, which may be a key feature for 
designing future studies. The advantage of this is that prescribers are prompted in 
real time to address medication appropriateness issues to reduce the risk of ADE at 
the earliest possible point.  
Hospital managers will also have important roles in assigning funding to these 
computerised systems. It has been demonstrated that the extra costs associated 
with the implementation of CPOE with a CDSS are acceptable in the prevention of 
medication errors and preventable ADEs [250]. Further research should aim to 
identify how best to integrate these new computerised systems into routine clinical 
practice, and to explore the factors affecting implementation of computer-
generated recommendations.  
 
2.7 Conclusion 
Overall, these findings demonstrate that computerised interventions can be 
effective in significantly reducing PIMs in hospitalised older adults.  Larger scale 
multi-centre RCTs, at national and international levels, are required to further 
demonstrate the benefit of these interventions across different institutions, ideally 






2.8.1 Updated search methods 
An updated search of the eight electronic databases was conducted in August 2019 
to search for all potentially relevant articles published since October 2017, the date 
of the latest search prior to publication of the systematic review and meta-analysis 
[251]. Once duplicates were removed, records were excluded based on screening 
their titles and abstracts. Thereafter, potentially relevant articles were read in full 
to decide on their inclusion. Authors were contacted to provide any additional 
information that was necessary to decide on their eligibility for inclusion and/or to 
provide relevant data based on this review’s outcome measures [252-255]. 
2.8.2 Analysis methods  
Quantitative analysis was conducted on the additional studies from the updated 
search if they had a common comparable primary outcome measure with at least 
one other study, and if combining their results was considered appropriate. Review 
Manager 5.3 software was utilised to determine the pooled estimate of effect and 
95% confidence intervals (CIs), with p < 0.05 considered statistically significant. 
Where it was not possible or not appropriate to pool primary outcome data, a 
narrative synthesis was provided. Risk of bias in the additional studies was assessed 
using Cochrane’s EPOC criteria [239]. 
2.8.3 Updated search results 
A total of 234 records were screened after the removal of duplicates, of which 214 
records were excluded based on their titles and abstracts. Where available, the full 
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texts of the remaining records were assessed for inclusion. This resulted in one 
article meeting the eligibility criteria, which was included in the updated systematic 
review, as shown in Figure 2.3. 
 
        Figure 2.3: PRISMA flow diagram of updated search strategy results  
 
 
2.8.4 Updated narrative synthesis and meta-analysis 
The article from Kim et al. was the only one deemed eligible for inclusion after the 
updated literature search [255]. The aim of this additional study was to identify the 
effect of the introduction of a CPOE template that altered the default dose listed for 
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opioids, benzodiazepines, and non-steroidal anti-inflammatory drugs (NSAIDs) for 
all older adults (aged ≥ 65 years) in the emergency departments of two university-
affiliated hospitals in the USA [255]. The primary outcome measure in this study 
was the difference in frequency of the medications of interest with the 
recommended starting dose in older adults between two 4-month time periods: 
from May – August 2015 and May – August 2016, before and after the 
implementation of a modified CPOE template, which was introduced in both 
hospitals in September 2015. Pre-intervention, 2561 doses were administered to 
1002 patients, of which 1863 were not in line with the recommended dose (72.7%). 
Post-intervention, 2700 doses were administered to 944 patients, whereby 
physician prescribers implemented 22.5% of default starting dose 
recommendations, meaning that 1823 doses that were not in line with the 
recommended dose (67.5%). The absolute risk reduction and relative risk reduction 
in non-recommended doses were 5.2% and 7.2% respectively. This reduction in PIP 
was found to be statistically significant (67.5% versus 72.7%; p < 0.001). However, it 
should be noted that a statistically significant difference was reported in one of the 
hospital sites (a 9% improvement in recommended dosing) but not in the other. 
Kim et al. did not investigate the effect of the intervention on patient outcomes, 
and this additional study was judged to have a low risk of bias overall.  
No data was available on the reduction of the proportion of patients with PIMs 
from the Kim et al. article. Therefore, the study results were not amenable for 
inclusion in the previously published meta-analysis. However, the nature of the 
intervention and results reporting in Kim et al. were very similar to that of one of 
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the original eight included studies (the one conducted by Griffey et al.) [201], which 
meant it was possible to pool these results together for a new meta-analysis (Figure 
2.4). This meta-analysis found that non-recommended doses were less likely to be 




Figure 2.4: Forest plot for the odds ratio for the reduction in the proportion of 
non-recommended doses prescribed post-intervention 
 
2.8.5 Discussion 
The study from Kim et al. showed a significant reduction in the number of non-
recommended doses of high-risk medications in hospitalised older adults. These 
findings are line with the studies from the initial search, whereby seven of the eight 
interventions were found to significantly reduce PIP in this patient group. The 5.2% 
absolute risk reduction in non-recommended doses (i.e. PIMs prescribed) post-
intervention is at the higher end of the range found in the original systematic 
review (2% – 5.9%), but the 7.2% relative risk reduction for this outcome is below 
the range from the original included studies (14% – 77.6%) [251]. In the Kim et al. 
study, prescribers implemented 22.5% of default starting dose recommendations 
from the computer, which was below the range of 29.3% – 95% found in the 
original articles, and no reasons were provided for prescribers’ non-implementation 
of recommendations.   
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With the addition of the Kim et al. paper after the updated search, eight of the nine 
included studies were conducted in the USA, which impacts on the generalisability 
of the findings to hospital settings in other countries. In addition, the transferability 
of the findings could also be questioned given that a statistically significant 
reduction in PIP was found in only one of the two hospital settings in the Kim et al. 
study, despite having the ‘same’ computerised intervention. As with the majority of 
the original included articles, Kim et al. did not investigate the effect of the 
intervention on patient outcomes. Given that this updated systematic review has 
shown that computerised interventions significantly reduce PIP in hospitalised older 
adults, it is imperative that future studies focus on demonstrating significant 
improvements in patient outcomes, and not just on reducing PIP.  
Due to time constraints, this update to the previously published systematic review 
was conducted solely by the primary researcher. Hence, it is possible that relevant 
studies were unintentionally omitted. Therefore, I recommend that an updated 
systematic review and meta-analysis be conducted by multiple researchers prior to 




                     
Chapter 3: Factors affecting prescriber 
implementation of computer-generated 
medication recommendations in the SENATOR 
trial – a qualitative study 
 
 
3.1 Chapter description 
In Chapter 2, the systematic review and meta-analysis found that computerised 
interventions can be significantly effective in reducing PIP in hospitalised older 
adults. However, the prescriber implementation rates of computer-generated 
recommendations were found to vary widely in the included studies which reported 
this measure, and the reasons for non-implementation had not been 
comprehensively explored across the studies. In this chapter, I conduct a qualitative 
interview study alongside the SENATOR trial to identify the key factors affecting 
prescriber implementation of SENATOR’s computer-generated medication 
appropriateness recommendations, which were targeted at reducing PIP and ADRs 
in hospitalised older adults.  
 
The work of this chapter has been accepted in Drugs & Aging, subject to revisions. 
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3.2 Abstract 
3.2.1 Introduction 
The SENATOR trial intervention included the provision of computer-generated 
medication recommendations to physician prescribers caring for hospitalised older 
adults (≥ 65 years), with the aim of reducing in-hospital adverse drug reactions. 
Interim data analysis during the trial revealed that the prescriber implementation 
rates of the computer-generated STOPP/START recommendations were lower than 
expected across all six trial sites. The aim of this qualitative study was to identify 
the key factors affecting prescriber implementation of the medication 
recommendations in the SENATOR trial. 
3.2.2 Methods 
Semi-structured interviews were conducted with trial researchers and physician 
prescribers who were provided with SENATOR recommendations. Content analysis 
was used to identify the key themes that influenced prescriber implementation of 
SENATOR recommendations. 
3.2.3 Results 
Interviews were conducted with ten trial researchers and fourteen physician 
prescribers across the six trial sites between November 2017 and May 2018. 




i) Computerised output: the software could not evaluate the entire clinical 
context of patients and thus frequently produced recommendations of low 
clinical relevance.  
ii) Acute hospital environment: participants felt that there was often a 
disconnect between the time prescribers were reviewing the patient and the 
point at which the recommendations were provided.  
iii) Prescriber role and identity: implementation was facilitated by the 
recommendations reaching a ‘decision-maker’. However, prescriber inertia 
was highly pervasive, with a particular reluctance among those in specialised 
roles to prescribe outside their own specialty.  
iv) Patient-specific details: interviewees declared that implementation was 
affected by the patient’s acute clinical status, prescribers’ familiarity with 
the individual patient and, to a lesser extent, the patient’s own preferences.  
3.2.4 Conclusion 
This study has demonstrated that the clinical relevance of the SENATOR prescribing 
recommendations was a significant factor affecting their implementation. Whilst 
software refinement will be necessary to improve the quality of recommendations, 
future interventions will need to be multifaceted to overcome the complex 









It was demonstrated in Chapter 2 that computerised interventions can significantly 
reduce PIP in hospitalised older adults, but with limited benefits proven for patient 
outcomes [251]. The SENATOR project included a multi-centre RCT whereby the 
intervention involved the provision of computer-generated pharmacological and 
non-pharmacological recommendations to attending physician prescribers 
providing care to older adults in the hospital setting, with the trial’s primary aim 
being to reduce in-hospital ADRs in this patient cohort [202]. The pharmacological 
recommendations were based on version 2 of the STOPP/START criteria [88], as 
well as drug-drug and drug-disease interactions identified by approved electronic 
databases.  
An RCT by O’Connor et al. had previously demonstrated that relatively high 
prescriber implementation rates of STOPP and START recommendations were 
associated with a clinically significant reduction in the proportion of older patients 
experiencing in-hospital ADRs when comparing the intervention and control groups 
(21% versus 11.7%) [148]. However, interim data analysis from the SENATOR trial 
after 12 months of patient recruitment showed that the prescriber implementation 
rates of the STOPP and START recommendations were lower than expected across 
all six trial sites. A qualitative study alongside the SENATOR RCT was not planned 
from the outset, but it was deemed of utmost importance to investigate the 
possible reasons for the observed low implementation rates as this may impact on 
the primary outcome of the trial (i.e. hospital-acquired ADRs). Qualitative studies 
conducted in conjunction with RCTs have been shown to be important in the 
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evaluation of complex interventions, and are especially important in multi-centre 
trials, where the ‘same’ intervention may be delivered in different ways [256, 257].  
Thus, the aim of this qualitative study was to identify the factors affecting 
prescriber implementation of the computer-generated STOPP/START 
recommendations in the SENATOR trial intervention, with a view to informing the 




3.4.1 Context and study setting 
This qualitative study was undertaken in conjunction with a larger European 
research project: the SENATOR study, which included an RCT that was conducted in 
six large acute teaching hospitals in six European countries (Table 3.1). Briefly, as 
part of the SENATOR intervention, computer-generated pharmacological and non-
pharmacological recommendations were provided to physicians caring for the 
intervention patient group, with the primary aim of reducing in-hospital ADRs. All 
patients randomised were multimorbid older adults (≥ 65 years) with an expected 
length of hospital stay > 48 hours. Primary researchers working with the trial were 
involved with patient recruitment, data collection, data entry into the SENATOR 
software engine, patient randomisation, and contacting the attending team of 
physicians (via telephone or face to face, a written note in the patient’s clinical 
record, and email) to inform them that the patient was randomised to the trial 
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intervention arm, and that computer-generated recommendations were available 
to be reviewed in the patient’s clinical record (either paper-based or electronic 
record depending on the hospital site). For more information about the RCT, the 
trial methods have been published in detail elsewhere [202].   
 
3.4.2 Study design and recruitment 
Ethical approval for this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Republic of Ireland (Appendix 7). 
The Consolidated Criteria for Reporting Qualitative Research (COREQ) checklist was 
used to guide reporting in this study (Appendix 8) [258]. Semi-structured interviews 
were conducted with primary researchers working with the trial and prescribers 
(medical or surgical) who were provided with the SENATOR recommendations. 
Semi-structured interviews were chosen as the preferred method of data collection 






Cork University Hospital, Cork, Republic of Ireland. 
2 Aberdeen Royal Infirmary, Aberdeen, United Kingdom. 
3 Landspitali University Hospital, Reykjavik, Iceland. 
4 Ghent University Hospital, Ghent, Belgium. 
5 Hospital Universitario Ramón y Cajal, Madrid, Spain. 
6 Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy. 
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as they tend to elicit more in-depth descriptions of participants’ experiences and 
perspectives [259].  
Interview participants were eligible to be recruited from any of the six hospitals 
involved with the SENATOR trial (Table 3.1). The authors planned to interview i) 
two medical prescribers per site, ii) one surgical prescriber per site, and iii) two 
primary researchers per site where possible (as some sites only had one primary 
researcher still working with the trial). The primary researchers involved with the 
SENATOR trial were recruited using purposive sampling as there were limited 
numbers of primary researchers at each site. Snowball sampling was used to recruit 
prescribers, whereby the SENATOR primary researchers and their colleagues 
referred the interviewer to prescribers in their site who would participate in the 
study. Participants were contacted via email and provided with an information 
sheet and consent form in their native language in advance of the interview.  
3.4.3 Data collection 
Two separate topic guides comprising a similar line of questioning were formulated 
for both prescribers and primary researchers, and these were based on a review of 
the literature, the TDF [217], and the research group’s practical knowledge of the 
RCT (Appendix 9). Careful consideration was given to the language used, knowing 
that English would not be the first language for all participants. The topic guide for 
interviewing prescribers was piloted with a prescriber who had received SENATOR 
recommendations in the lead trial site, and this interview was included in data 
analysis. The topic guide for interviewing primary researchers was piloted with a 
primary researcher working with a similar RCT in the OPERAM project [203], who 
83 
 
was very familiar with the SENATOR trial procedures. The topic guides were 
iteratively refined during the study to ensure that emerging themes were explored 
in subsequent interviews. 
All semi-structured interviews were conducted in English by the principal 
investigator of this study (KD), who was a primary researcher with the SENATOR 
trial at the time of the interviews. All but one of the interviews were conducted in 
person. One interview was conducted face to face via Skype® as the primary 
researcher was not available at the time the interviewer visited the trial site. The 
interviewer had established a rapport with some of the primary researchers prior to 
the qualitative study during trial meetings and teleconferences, but no relationship 
between the interviewer and prescriber participants was established prior to study 
commencement.  
The interviews were conducted in a private area at the participant’s workplace from 
November 2017 to May 2018. Participants were briefed about the study and 
reassured that all interviews would be anonymised. All interviewees provided 
written informed consent for participation, and had the opportunity to withdraw 
from the interview at any time. Interviewees were provided with a sample of a 
SENATOR report in their native language during the interview as a reminder of the 
report design and the types of recommendations provided (sample report shown in 
Appendix 10). Field notes were recorded after each interview, and were used to 
refine topic guides and inform data analysis. Interviews were audio-recorded and 
transcribed verbatim. Data analysis coincided with data collection, and sampling 
continued until no new themes emerged. An additional three interviews were 
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conducted without any new themes appearing to confirm that data saturation had 
been reached [260].  
3.4.4 Data analysis 
All transcripts were entered into NVivo® Version 11 to facilitate analysis. The data 
were analysed in four phases. Phase 1 was a familiarisation phase, which involved 
reading and re-reading of the transcripts. Phase 2 involved conventional content 
analysis [261], which comprised open coding to inductively create initial, non-
hierarchical codes. These initial codes were subsequently categorised to generate 
the evolving themes and subthemes. In Phase 3, directed content analysis was 
employed whereby the transcripts were deductively coded using the TDF to identify 
the domains present [261]. To ensure validity of the findings, a second researcher 
(SC) independently identified themes and TDF domains from a sample of ten 
interview transcripts, with the predominant domains identified through consensus 
discussion between two researchers (KD and SC). Three factors were considered 
when identifying predominant domains: i) the frequency of the beliefs in each 
domain, ii) the presence of conflicting beliefs, and iii) the perceived strengths of the 
beliefs impacting implementation, as per Patey et al. [262]. Lastly, the evolving 
themes (from Phase 2) and predominant TDF domains (identified in Phase 3) were 
reviewed further in order to refine the main themes which reflected the key factors 





A total of 24 interviews were conducted (with 12 medical prescribers, 2 surgical 
prescribers, and 10 primary researchers) across all six SENATOR RCT sites. The 
average interview length was 24 minutes (range 18-64 minutes). Demographic 
details of the interviewees are shown in Table 3.2.  
Table 3.2: Characteristics of interview participants 
 Number 
Participant type  
      Medical Prescriber 12 
      Surgical Prescriber 2 
      Primary Researcher 10 
Gender  
      Male 13 
      Female 11 
Years of post-qualification 
experience 
 
      < 5 years 6 
      ≥ 5 to < 10 years 6 
      ≥ 10 to < 15 years 3 
      ≥ 15 to < 20 years 4 




3.5.1 Main themes 
Four main themes emerged as the key factors affecting prescriber implementation 
of the STOPP/START recommendations in the SENATOR RCT, namely the 
computerised output, the acute hospital environment, prescriber role and identity, 
and patient-specific details. Subthemes are displayed under each of these to help 
explain the findings, with additional quotations to support these themes in 
Appendix 11. 
 
Theme 1 – Computerised Output 
Aid to prescribing, but cannot be trusted blindly 
Overall, participants expressed positivity toward the concept of the intervention, 
and would welcome computerised interventions like SENATOR to be an aid to 
prescribing in multimorbid older adults. However, most participants acknowledged 
that the computerised recommendations could not be trusted without careful 
consideration – the software could not take into account the entire clinical context 
of the patient, and therefore produced recommendations that were not always 
specific to each individual patient. 
“I would not trust them blindly. I have gotten bad and good 
recommendations, and that’s just because the computer programme can’t 




Recommendations of low relevance contributing to prescriber fatigue 
The general consensus from interviewees was that the software generated a high 
proportion of recommendations that were of low clinical relevance or inappropriate 
for the given patient, and that this was one of the main factors why the 
recommendations were not implemented. When prescribers initially saw reports 
that contained recommendations that were of low relevance, this would have 
resulted in their devaluation of the perceived benefits of future reports, 
contributing to decreased engagement with the SENATOR reports and non-
implementation of the recommendations.  
“I think when people have seen these reports and they’ve seen 
recommendations that are inappropriate or irrelevant, I think that can sort of 
change their perception of the study and of these SENATOR reports, and it can 
sort of devalue them as well. So, I think maybe…when they see a report the 
next time that they pay less attention, that they have less trust in it”. [Primary 
Researcher 7] 
Provision of the recommendations 
The majority of interviewees liked the design of the report. However, many pointed 
out that whilst the colours on the report would have grabbed the attention of 
prescribers, the overall length of the report and the large amount of writing would 
have been off-putting to readers.  
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“It’s a little bit lengthy maybe because it takes a couple of minutes to read 
through this and…it’s colourful but it’s rather dull…in continuous text”  
[Medical Prescriber 12] 
Many prescribers appreciated the face-to-face delivery of the report from the 
primary researcher as it allowed for discussion on the rationale behind the 
recommendations, and facilitated their review. However, some primary researchers 
felt that the status of the person communicating the presence of the 
recommendations was a factor affecting their implementation. 
“I think because I’m not a doctor, it’s sometimes difficult to discuss it with 
them because yeah you can always see you’re not on the same level…” 
[Primary Researcher 1] 
 
Theme 2 – Acute Hospital Environment 
Right setting for the intervention? 
Participants questioned whether the acute hospital environment was the best 
setting to conduct this intervention. Some highlighted that making changes in the 
hospital setting allows for prescribers to monitor patients afterwards. However, 
many pointed out that the recommendations were focused on the patient’s chronic 
disease management, whereas the prescribers were primarily focused on the acute 
issues. Interviewees suggested that it may be more suitable to implement the 
recommendations when patients were in a non-acute setting.  
89 
 
“I think an outpatient setting or a GP setting is a more appropriate place to 
change a patient’s long-term medications - that really you should be making 
changes when somebody is well”. [Primary Researcher 7] 
Timing of the intervention and location of the recommendations 
Participants strongly felt that the timing of the intervention was a key factor 
affecting implementation; the recommendations were usually not provided at the 
time the patients’ medications were being reviewed by the prescriber. 
“…there was a disconnect between when I saw the report and when I saw the 
patient, which made it hard maybe to implement any changes that may have 
seemed reasonable”. [Medical Prescriber 1] 
The location of the report may also have been an important factor. Interviewees 
stated that prescribers simply may not have seen the recommendations and could 
easily go unnoticed in the medical notes or in an email inbox.  
“Well it could be because people didn’t look at it…if the information doesn’t 
get to them, they probably don’t accept anything…” [Medical Prescriber 10] 
Many suggested that provision of the recommendations at the point of prescribing 
or integration of the recommendations with an electronic prescription record 
would increase their visibility and potentially increase their implementation rate. 
Unfamiliar intervention in a busy environment  
An additional issue identified was that many prescribers did not become familiar 
with the intervention as it was not ubiquitous for all older patients within the 
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hospital sites, which may have resulted in reduced engagement with the 
intervention. However, even when prescribers may have intended on reviewing or 
implementing the recommendations, they may not have found the time or simply 
forgot about the intervention due to several other work commitments.  
“But I think I don’t use it enough to immediately be able to read it through 
quickly which…when you’re working under pressure and time constraints in a 
hospital - if something isn’t easy and intuitive to read quickly in less than 30 
seconds, you don’t have time, you just move on”. [Medical Prescriber 8] 
 
Theme 3 – Prescriber role and identity  
Responsibility 
Participants acknowledged that prescribers must take ownership of the 
medications prescribed for patients under their care in hospital. Whilst most 
prescribers were happy to review the SENATOR recommendations, some attending 
prescribers showed a reluctance to act on the recommendations in the hospital 
environment or to take sole responsibility for older patients’ pharmacotherapy. 
“…whose role it is to actually do it? At the moment, I’d say it’s nobody’s role. 
Nobody really takes it upon themselves, I would say, to actively review 





Prescriber specialty and fear of encroachment 
It was clear from the interviews that prescribers were much less comfortable in 
acting on recommendations that were outside their field of specialist knowledge. 
Interviewees stated that surgical prescribers were much less likely to implement 
the SENATOR recommendations than medical prescribers, as surgeons were 
concerned primarily on the acute surgical issue, with less focus given to the 
patient’s chronic medications. Prescribers expressed reluctance in making changes 
that might encroach on other prescribers’ decisions (e.g. the patient’s GP or other 
hospital specialists).  
“…for me personally, it’s mainly if someone else started the medication, and 
they’re going to follow up in that clinic, I’m much less likely to stop something 
that maybe is, that feels out of my specialty and is being followed up by 
another specialist…” [Medical Prescriber 6] 
Prescriber outlook toward research studies 
It was highlighted that some prescribers who were more open-minded towards 
research studies were more likely to engage with the intervention and act on the 
recommendations, whilst others may have appeared less interested and were less 
likely to implement the recommendations.  
“…there are clearly two groups – the doctors who are very enthusiastic and 




Prescriber experience and the need for a ‘decision-maker’ 
Interviewees recognised that junior prescribers may be more reluctant to change 
patients’ medications than their more experienced colleagues. However, several 
participants felt that many junior prescribers have the knowledge and skills 
required to implement these recommendations, but lack the authority to adjust 
patients’ medications without consulting a more senior colleague.  
“When we discuss the recommendation with the junior doctors, they listen to 
our discussion, but they are not in a position to change the medication. They 
have to discuss with the senior person, either registrar or consultant”. 
[Primary Researcher 9] 
Participants indicated that whilst prescriber experience may be influential, it was 
more important that the recommendations were reviewed by a ‘decision-maker’ in 
the prescribing team, whereby participants most commonly considered the 
decision-maker to be a more senior prescriber. 
“I think it’s helpful, or more helpful, to speak with the senior doctor, who is a 
decision-maker. I think the senior person on a medical team would be more 







Theme 4 – Patient-specific details 
Acute status of the patient  
Many interviewees recognised that the intervention patients were acutely unwell, 
and that prescribers were more likely to make prescription changes when patients 
were more stable. If, however, the recommendations were related to the reason 
for admission, then this would increase the likelihood that recommendations would 
be implemented. Prescribers stated that if the patient was not having any problems 
with certain medications, then it was unlikely that they would make any changes to 
these prescriptions. 
“…so people, say, are on lots of stable medications come in with something 
completely different, I don’t really feel that my role then is to meddle, muddy 
the waters. When people have come in with something that might be related 
to their medication, I think then yeah that’s fine”. [Medical Prescriber 6] 
Knowing the patient  
Whilst some prescribers emphasised that they were happy to review the SENATOR 
recommendations as they knew about the patients under their care, interviewees 
also described that hospital prescribers were often reluctant to act on the 
recommendations as they did not know enough about these complex multimorbid 
patients (who were only recently admitted to hospital), or their pharmacotherapy.  
“I don’t know whether that’s appropriate or not because I don’t know what 
the decision was to put them on it in the first place”. [Surgical Prescriber 2] 
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Patient preference  
Some interviewees stated that the patient’s preference was a factor in whether the 
recommendations were implemented, and that patients would be resistant to 
deprescribing of certain medications:  
“Of course, also patients’ will. Like it always suggested to stop the sleep 
medication but most of the people we try to stop the sleeping medication, 
they will shoot you”. [Medical Prescriber 4] 
 
3.5.2 Predominant TDF domains 
Six domains were found to be predominant in influencing prescriber 
implementation of the SENATOR recommendations (Table 3.3), and these were 
pervasive in the four main themes depicted. Some of the supporting quotations 









Table 3.3: Behavioural determinants affecting implementation of the SENATOR 


















“It’s the right place to do it, absolutely. Here we are starting 
a lot of new drugs. Here we have the possibility to monitor 
the response and the side effects”. [Medical Prescriber 12] 
 
“If you’re trying to do it in hospital, I think you’re gonna get a 
lot of the problems we encountered where people don’t have 






“…if it was present right at the time where they’re dealing 
with the patient, where they’re focused on the patient, I 
think that could absolutely have improved uptake of the 





“If instead having it inside the history, it was…it appeared 
with the programme, with the prescription programme, 
because you have to use it - there’s no other way, and 
probably they would pay more attention”.                   











“It looks like instead of holistic treatment of the patient, each 
consultant is treating their part”.  [Primary Researcher 9] 
 
“They don’t feel it’s their place. They feel it’s a GP’s job so 
they don’t want to get involved or they’re not confident 





“Well I think it’s my responsibility to do so as a doctor and 
I’m the one who has to decide which medicines I give to 






Table 3.3 (continued): Behavioural determinants affecting implementation of the 



















“…if we could filter out the irrelevant or inappropriate 
recommendations, I think that the whole value of the report 
would go upwards very significantly. Because undoubtedly 
there is a fatigue as well when you get lots and lots of 
recommendations”. [Primary Researcher  7]  
 
 
Need for a 
‘decision-maker’ 
 
“I think it’s probably more important that it’s targeted at the 





“…it’s all about reminders. I think people are well-





Focus on other 
work commitments   
 
“…they were rushed, they were busy doing something else, 
and the recommendations that I would have highlighted to 
them would not have been seen as a priority, it would have 
been something that they would have come back to at a 
later stage”. [Primary Researcher 7] 
 
 
Priority is managing 
the acute issues of 
the patient 
 
“…when the patients are admitted in secondary care in 
hospital, the clinical team only deals with the acute problem. 
They are not interested in looking into the other 








“I’m not gonna start interfering with somebody’s 
medications unless there’s a glaring danger in them or I see 
something that’s absolutely contraindicated…”                
[Surgical Prescriber 2] 
 
 
Intrinsic motivation  
 
“I think it depends on the person itself if they are open-





Table 3.3 (continued): Behavioural determinants affecting implementation of the 
SENATOR recommendations within the predominant TDF domains 
 
3.5.2 Suggestions for future interventions  
Some suggestions made by interviewees for future interventions included: 
 Having a pilot phase prior to full intervention rollout. 
 Integrating the recommendations with electronic prescribing.  
 Providing an informed rationale on how each recommendation was 
generated. 
 Adjusting the algorithms to avoid unnecessary recommendations being 
produced. 
 Streamlining the number of recommendations to focus on the most relevant 

















“They have conditions that are out of my range of 
knowledge, and their treatment often…their treatment of 
one condition might collide with another condition that I’m 






“…they didn’t have a complete picture of the patient when I 
discussed the recommendation. So, I’m thinking that also is 
one of the reasons why they don’t adapt the change”. 
[Primary Researcher 9] 
 
 




This study has generated a deeper understanding of the key factors that affected 
prescriber implementation of the computer-generated medication 
recommendations in the SENATOR RCT. Significantly, many of the SENATOR 
software-generated recommendations were considered of no clinical relevance or 
inappropriate for the individual patient during the acute care setting, and thus were 
unlikely to be implemented. The SENATOR intervention targeted a wide range of 
PIP instances on the basis of STOPP/START criteria version 2. Previous researchers 
have encountered difficulties computerising these criteria [263], which were not 
designed specifically to be put into computerised algorithms, and this may be a 
reason for the difficulty with routinely providing recommendations of high clinical 
relevance tailored for each patient. Pilot testing the SENATOR software intervention 
might have identified opportunities for software modification early on in order to 
reduce the number of irrelevant recommendations produced, as well as to 
overcome some of the issues identified with delivery of the recommendations to 
prescribers. Pilot testing did not take place in the SENATOR trial because of time 
constraints within the project that arose because of unforeseen difficulties with 
completion of the software construction and challenges with interfacing the 
software with the electronic case report form. By the time these issues were 
resolved, there was no time left within the project timeline in which pilot testing of 
SENATOR software-generated prescribing advice reports could be accommodated 
given the practical imperative to complete the substantive clinical trial. 
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The high proportion of irrelevant SENATOR recommendations may have 
overwhelmed prescribers and thereby incurred user fatigue with the intervention, 
such that clinically important recommendations may also have been ignored [264]. 
A recent systematic review indicated that computerised interventions which target 
fewer PIP instances in hospitalised older adults may have greater recommendation 
implementation rates than those targeting a wider range of PIP issues [251]. Future 
interventions of this kind may need to consider producing a smaller number of 
recommendations that are of high clinical relevance, which are tailored to the 
specific needs of individual patients in order to increase prescriber implementation 
rates and reduce PIP.  
The acute hospital environment is well-known for being conducive to inappropriate 
prescribing [265, 266]. The timing of the SENATOR intervention seemed to be 
inconvenient for some hospital prescribers, who often had several other competing 
tasks as part of their busy workload. During the trial, prescribers were commonly 
informed of the recommendations being present in the patients’ medical records at 
a time when they were not reviewing the patient. Whilst prescribers may have 
intended to examine the SENATOR recommendations, time constraints coupled 
with their workload may have distracted some prescribers from the intervention. 
Prescriber implementation rates may be improved if the recommendations are 
provided simultaneously with the act of prescribing [70]. Although enhancing the 
environment in which prescribers work is not a simple undertaking, the 
incorporation of this type of medication optimisation intervention with hospital 
electronic prescribing systems may aid integration into prescribers’ workflow and 
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facilitate review of the prescribing recommendations [267, 268]. Equally, it may be 
useful to evaluate if there is increased implementation of these recommendations 
in other care settings, where patients are more stable, and to further assess if there 
is a greater impact on patient outcomes.   
Whilst computerised interventions are often assumed to provide solutions to 
minimising inappropriate prescribing, this study corroborates previous findings 
which show that simply providing computer-generated recommendations does not 
guarantee their uptake [269, 270]. In the present study, even when the 
computerised output was accurate, and the clinically relevant SENATOR 
recommendations were reviewed by prescribers, they were still not always 
implemented. These findings have highlighted the importance of targeting 
interventions like this at the decision-makers on the prescribing team as one way to 
increase the likelihood of recommendation uptake [271]. Prescriber inertia was 
notably pervasive in the interviews, and was previously found to be the 
predominant reason for non-implementation of computer-generated guideline-
based recommendations in a primary care study [272]. This inertia may be due to 
fear of negative consequences of changing therapy [273], with a particular 
reluctance to make prescribing changes outside of one’s own specialty [274]. More 
education and training on geriatric pharmacotherapy is therefore required at both 
undergraduate and postgraduate levels to reduce this prescriber inertia and to 
make all prescribers more confident in routinely optimising older adults’ 
pharmacotherapy [111].  
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Participants recognised that patients’ own beliefs also influenced the 
implementation of the SENATOR recommendations, particularly as some patients 
preferred to continue taking certain medicines that may be considered ‘potentially 
inappropriate’. More patient education may be required as previous trials have 
shown that it can be a significant facilitator in discontinuing PIMs in older adults 
[275, 276]. Moreover, being highly familiar with the patient’s clinical details was 
considered an important promoter in prescribers acting on the SENATOR 
recommendations. Hospital prescribers stated that they often know much less 
about the patients, their comorbidities, or their established pharmacotherapy 
compared to the GP or other hospital specialists [277, 278]. However, there is 
evidence that GPs frequently do not receive information on the specific indications 
of hospital-initiated medications [279], emphasising the need for better 
information exchange, particularly at care transitions points, to facilitate informed 
prescriber decisions for older adults in all care settings.   
It has already been established above that the person who receives the prescribing 
recommendations is a significant factor affecting implementation (e.g. based on 
their level of seniority). However, the person who delivers the prescribing 
recommendations may also be a factor. A recent study has demonstrated that the 
type of healthcare professional providing STOPP/START recommendations and the 
approach taken by that person may substantially influence prescriber 
implementation rates [280]. Hierarchical differences were implicit in the comments 
from primary researchers in this study, as they suggested that physician prescribers 
may have appeared less interested in reviewing the recommendations if they were 
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not provided by a fellow physician. Future interventions must consider the 
importance of the particular healthcare professional that provides these types of 
recommendations, and to balance this against other factors such as cost. 
Ultimately, the SENATOR trial demonstrated a negative result for its primary 
outcome, i.e. no significant difference in the proportion of patients experiencing a 
non-trivial in-hospital ADR between the intervention and control groups, probably 
attributable to a low implementation rate of the computer-generated STOPP/START 
recommendations [281]. When complex interventions produce negative results, as 
in the SENATOR trial, one may reasonably question if the intervention is inherently 
ineffective, whether it was improperly employed, or applied in an unsuitable clinical 
context [282]. Qualitative studies are increasingly advocated in such circumstances 
as they can draw upon the experiences of those involved with the trial to enable a 
better understanding of the quantitative results [283]. Although this qualitative 
study was not used to adjust the SENATOR intervention, it should help inform the 
design of future interventions of a similar kind. Coordinators of future RCTs with 
complex interventions should strongly consider the inclusion of parallel qualitative 
study components, with integration of these findings along with the main trial 
results. 
3.6.1 Strengths and limitations 
A robust theoretical framework was used to structure the topic guides, with 
inductive and deductive approaches both used in data analysis. It has been shown 
that TDF-based interviews elicit additional themes from participants that would not 
otherwise be reported compared to studies without a theoretical basis [284, 285]. 
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The relevance of these findings is reinforced by the sampling of participants from 
six hospitals across Europe. The emergence of common themes from a wide spread 
of geographical locations enhances the transferability of the findings. Furthermore, 
all interviews were conducted by the same researcher across all sites, allowing for 
consistency in both data collection and analysis. 
However, a limitation to this study is that the number of eligible interviewees from 
each site was limited to those who were proficient in English. As it was not the first 
language of some interviewees, this may have impeded their potential to fully 
express their exact views. Additionally, the responsibility of selecting prescribers to 
participate in this study was largely assigned to members of the SENATOR research 
teams at each site. This delegation of duties, coupled with busy work schedules, 
may be the main reasons for the small sample size of surgical prescribers 
interviewed.  
Finally, one interview was conducted face to face via Skype®; however, this was not 
perceived to be an issue as the interviewer had previously built a rapport with this 
primary researcher in person at a trial meeting. Skype® has been shown to be a 
viable research medium to conduct semi-structured interviews, and could be 
considered for future qualitative studies alongside multi-centre RCTs where 








This study clearly demonstrates the value of qualitative evaluation methods in 
assessing the delivery of complex interventions within RCTs. The findings highlight 
the difficulties associated with optimising prescribing in hospitalised older adults, 
and that a multifaceted approach will be required to tackle these issues. The key 
factors affecting prescriber implementation of computer-generated medication 
recommendations in the SENATOR RCT have been identified across six European 
acute hospital sites. As with previous research, these results suggest that 
prescribers generally welcome computerised interventions, such as SENATOR, in 
the hospital setting as an aid to prescribing in complex multimorbid older adults 
[288]. Whilst future researchers must endeavour to improve the clinical relevance 
of these computer-generated medication recommendations, it is also important 
that they identify the most appropriate person to receive the recommendations, 
the best time for the intervention to occur, and to develop a greater understanding 










                     
Chapter 4: Computer-generated STOPP/START 
recommendations for hospitalised older adults: 
evaluation of the relationship between clinical 




4.1 Chapter description 
In Chapter 3, one of the key factors perceived to affect prescriber implementation 
of the computer-generated STOPP/START recommendations in the SENATOR trial 
was the clinical relevance of the recommendations. In this chapter, in order to 
further substantiate the qualitative findings of Chapter 3, I systematically evaluate 
the clinical relevance of the computer-generated STOPP/START recommendations 
using a validated scale from the literature. In addition, I investigate if the 
adjudicated degree of clinical relevance of the recommendations was associated 
with their implementation. 
 
The work of this chapter has been accepted in Age and Ageing, subject to revisions. 
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4.2 Abstract 
4.2.1 Introduction 
Findings from a qualitative study conducted alongside the SENATOR randomised 
controlled trial indicate that the perceived clinical relevance of computer-generated 
STOPP/START recommendations was a key factor affecting their implementation by 
physician prescribers caring for hospitalised older adults in the trial. The aim of the 
present study was to systematically evaluate the clinical relevance of these 
recommendations and to establish if clinical relevance significantly affected the 
implementation rate. 
4.2.2 Methods 
A pharmacist-physician pair retrospectively reviewed the case records for all 
SENATOR trial intervention patients at Cork University Hospital, the trial’s lead 
recruitment site, and assigned a degree of clinical relevance for each STOPP/START 
recommendation based on a previously validated six-point scale. The chi-square 
test was used to quantify the differences in prescriber implementation rates 
between recommendations of varying clinical relevance, with statistical significance 
set at p < 0.05.  
4.2.3 Results 
In 204 intervention patients, the SENATOR software produced 925 STOPP/START 
recommendations. Nearly three quarters of recommendations were judged to be 
clinically relevant (73.6%), whilst the remainder were judged to be of ‘no clinical 
relevance’ (21.5%) or of potential ‘adverse significance’ if implemented (4.9%). 
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However, nearly half of the clinically relevant recommendations were judged to be 
of ‘possibly low relevance’ (320/681; 47%). Recommendations considered to be of 
higher clinical relevance were significantly more likely to be implemented than 
those of lower clinical relevance (p < 0.05). 
4.2.4 Conclusion 
A large proportion (61%) of the computer-generated STOPP/START 
recommendations provided were either of potential ‘adverse significance’, of ‘no 
clinical relevance’, or of ‘possibly low relevance’. The adjudicated clinical relevance 
of computer-generated medication recommendations significantly affects their 
implementation. Meticulous software refinement is required for future 
interventions of this type to increase the proportion of recommendations that are 
of high clinical relevance. This should facilitate their implementation, resulting in 






                     
4.3 Introduction 
The prescriber implementation rates of computer-generated recommendations to 
reduce PIP in hospitalised older adults have been found to range from 29.3% – 95% 
[251]. However, limited research has been conducted to identify the intervention 
components which significantly affect implementation. When the interim analysis 
from the SENATOR trial revealed that prescriber implementation was lower than 
anticipated, a qualitative study was conducted to explore possible reasons for non-
implementation, as described in Chapter 3. The interview participants perceived 
that one of the key factors affecting implementation was the clinical relevance of 
the computer-generated recommendations, and they indicated that the SENATOR 
software was producing a high proportion of recommendations that were of low or 
doubtful clinical relevance for individual patients.  
However, rather than simply accepting these qualitative findings at face value, it 
would be of great significance to quantitatively corroborate a clear association 
between the relevance of recommendations and their rate of implementation. 
Therefore, the aim of this study was to systematically evaluate the clinical relevance 
of the computer-generated STOPP/START recommendations in the SENATOR trial 






4.4.1 Context and study setting 
The SENATOR RCT was conducted in six large acute teaching hospitals in six 
European countries. All patients recruited were multimorbid older adults (≥ 65 
years) who consented to their enrolment in the trial within 60 hours of hospital 
admission, who were prescribed medications for ≥ 3 active chronic medical 
disorders, and who had an expected length of hospital stay > 48 hours. More details 
on patient eligibility criteria and other pertinent trial information are published 
elsewhere [202].  
This study evaluating the clinical relevance of SENATOR’s STOPP/START 
recommendations was conducted in the RCT’s lead recruitment site only, Cork 
University Hospital – an 810-bed tertiary referral centre within the Munster 
province of the Republic of Ireland. All patients who were randomised to the 
intervention arm at this site were included in the present study. In Cork University 
Hospital, the SENATOR software generated a paper-based report detailing the 
STOPP/START recommendations, which was provided in each intervention patient’s 
paper-based clinical record, and was also sent via email to the consultant with 
responsibility for clinical care of the patient (sample report provided in Appendix 
10). Of the 114 STOPP/START criteria (version 2), recommendations based on 3 
criteria were excluded from the analysis: STOPP A1, START I1, and START I2, with 
reasons for exclusion provided in Appendix 12. 
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4.4.2 Data collection 
A pharmacist and physician independently and retrospectively reviewed all 
intervention arm patients’ medical records, drug chart, laboratory test results, and 
STOPP/START recommendations. Through consensus agreement, the pharmacist-
physician pair then assigned a degree of clinical relevance for each STOPP/START 
recommendation based on a previously validated six-point scale with the following 
categories: 0: ‘adverse significance’, 1: ‘no clinical relevance’, 2: ‘possibly low 
relevance’, 3: ‘possibly important relevance’, 4: ‘possibly very important relevance’, 
and 5: ‘possibly life-saving’ [289]. The pharmacist (KD) and physician (DC) were very 
familiar with the STOPP/START criteria and SENATOR’s computerised algorithms, 
and, at the time of the reviews, had three years and ten years post-qualification 
experience respectively in optimising the pharmacotherapy of hospitalised older 
adults. 
Inter-rater reliability (IRR) was determined among a sample of three pharmacists 
and three physicians (one consultant geriatrician, and two specialist registrars in 
geriatric medicine) in applying the scale to independently assign a degree of clinical 
relevance to STOPP/START recommendations from twenty randomly-selected 
intervention cases, each with at least three STOPP/START recommendations. The 
study design for this IRR assessment is provided in Appendix 13, with the 
standardised intervention case format provided in Appendix 14.
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4.4.3 Data analysis 
Statistical analysis was performed using SPSS® Version 22 and Microsoft® Excel. Data 
on prescriber implementation were extracted from the RCT’s electronic case report 
form, whereby implementation was defined as the prescriber discontinuing or 
initiating a medication in accordance with the recommendation at any point prior 
to hospital discharge. The percentage prescriber implementation rates were 
calculated for recommendations at each degree of clinical relevance. The chi-square 
test was used to determine if there were any significant differences between i) the 
proportion of recommendations and ii) the prescriber implementation rates of 
recommendations at varying degrees of clinical relevance, with differences 
considered statistically significant at p < 0.05.  
In the assessment of IRR, the Fleiss kappa statistic was used to determine the 
agreement between all raters and across the subgroups of raters (i.e. pharmacists 
and physicians). Cohen’s kappa statistic was used to determine the level of 
agreement between the individual raters. The kappa statistic was interpreted 
according to the following ranges: slight if 0.01 – 0.2, fair if 0.21 – 0.4, moderate if 
0.41 – 0.6, substantial if 0.61 – 0.8, and almost perfect if 0.81 – 0.99 [290]. 
 
4.5 Results 
In Cork University Hospital, there were 204 SENATOR intervention patients (51% 
male), with a mean age of 77.4 years (standard deviation [SD] 6.91; range 65 – 92). 
In total, the SENATOR software generated 925 STOPP/START recommendations 
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(mean 4.5/patient; SD 2.9; range 0 – 17), which included 563 STOPP 
recommendations (mean 2.8/patient; SD 2.3; range 0 – 13), and 362 START 
recommendations (mean 1.8/patient; SD 1.5; range 0 – 7).  
4.5.1 Clinical relevance evaluation 
Almost three quarters (73.6%) of recommendations were deemed to be clinically 
relevant, i.e. assigned to categories 2, 3, or 4 – ‘possibly low relevance’, ‘possibly 
important relevance’, or ‘possibly very important relevance’ (Table 4.1). The 
remaining 26.4% of recommendations were either category 1, i.e. of ‘no clinical 
relevance’ (21.5%), or category 0, i.e. of possible ‘adverse significance’ to the 
patient if implemented (4.9%). No recommendations were judged to be ‘possibly 
life-saving’. 
When comparing the clinical relevance of STOPP and START recommendations in 
Table 4.2, there was a statistically significantly greater proportion of START 
recommendations i) of possible ‘adverse significance’ (7.2% versus 3.4%; p < 0.05), 
and ii) of ‘possibly very important relevance’ (12.2% versus 5.7%; p < 0.05). 
Conversely, there was a statistically significantly greater proportion of STOPP 
recommendations of ‘possibly low relevance’ (37.7% versus 29.8%; p < 0.05). 
Of the possible 79 STOPP and 32 START rules that were included in this study, 49 
different STOPP recommendations and 24 different START recommendations 
triggered respectively. The clinical relevance of the recommendations based on the 
individual STOPP and START criteria, as well as the drug classes that were the basis 
for these recommendations, are displayed in Appendix 15 and Appendix 16.
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Table 4.1: Prescriber implementation rates of recommendations categorised according to their degree of clinical relevance 
 
Degree of clinical 
relevance 
 
0 - Adverse significance 
 
1 - No clinical relevance 
 
2 - Possibly low relevance 
 
3 - Possibly important 
relevance  
 
4 - Possibly very important 
relevance 
 









































0 versus 2,3,4:  p < 0.05
‡
 1 versus 2,3,4:  p < 0.05
‡
 2 versus 0,1,3,4:  p < 0.05 3 versus 0,1,2,4:  p < 0.05 4 versus 0,1,2,3:  p < 0.05 - 
 
Most common type 
of STOPP/START 
recommendation 
within the category 
 
 
Possible reason for 
assigning this degree 
of relevance: 
 
START A3: Antiplatelet therapy 
(aspirin or clopidogrel or 
prasugrel or ticagrelor) with a 
documented history of coronary, 
cerebral or peripheral vascular 
disease. (n = 22; 48.9%) 
Recommendation to start an 
antiplatelet but patient already 
prescribed an anticoagulant – 
increased risk of bleeding.  
 
STOPP J3:  β-blockers in diabetes 
mellitus with frequent 
hypoglycaemic episodes (risk of 
suppressing hypoglycaemic  
symptoms). (n = 40; 20.1%) 
 
Recommendation triggered for 
all diabetic patients prescribed β-
blockers. Patient not presenting 
with frequent hypoglycaemic 
episodes – thus, not relevant. 
 
STOPP A2: Any drug prescribed 
beyond the recommended duration, 
where treatment duration is well 
defined. (n = 104; 32.5%) 
 
 
Recommendation to stop long-term 
high-dose PPI. Not of high clinical 
relevance in a patient who may 
have a more serious acute issue to 
be dealt with.   
 
START A6: Angiotensin 
Converting Enzyme (ACE) 
inhibitor with systolic heart 
failure and/or documented 
coronary artery disease.             
(n = 24; 8.4%) 
Recommendation may be 
possibly important in 
reducing the risk of 
cardiovascular events in those 
with coronary artery disease.  
 
START A1: Vitamin K antagonists 
or direct thrombin inhibitors or 
factor Xa inhibitors in the 
presence of chronic atrial 
fibrillation. (n = 13; 17.1%) 
 
Recommendation to start an 
anticoagulant in a patient with 
atrial fibrillation may be possibly 
very important in the prevention 
of future stroke. 
- 
* Includes all recommendations with data available regarding prescriber        † Difference in prescriber implementation rates between categories of clinical relevance; statistically significant difference observed where p < 0.05 
  
   
 
  ‡ No statistically significant difference observed between the implementation rates of recommendations of potential ‘adverse significance’ (category 0) and recommendations of ‘no clinical relevance’ (category 1). 
  











0 - Adverse 
significance 
 
1 - No clinical 
relevance 
 
2 - Possibly low 
relevance 
 

















STOPP/START Recommendations  
(% Total STOPP/START) 





Difference between proportion of START and 
STOPP at different categories of relevance* 
 




* Statistically significant difference where p < 0.05 
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4.5.2 Prescriber implementation rates 
Data on prescriber implementation were obtained for 884/925 (95.6%) 
recommendations. Data was unavailable for the following recommendations:  
i) all STOPP A3 recommendations, which were later removed from the 
intervention (n = 20),  
ii) two patients without implementation data in the electronic case report form 
(n = 15),  
iii) all START B3 recommendations, as there were no data on oxygen prescribing 
(n = 5), and  
iv) one STOPP N recommendation that triggered inappropriately (n = 1). 
Table 4.1 illustrates the prescriber implementation rates for the recommendations 
according to each assigned category of clinical relevance. As the clinical relevance 
of recommendations increases, so too does the implementation rate, with 
statistically significant differences in implementation rates between 
recommendations of all categories identified (p < 0.05), the only exception being 
between recommendations of potential adverse significance and recommendations 
of no clinical relevance (6.7% versus 11.7%; p = 0.33).  
4.5.3 Inter-rater reliability (IRR) results 
When assessing IRR in choosing the same degree of clinical relevance for 
recommendations, the Fleiss kappa coefficient was found to be fair (0.24). Kappa 
was higher among pharmacists (0.27) than among physicians (0.17). The mean 
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Cohen’s kappa coefficient between individual raters was also found to be fair 
(kappa = 0.24).  
 
4.6 Discussion 
This is the first study to evaluate the clinical relevance of computer-generated 
STOPP/START recommendations. The key finding is that increasing clinical 
relevance of recommendations associated with significantly higher implementation 
rates by prescribers. The results from this sample of acutely ill hospitalised 
multimorbid older patients show that nearly three quarters of STOPP/START 
recommendations were deemed to be clinically relevant (73.6%), whilst 
approximately one quarter of the recommendations were of no clinical relevance or 
of potential adverse significance (26.4%). Although most STOPP/START 
recommendations were deemed clinically relevant, it is acknowledged that nearly 
half of the clinically relevant recommendations were deemed to have ‘possibly low 
relevance’, i.e. category 2 on the six-point clinical relevance scale (320/681; 47%). 
Whilst these recommendations were correctly triggered by the SENATOR software, 
they may have been addressing issues that were of minor significance at the time of 
hospital admission, when the focus may have been on the patient’s acute illness. 
For example, nearly half of all benzodiazepine-related recommendations were 
judged to be of possibly low relevance. Although it is well-known that this drug 
class is a common contributing factor to ADRs (principally falls) in older adults [291], 
deprescribing benzodiazepines may not have been a priority at the time the 
recommendations were provided. Recommendations like these may have been 
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more clinically relevant later in the admission (such as pre-discharge), or in another 
setting (such as primary care or ambulatory care), where the patient may have 
been more stable, and it may have been easier to implement medication changes. 
Thus, the care setting and timing of the intervention must be key considerations for 
future studies.   
The proportion of clinically relevant computer-generated recommendations can 
vary widely depending on the healthcare setting and the medications targeted 
[292-295]. However, there are few studies in the literature that have evaluated the 
clinical relevance of computer-generated recommendations concerning medication 
appropriateness in hospitalised older adults. One research group has previously 
reported findings similar to this in a pilot study, with 74.5% of computerised alerts 
deemed clinically relevant [293]. However, when medication alerts in one of their 
subsequent studies were based on a broader set of Beers criteria [296], it was 
found that only 30% of the alerts were clinically relevant in the intervention group 
[294]. In contrast, the present study has shown that the STOPP/START version 2 
recommendations, i.e. another broad set of criteria, had a substantially higher 
proportion of clinically relevant recommendations.  
Many of these previous studies have simply judged the computer-generated 
recommendations in a dichotomous manner - clinically relevant or not clinically 
relevant [293-295]. However, in the present study, it was considered important to 
transcend this and qualify clinical relevance in a more nuanced fashion, i.e. to 
assess the degree of clinical relevance, by applying a defined scale. Beaudoin et al. 
used a five-point Likert scale, ranging from 1 (not relevant) to 5 (very relevant), to 
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evaluate the clinical relevance of computerised rule-based alerts concerning 
antimicrobials [297]; however, a limitation to this Likert scale is that it does not 
explicitly consider the possibility that the recommendations may be potentially 
inappropriate, and thereby have the potential to cause harm to the patient. The 
scale chosen for use in this study had been previously employed to assess the 
clinical relevance of pharmacist recommendations in a Belgian hospital, which 
found low agreement between evaluators (range of kappa values: 0.15 – 0.25) 
[289]. Similar agreement was found between the raters in this study (kappa = 0.24). 
Furthermore, Bech et al. found only slight agreement between raters when 
assessing the clinical relevance of drug-related problems among older patients 
using a five-point scale [298]. This lack of agreement among healthcare 
professionals in evaluating clinical relevance highlights the complexities associated 
with selection of appropriate pharmacotherapy in older adults [70].  
This study is important in that it was not merely indicated whether the 
recommendations were relevant or not, but rather their degree of clinical relevance 
was also qualified. If it is known that recommendations pertaining to certain criteria 
or particular drug classes are more likely to be clinically relevant, then one can 
prioritise these recommendations in future interventions. For example, in a 
hospitalised patient presenting with falls, the software should prioritise 
recommendations relating to deprescribing of benzodiazepines over those relating 
to proton pump inhibitors (PPIs). Provision of the most clinically relevant 
recommendations only, or ensuring that these recommendations appear as 
priorities, should help reduce the phenomenon of ‘alert fatigue’ [194]. However, 
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designing the software to take account of competing influences on clinical decision 
making, and ranking the recommendations in order of priority is a significant 
technical challenge [299]. This study has provided evidence on which 
recommendations may be more clinically relevant than others, and thus may 
inform ranking systems within future computerised algorithms. 
The present study corroborates the findings from the contemporaneous SENATOR 
qualitative study, which indicated that the clinical relevance of the computer-
generated STOPP/START recommendations was a key influence on their 
implementation by prescribers [300]. These results show a clear association 
between these two factors – recommendations of higher clinical relevance had a 
greater probability of being implemented by prescribers. Previous research has 
shown that computer-generated recommendations that were inappropriate or 
erroneously triggered were unlikely to be adopted by physicians or were overridden 
within the software programme [301]. However, the potential risk remains that 
some users may blindly follow inappropriate recommendations; this increases the 
risk of error and possible patient harm [302, 303].  
The results showed that a significantly greater proportion of START 
recommendations were either of ‘possibly very important relevance’ or of possible 
‘adverse significance’ in comparison to STOPP recommendations. Thus, certain 
START recommendations had the potential to be of great benefit in some patients, 
but could have caused serious harm if implemented in other patients. This indicates 
a lack of specificity in the computerised algorithms, resulting in the identification of 
more supposed instances of PIP than actual instances [304]. However, this lack of 
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specificity is not purely an algorithm issue – it could also have originated from the 
criteria themselves. For example, previous research has highlighted that some of 
the STOPP/START criteria contain broad definitions, e.g. START A3 criterion (version 
2) refers to “…a documented history of coronary, cerebral or peripheral vascular 
disease”. Whilst this phrasing allows the criteria to be applicable to a large 
proportion of older adults, broad definitions such as this are more susceptible to 
clinician interpretation [193]. Thus, some criteria may not be as explicit as they 
should be for the purposes of designing computerised algorithms, and previous 
research groups have outlined some of the complexities encountered in this 
process [193, 263, 305]. Further iterations of STOPP/START criteria will likely need 
to be much more specific, especially if the intention is to incorporate them into 
computerised algorithms, which should facilitate the production of more clinically 
relevant recommendations that are tailored to individual patients.  
However, simply producing clinically relevant STOPP/START recommendations does 
not guarantee their uptake; the medium through which the recommendations are 
delivered to prescribers also significantly affects their implementation [280]. In the 
present study, it was found that even the recommendations deemed to have 
possibly very important relevance were not implemented 30% of the time. One 
reason for this may have been due to the production of a high proportion of 
recommendations that were of potential adverse significance, not clinically 
relevant, or of low clinical relevance (61% of recommendations). These may, 
unwittingly, have undermined the trustworthiness of the SENATOR advice reports, 
and resulted in decreased engagement by clinicians with the most important 
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recommendations [300]. Increasing the proportion of recommendations of higher 
clinical relevance will be essential in minimising user fatigue with future 
computerised interventions, and enhancing the likelihood of clinically important 
recommendations being implemented.  
As with many studies of this type, they are limited by their retrospective design, 
and the subjectivity of raters must be considered as a potential source of bias. This 
is the first study that the authors are aware of which determines the IRR among 
healthcare professionals in evaluating the clinical relevance of computer-generated 
STOPP/START recommendations. However, failure to achieve high IRR may have 
been due to the scale used; it has been previously shown that rating scales with 
poor IRR are likely to result in low estimates of IRR in subsequent studies [306]. 
Furthermore, a scale with fewer categories or more specific categories would allow 
less room for discrepancy between raters, and should produce a higher IRR kappa 
value. Agreement may have been affected by raters simply interpreting the scale 
differently [307]. Future IRR studies using this scale could consider the use of 












This study quantifiably substantiates the findings from a recent qualitative study, 
which suggested that the clinical relevance of the STOPP/START recommendations 
in the SENATOR intervention was one of the key influences affecting their 
implementation. The present study shows that a large proportion (61%) of the 
STOPP/START recommendations provided were either of potentially adverse 
significance, irrelevant, or of low clinical relevance for the individual patients at the 
point of hospital admission. Recommendations of higher clinical relevance had 
significantly enhanced prescriber implementation rates. This study has also 
indicated the types of recommendations, based on the different physiological 
systems and drug classes, which are more likely to be of high clinical relevance; 
these findings may aid in the ranking of medication recommendations in future 
research. Future computerised interventions aimed at medication optimisation in 
multimorbid older adults must be meticulously designed to provide tailored advice 
specific to individual patients’ pharmacotherapy, thereby minimising the number of 
recommendations that are irrelevant or of low clinical relevance. Achieving greater 
proportions of recommendations that are of high clinical relevance should facilitate 
implementation by prescribers, resulting in the resolution of PIP issues and 







Chapter 5: Prescriber implementation of 
STOPP/START recommendations for hospitalised 
older adults: a comparison of a pharmacist 
approach and a physician approach 
 
 
5.1 Chapter description 
In Chapter 4, I evaluated the clinical relevance of computer-generated medication 
appropriateness recommendations, and the findings showed that clinical relevance 
was a significant factor affecting their implementation by prescribers in the 
SENATOR trial. However, medication appropriateness recommendations provided 
by a healthcare professional, such as a pharmacist or physician, are likely to be 
clinically relevant. Whilst the degree of relevance may still influence 
implementation, it is likely that there are other factors at play. 
In this chapter, I compare the prescriber implementation rates of STOPP/START 
recommendations from similar pharmacist and physician interventions to help 
identify factors affecting prescriber implementation of medication appropriateness 
recommendations in the hospital setting, which could then be explored in depth 




The work of this chapter has been published as: Dalton K, O’Mahony D, O’Sullivan 
D, O’Connor MN, Byrne S. Prescriber implementation of STOPP/START 
recommendations for hospitalised older adults: a comparison of a pharmacist 

























Two RCTs conducted simultaneously in the same acute university teaching hospital 
in the Republic of Ireland have shown that provision of recommendations based on 
STOPP/START criteria to attending prescribers can reduce in-hospital ADRs in older 
adults (≥ 65 years). One of the RCT interventions was conducted by a physician and 
the other by a pharmacist. The aims of the present study were to compare the 
prescriber implementation rates of STOPP/START recommendations between the 
physician approach and the pharmacist approach in these two RCTs and to provide 
a narrative summary of the comparable clinical outcomes. 
5.2.2 Methods 
Data were extracted from the two RCT published papers and their associated 
computerised databases to calculate the percentage prescriber implementation 
rates for the STOPP/START recommendations. The chi-square test was used to 
quantify the differences in prescriber implementation rates, with differences 
considered statistically significant where p < 0.05. 
5.2.3 Results 
Prescriber implementation rates of the STOPP and START recommendations made 
by the physician were 81.2% and 87.4% respectively, significantly higher than those 
made by the pharmacist (39.2% and 29.5% respectively), p < 0.0001. A greater 
absolute risk reduction in patients with ADRs was shown with the physician’s 




This study shows that the methods of communication and the medium through 
which the STOPP/START recommendations are delivered significantly affect their 
implementation. Non-implementation of some pharmacist-delivered 
recommendations may be contributing to preventable ADRs in older adults. Thus, 
future research should aim to identify the factors influencing prescriber 
implementation of pharmacist recommendations in order to inform the design of 














The STOPP and START criteria are well recognised tools for aiding identification of 
PIP in older adults, and have been utilised in a range of healthcare settings 
worldwide [88, 308]. Used in tandem, the criteria can be routinely applied to older 
patients’ pharmacotherapy and concurrent diagnoses to identify PIMs (via STOPP 
criteria) and PPOs (via START criteria). Studies deploying these criteria as part of the 
intervention routinely result in improvements in medication appropriateness [146, 
174]. Two RCTs conducted in the same large acute university teaching hospital in 
the Republic of Ireland demonstrated a clinically significant absolute risk reduction 
in incident ADRs in multimorbid older adults arising from physician-delivered and 
pharmacist-delivered pharmacotherapy recommendations to attending prescribers 
[147, 148]. Both RCTs included the primary researcher (physician or pharmacist) 
providing recommendations based on STOPP/START criteria version 1 (Appendix 
17) [7] to attending physician prescribers caring for hospitalised older adults.  
The primary aim of the present study was to compare the prescriber 
implementation rates of STOPP and START recommendations from these two RCTs 
conducted simultaneously in the same Irish university teaching hospital, where the 
recommendations were delivered by a physician in one trial and by a pharmacist in 
the other trial [147, 148]. Secondary aims were to identify components within the 
interventions that may have affected prescriber implementation, to compare the 
prescriber implementation of the pharmacist’s STOPP/START recommendations 
with other pharmacist-delivered recommendations, and to provide a narrative 




5.4.1 Study setting and intervention details 
Both RCTs were conducted in Cork University Hospital, an 810-bed tertiary referral 
centre in the Munster province of the Republic of Ireland. Participants were 
enrolled within 48 hours of their presentation to hospital with acute illness. The 
interventions in both RCTs primarily aimed to reduce non-trivial in-hospital ADRs in 
older adults (≥ 65 years), and are briefly summarised below. 
In both RCTs [147, 148], the primary researcher applied the STOPP/START criteria 
(version 1) [7] at a single time point to the medication list of intervention patients 
within 48 hours of hospital admission, and placed a printed report in the patient’s 
clinical records with STOPP/START-based recommendations. The primary 
researcher in each trial verbally notified the attending prescribers of the 
recommendations and answered any clarifying questions that they may have had. 
In RCT 1, the physician verbally notified the attending prescribers of the 
STOPP/START-based recommendations for all patients [148]; in RCT 2, the 
pharmacist verbally notified the attending prescribers of the recommendations for 
approximately one third of patients, but provided mobile phone contact details on 
the printed report in case prescribers wanted verbal clarification on the 
pharmacist’s advice [147]. In RCT 2, the pharmacist’s STOPP/START-based 
recommendations were provided in conjunction with recommendations based on 
other medication appropriateness issues, i.e. including drug-drug interactions, need 
for renal and hepatic dose adjustments, and other PIP instances identified utilising 
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Beers criteria (version 3) [309] and PRISCUS criteria [156], as well as issues based on 
medication reconciliation, which has been defined as the “process of identifying the 
most accurate list of all medications a patient is taking - including name, dosage, 
frequency, and route - and using this list to provide correct medications for patients 
anywhere within the health care system” and “involves comparing the patient’s 
current list of medications against the physician’s admission, transfer, and/or 
discharge orders” [310]. The medication reconciliation issues in RCT 2 were 
primarily due to medications omitted and incorrect doses prescribed on admission 
[169]. In RCT 1, the physician was a specialist registrar (i.e. senior resident) in 
geriatric medicine with 3 years of specialist clinical experience [148]. In RCT 2, the 
pharmacist was fully registered with 4 years of postgraduate experience in 
providing pharmaceutical care to older adults.  
Both trials used a cluster randomised design. In each RCT, two lists of attending 
consultant prescribers were created such that the combined rates of ADRs in these 
groups were known to be comparable from previous work undertaken by this group 
[85]. Having finalised the lists, one group of attending consultant prescribers was 
assigned as the intervention arm of the study and the other was assigned as the 
control arm. The intervention clusters in both RCT 1 and RCT 2 included individuals 
admitted under the care of specialists in cardiology, respiratory medicine, 
endocrinology, renal medicine, and orthopaedics. The intervention cluster in RCT 1 
also consisted of patients admitted under the care of specialists in radiation 
oncology, whilst the intervention cluster in RCT 2 also included patients admitted 
under the care of specialists in rheumatology, general and vascular surgery, and 
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general internal medicine. To avoid potentially biased enrolment of patients into 
either arm of the study, the primary researcher in each RCT approached 
prospective trial participants in the order of their admission to the hospital’s 
emergency department to assess their eligibility for the trial. RCT 1 was conducted 
from May 2011 to May 2012. RCT 2 was conducted from June 2011 to July 2012. No 
patient in either RCT received the intervention from the other RCT. Patients in the 
intervention and control groups in both RCTs received standard medical and 
pharmaceutical care from physicians and pharmacists who routinely work in the 
hospital. Implementation of recommendations was assessed by the primary 
researcher at day 7 – 10 or at the point of hospital discharge (whichever came first). 
Further details (e.g. such as study design and patient characteristics) can be found 
in the published papers describing these RCTs [147, 148, 169].   
5.4.2 Data extraction and analysis 
As part of this secondary data analysis, data were extracted from the papers based 
on the RCTs [147, 148, 169], and their associated computerised databases, stored 
locally in Microsoft® Access. The percentage prescriber implementation rates for 
the STOPP and START recommendations were calculated for both RCTs. The chi-
square test was used to compare the prescriber implementation rates of the STOPP 
and START recommendations in the pharmacist and physician intervention groups, 
as well as to quantify any differences between the implementation of STOPP/START 
recommendations and other recommendations included in the pharmacist’s 
intervention. Differences were considered statistically significant where p < 0.05. 




5.5.1 Prescriber implementation of STOPP and START 
recommendations 
Tables 5.1 and 5.2 show the prescriber implementation rates of STOPP and START 
recommendations from the physician and pharmacist respectively, divided 
according to the relevant physiological systems.  
In 360 intervention patients in RCT 1, the physician made 292 STOPP 
recommendations (0.81/patient) and 159 START recommendations (0.44/patient), 
i.e. a total of 1.25 STOPP/START recommendations per patient.  Attending 
prescribers implemented 237 of the physician’s 292 STOPP recommendations 
(81.2%) and 139 of the physician’s 159 START recommendations (87.4%). In 361 
intervention patients in RCT 2, the pharmacist made 255 STOPP recommendations 
(0.71/patient), and 44 START recommendations (0.12/patient), i.e. a total of 0.83 
STOPP/START recommendations per patient. Attending prescribers implemented 
100 of the pharmacist’s 255 STOPP recommendations (39.2%) and 13 of the 








Table 5.1: Prescriber implementation rates for STOPP recommendations: 
physician versus pharmacist 
 
 
STOPP criteria Physician Pharmacist p-value 
Cardiovascular System 22/26   
(84.6%)  
14/26   
(53.9%) 
  0.0162* 
Digoxin at a long-term dose > 125µg  per day with impaired 
renal function 
1/1 -  
Loop diuretic for dependent ankle oedema only 4/6 1/2  
Loop diuretic as first-line monotherapy for hypertension 4/4 0/1    
Non-cardioselective  β-blocker with COPD or asthma  9/9 2/7    
β-blocker in combination with verapamil 1/1 -  
Calcium channel blockers with chronic constipation 2/4 9/11  
Use of aspirin and warfarin in combination without 
histamine H2 receptor antagonist or PPI (high risk of 
gastrointestinal bleeding) 
- 1/4  
Aspirin at dose > 150mg day  - 1/1  
Aspirin without coronary, cerebral, or peripheral arterial 
symptoms or occlusive arterial event 
1/1 -  
Central Nervous System 37/46   
(80.4%) 
15/33   
(45.5%) 
  0.0012* 
Tricyclic antidepressants with dementia 3/3 -  
Tricyclic antidepressants with glaucoma 1/1 -  
Tricyclic antidepressants in chronic constipation 3/3 3/4  
Tricyclic antidepressants in combination with an opiate or 
calcium channel blocker 
1/1 6/8  
Long-term (> 1 month) use of long-acting benzodiazepines 16/25 4/16    
Long-term (> 1 month) use of neuroleptics as hypnotics 4/4 -  
Long-term (> 1 month) use of neuroleptics in those with 
parkinsonism 
2/2 1/1  
Phenothiazines in patients with epilepsy  - 0/1  
SSRIs with a history of clinically significant hyponatraemia  5/5 1/1  
Prolonged use (> 1 week) of 1st generation antihistamines 2/2 0/2    
Gastrointestinal System 85/96   
(88.5%) 
39/118   
(33%) 
< 0.0001* 
Prochlorperazine or metoclopramide with parkinsonism - 1/3  
PPI for peptic ulcer disease at full therapeutic dose for > 8 
weeks 
85/96 38/115  
Respiratory System - 1/3   
(33.3%) 
- 
Theophylline as monotherapy for COPD - 1/1  
Nebulised ipratropium with glaucoma - 0/2  
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Table 5.1 (continued): Prescriber implementation rates for STOPP 
recommendations: physician versus pharmacist 
Musculoskeletal System 15/20   
(75%) 
5/13   
(38.5%)    
  0.0358* 
NSAID with history of peptic ulcer disease or 
gastrointestinal bleeding unless with concurrent H2 
receptor antagonist, misoprostol or PPI 
2/2 -  
NSAID with moderate-severe hypertension 4/6 3/5  
NSAID with heart failure 1/1 0/1  
Long-term (> 3 months) use of NSAIDs for symptom relief 
in mild osteoarthritis 
6/9 1/3  
Warfarin and NSAID together - 1/4  
NSAIDs with chronic renal failure 2/2 -  
Urogenital System 9/12   
(75%) 
3/7   
(42.9%) 
0.1612 
Bladder antimuscarinic drugs with dementia 4/7 1/2  
Antimuscarinic drugs with glaucoma 1/1 -  
Antimuscarinic drugs with chronic constipation 3/3 2/5  
Alpha-blockers in males with frequent incontinence (≥ 1 
episode daily) 
1/1 -  
Endocrine System - 0/1   (0%) - 
β-blockers in those with diabetes mellitus and frequent 
hypoglycaemic episodes  
- 0/1  
Drugs that adversely affect those prone to falls 30/46   
(65.2%) 
12/36   
(33.3%) 
  0.0042* 
Benzodiazepines 19/27 10/26    
Neuroleptic drugs 3/5 1/4  
1st generation antihistamines 2/2 0/2    
Vasodilator drugs in those with persistent postural 
hypotension 
1/1 -  
Long-term opiates 5/11 1/4  
Analgesic drugs 16/18   
(88.9%) 
7/9   
(77.8%) 
0.4436 
Regular opiates for > 2 weeks in those with constipation 
without concurrent laxatives  
12/14 7/9  
Use of long-term powerful opiates as first line therapy for 
mild-moderate pain 
2/2 -  
Long-term opiates in those with dementia unless 
indicated for palliative care or moderate-severe chronic 
pain syndrome 
2/2 -  
Duplicate drug class prescriptions 23/28   
(82.1%) 
4/9   
(44.4%) 






COPD: Chronic obstructive pulmonary disease      PPI: Proton pump inhibitor      SSRI: Selective serotonin re-uptake inhibitor                         




Table 5.2: Prescriber implementation rates for START recommendations: 
physician versus pharmacist 
 
 
START criteria Physician Pharmacist p-value 
Cardiovascular System 29/37   
(78.4%) 
4/15   
(26.7%) 
  0.0005* 
Warfarin with chronic atrial fibrillation 15/18 -  
Aspirin with chronic atrial fibrillation where warfarin is 
contraindicated 
2/3 0/1  
Aspirin or clopidogrel with a documented history of 
atherosclerotic coronary, cerebral or peripheral vascular 
disease in patients with sinus rhythm 
0/2 2/5  
Antihypertensive therapy where systolic blood pressure 
consistently > 160 mmHg 
1/1 -  
Statin therapy with history of coronary, cerebral, or 
peripheral artery disease without contraindication 
8/9 1/3  
ACE inhibitor with chronic heart failure 3/4 1/4  
ACE inhibitor following acute myocardial infarction - 0/1  
β-blocker with chronic stable angina - 0/1  
Gastrointestinal System 1/1   
(100%) 
- - 
Proton Pump Inhibitor with severe gastro-oesophageal 
acid reflux disease or peptic stricture requiring dilatation 
1/1 -  
Musculoskeletal System 97/109   
(89%) 
6/19   
(31.6%) 
< 0.0001* 
Bisphosphonates in patients taking maintenance oral 
corticosteroid therapy 
14/18 1/10    
Calcium and vitamin D supplementation in patients with 
known osteoporosis, fragility fracture or dorsal kyphosis 
83/91 5/9    
Endocrine System 12/12 
(100%) 
3/10   
(30%) 
0.0004* 
Metformin with type 2 diabetes mellitus +/- metabolic 
syndrome 
ACE inhibitor or angiotensin 2 receptor blocker in 
patients with diabetes and nephropathy 
Antiplatelet  therapy in those with diabetes mellitus and 
one or more major cardiovascular risk factors 
Statin  therapy in patients with diabetes mellitus and one 





























In total, attending prescribers implemented 83.4% of the physician’s STOPP/START 
recommendations (376/451) compared to 37.8% of the pharmacist’s STOPP/START 
recommendations (113/299). When comparing the physician and pharmacist 
interventions, there was a statistically significant difference between prescriber 
implementation rates of the total STOPP, total START, and total STOPP/START-
combined recommendations (p < 0.0001).  
Of the ten categories of STOPP criteria, recommendations were made by both 
physician and pharmacist across eight of these categories. The physician achieved 
higher implementation rates than the pharmacist for recommendations across all 
eight STOPP categories, with the absolute differences ranging from 11.1% to 55.5%. 
The largest absolute difference observed was for recommendations based on the 
gastrointestinal system. This was primarily due to the low implementation rate of 
pharmacist recommendations to deprescribe PPIs (38/115), which was the most 
common type of STOPP/START recommendation provided in both RCTs. There were 
statistically significant differences in the implementation rates of recommendations 
across six of the eight STOPP categories, with the exceptions being 
recommendations based on urogenital system drugs and analgesic drugs. Of the six 
categories of START criteria, recommendations were made by both physician and 
pharmacist across three of these categories. The physician achieved statistically 
significantly higher implementation rates than the pharmacist for 
recommendations across all three START categories, with the absolute differences 
ranging from 51.7% to 70%.  
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Of the 65 individual STOPP criteria, recommendations based on 22 of these were 
prevalent in both RCTs. The physician achieved higher implementation rates than 
the pharmacist for recommendations based on 19 of these 22 STOPP criteria, as 
shown in Table 5.1. The pharmacist achieved a higher implementation rate than the 
physician for recommendations based on one of the STOPP criteria – STOPP rule 
A8: “Calcium channel blockers with chronic constipation (may exacerbate 
constipation)”. Of the 22 individual START criteria, recommendations based on 8 of 
these criteria were prevalent in both RCTs. The physician achieved higher 
implementation rates than the pharmacist for recommendations linked to 6 of 
these 8 START criteria, as shown in Table 5.2. The pharmacist achieved a higher 
implementation rate than the physician for recommendations based on one of the 
START criteria – START rule A3: “Aspirin or clopidogrel with a documented history of 
atherosclerotic coronary, cerebral or peripheral vascular disease in patients with 
sinus rhythm”. 
5.5.2 Number of recommendations made and focus of intervention 
Of the 360 patients randomised to the intervention arm in RCT 1, the physician 
made 451 recommendations in 233 patients (1.94 recommendations per patient). 
Of the 361 patients randomised to the intervention arm in RCT 2, the pharmacist 
made 1000 recommendations in 296 patients (3.38 recommendations per patient). 
Thus, for patients where pharmacotherapy recommendations were provided, the 
pharmacist provided 1.44 more recommendations per patient in comparison to the 
physician.   
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In RCT 2, the pharmacist’s STOPP/START recommendations represented almost 30% 
of the total number of recommendations (299/1000), and 51.8% (299/577) of the 
medication appropriateness recommendations (i.e. including drug-drug 
interactions, need for renal and hepatic dose adjustments, and other PIP instances 
identified utilising Beers criteria version 3 [309] and PRISCUS criteria [156]) [169]. 
The remainder of the pharmacist’s recommendations concerned issues with 
medication reconciliation (n = 423), of which 326 were implemented (77.1%). The 
implementation rate of the pharmacist’s recommendations concerning medication 
reconciliation recommendations was approximately double the rate of those 
concerning STOPP/START criteria (77.1% versus 37.8%; p < 0.0001).  
5.5.3 Pharmacist medication reconciliation recommendations based 
on START criteria 
On initial viewing of the START recommendations in both RCTs, it is evident that the 
physician made 3.67 times more START recommendations per patient in RCT 1 
compared to the pharmacist in RCT 2 (0.44 START/patient versus 0.12 
START/patient). The physician did not conduct medication reconciliation, whereas 
the pharmacist did. Therefore, as part of the pharmacist’s intervention, there were 
322 recommendations to prescribe “missing medications” (i.e. medications that 
were prescribed prior to admission but omitted from the patient’s list of 
medications on admission), of which 71 (22.0%) would have been identified by the 
START criteria based on the patients’ lists of prescribed medications on admission 
and comorbidities (Table 5.3). Fifty-eight of these recommendations were 
implemented (81.7%). Prescribers were therefore substantially more likely to 
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implement a recommendation from a pharmacist to initiate a START criteria-based 
drug if it had previously been prescribed by a physician rather than based on the 
pharmacist’s recommendation alone (81.7% versus 29.5%; p < 0.0001).  
If the 71 recommendations to prescribe START criteria-based “missing medications” 
were factored in to the comparison between implementation of physician-delivered 
and pharmacist-delivered STOPP/START recommendations (Appendix 18), the 
physician would still achieve statistically significantly higher implementation rates 
for: 
i) the total START recommendations: 139/159 (87.4%) versus 71/115 (61.7%); 
p < 0.0001, and 
ii) the total STOPP/START recommendations: 376/451 (83.4%) versus 171/370 





Table 5.3: Pharmacist recommendations for “missing medications” identified by 






START-based medication reconciliation recommendations  
Cardiovascular System 22/27 
Warfarin with chronic atrial fibrillation 2/3 
Aspirin with chronic atrial fibrillation where warfarin is contraindicated 4/4 
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, 
cerebral or peripheral vascular disease in patients with sinus rhythm 
7/9 
Statin therapy with history of coronary, cerebral, or peripheral artery disease 
without contraindication 
8/9 
ACE inhibitor with chronic heart failure 0/1 
β-blocker with chronic stable angina 1/1 
Respiratory System 16/20 
Regular inhaled β2 agonist or anticholinergic agent for mild to moderate 
asthma or COPD 
5/7 
Regular inhaled corticosteroid for moderate-severe asthma or COPD, where 
predicted FEV1 < 50% 
11/13 
Central Nervous System 4/4 
Antidepressant drug in the presence of moderate-severe depressive symptoms 
lasting at least three months 
4/4 
Musculoskeletal System 8/12 
Disease-modifying anti-rheumatic drug (DMARD) with active moderate-severe 
rheumatoid disease lasting > 12 weeks 
0/1 
Bisphosphonates in patients taking maintenance oral corticosteroid therapy 1/2 
Calcium and vitamin D supplementation in patients with known osteoporosis, 
fragility fracture or dorsal kyphosis 
7/9 
Endocrine System 8/8 
Metformin with type 2 diabetes mellitus +/- metabolic syndrome 2/2 
ACE inhibitor or angiotensin 2 receptor blocker in patients with diabetes and 
nephropathy 
1/1 
Antiplatelet therapy in those with diabetes mellitus and one or more major 
cardiovascular risk factors 
1/1 
Statin therapy in patients with diabetes mellitus and one or more major 
cardiovascular risk factors 
4/4 
Total  58/71 




5.5.4 Clinical outcomes 
The comparable clinical outcomes from the two RCTs are displayed in Table 5.4. 
The physician’s intervention resulted in an absolute reduction of 9.3% in the 
proportion of patients who experienced a non-trivial in-hospital ADR in comparison 
to the control group, compared to the pharmacist’s intervention which resulted in 
an absolute reduction of 6.8% for this same outcome. The corresponding relative 
risk reductions for this outcome were 44.3% and 32.9% respectively. Neither 
intervention resulted in significant differences in median length of hospital stay or 
mortality when compared to controls.  
Table 5.4: Comparable clinical outcomes between interventions 




Adverse Drug Reactions (ADRs):  
 
Control Patients with ADRs (%) 
 
Intervention Patients with ADRs (%) 
 
Absolute Risk Reduction in patients with ADRs 
 























Median Length of Hospital Stay: 
 
Control Patients (IQR) 
 





8 days (4 – 14)  
 
8 days (4 – 14) 
 
Not stated  
 
 
9 days (5 – 16) 
 
8 days (5 – 13.5) 
 






















p = 0.9 
 
“died during their 
index hospital stay” 





There is a paucity of research comparing pharmacists and physicians in the 
provision of pharmacotherapy recommendations in hospitalised older adults. This is 
the first study to compare prescriber implementation rates of STOPP/START 
recommendations from one approach by a trained clinical pharmacist and another 
approach by a trained physician in geriatric medicine. These results have shown 
that the source of the STOPP/START recommendations and the communication 
methods through which they are provided may have a substantial impact on their 
implementation – it was found that physician prescribers in this particular hospital 
in the Republic of Ireland were statistically significantly more likely to implement 
STOPP/START recommendations from the physician’s approach than from the 
pharmacist’s approach in these two RCTs. There was a greater disparity between 
the two approaches in the implementation of START recommendations (87.4% 
versus 29.5%) compared to the implementation of STOPP recommendations (81.2% 
versus 39.2%).  
A small sample size may have prevented showing statistically significant differences 
in the prescriber implementation rates of certain STOPP or START 
recommendations between physician and pharmacist. Nevertheless, this study has 
demonstrated that the physician obtained statistically significantly higher 
implementation rates than the pharmacist for 10 of the 30 individual STOPP/START 
recommendations present in both interventions, including recommendations to 
deprescribe benzodiazepines and proton pump inhibitors. In recent years, there has 
been extensive research on deprescribing of these drugs in particular [311-314]. 
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The present study is consistent with previous findings that geriatricians may be 
more effective than other healthcare professionals with deprescribing in 
hospitalised older adults [313, 315].  
It is acknowledged that differences between the interventions, other than the 
individual healthcare professionals, may have had an influence on prescriber 
implementation rates, such as: 
i) The pharmacist provided other recommendations, not just STOPP/START 
recommendations like the physician did. 
ii) Both the pharmacist and physician provided all of the recommendations in 
written form. The physician also communicated all recommendations 
verbally, whereas the pharmacist verbally communicated approximately one 
third of these recommendations. 
iii) The physician had previously worked in the hospital prior to RCT 
commencement, whereas the pharmacist had not. 
The physician-delivered intervention was narrowly focused on providing 
recommendations based on the STOPP/START criteria only, whereas the 
pharmacist’s intervention involved the provision of recommendations based on 
STOPP/START as well as a wider range of drug-related problems. As previously 
stated, the pharmacist provided 1.44 more recommendations on average per 
patient than the research physician to attending prescribing teams. A recent 
systematic review suggests that computerised interventions which target a broader 
range of PIP issues in older adults may contribute to information overload, and 
consequently result in fewer recommendations being implemented [251]. Thus, in 
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the present study, the greater complexity of the pharmacist intervention compared 
to the physician intervention may have resulted in a lower implementation rate of 
pharmacotherapy recommendations by attending prescribers.  
Previous studies have shown that pharmacists and physicians prefer the use of 
verbal or face-to-face recommendations when working in collaboration to review 
pharmacotherapy [183, 316]. Recommendations communicated in this way are 
usually implemented at a higher rate than those provided by written means alone 
[317-320]. This suggests that the pharmacist might have achieved higher 
implementation rates if he had provided verbal reinforcement to prescribers 
regarding all the recommendations in the printed report. However, the high 
implementation rate of the pharmacist’s medication reconciliation 
recommendations (77.1%) suggests that the mode of delivery of the pharmacist’s 
recommendations may not have been the primary cause of the observed difference 
in STOPP and START recommendation implementation rates between the 
pharmacist and physician. Moreover, the contrast in implementation between 
pharmacist medication reconciliation recommendations and STOPP/START 
recommendations is noteworthy. This difference suggests that there may be an 
impediment to prescriber implementation of pharmacist interventions relating to 
prescribing appropriateness in older patients, and that physicians may be more 
accepting of the pharmacist’s role in medication reconciliation as distinct from 
prescribing appropriateness alterations.  
Both the pharmacist and the physician were highly familiar with the STOPP/START 
criteria prior to the start of the two RCTs. Previous studies have demonstrated that 
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IRR amongst pharmacists and physicians is high when provided with the same 
clinical information [321, 322]. Therefore, identification of PIP by either healthcare 
professional should not have been different. A key factor in achieving 
implementation of prescribing recommendations may be who provides them, and 
how they are delivered to prescribers. Physicians may be more likely to implement 
recommendations from fellow physicians, as this is customary practice in 
healthcare systems worldwide. Physicians may be less likely to implement 
pharmacists’ recommendations but the reasons for this are not fully understood. A 
qualitative study by Hughes et al. found that some pharmacists felt that doctors 
considered them to be subordinate on a professional level in relation to medication 
issues [323]. In that study, hierarchical differences were implicit in the doctors’ 
comments as they questioned the role of pharmacists in certain areas, such as 
having greater involvement with prescribing decisions, which some doctors viewed 
to be solely within the professional domain of the doctor. The same study 
suggested that this may be because of some doctors’ lack of awareness of 
pharmacist training, as well as some doctors feeling that greater pharmacist 
involvement would encroach on their prescribing role. Most of the studies in this 
area of research are focused on the relationships between pharmacists and 
physicians in primary care, and there appears to be limited research into exploring 
the factors affecting physician implementation of pharmacist recommendations in 
secondary care settings [323-325]. 
Prior to commencement of the RCTs, the research physician had previously worked 
in the same hospital training in geriatric medicine at specialist registrar level. As a 
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result, this particular physician may have already established a good professional 
rapport with some of the attending prescribers prior to RCT 1. This, in turn, may 
have contributed to an increased implementation of the STOPP/START 
recommendations offered by the research physician. In contrast, whilst the 
research pharmacist was experienced in providing pharmaceutical care for older 
adults, he had not previously worked in the hospital where the RCTs were 
conducted. Previous research has highlighted that key components to physician-
pharmacist collaboration are trust and knowing each other [326], and that 
pharmacists who work closely with physicians are more likely to be successful in 
optimising geriatric pharmacotherapy [70]. These interprofessional barriers may 
have contributed to the observed lower implementation rate of the pharmacist’s 
STOPP/START recommendations described in this study. 
Published studies providing details on prescriber implementation of pharmacist and 
physician STOPP/START recommendations are limited. An earlier RCT conducted by 
a physician in the same hospital (where medication appropriateness was the 
primary outcome measure) demonstrated a very high level of prescriber 
implementation of both the STOPP (91%) and START (97%) recommendations [146]. 
Although this intervention took place in the hospital where the STOPP/START 
criteria were developed, it is unlikely that this is the reason for the high 
implementation rates as the criteria are not routinely applied to older patients 
there due to resource constraints. The implementation rates of the pharmacist’s 
STOPP and START recommendations in this present study seem to be lower than 
those described in the literature to date (STOPP: 44% – 94% and START: 58%) [209, 
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327]. Therefore, these results support previous findings which indicate that a lower 
proportion of pharmacist-provided STOPP/START recommendations are 
implemented by prescribers in comparison to those provided by physicians.   
There are some limitations to this study. Firstly, although both the original 
pharmacist and physician interventions encompass STOPP and START 
recommendations, they were not designed to be directly compared. Differences 
between the interventions cannot be ruled out as possible contributing factors to 
the difference in outcomes observed. Secondly, this was a single-centre comparison 
between the prescriber implementation rates of recommendations provided by one 
pharmacist and one physician. Evaluating implementation of STOPP and START 
recommendations from a larger sample of pharmacists and physicians in a multi-
centre RCT setting would provide a more accurate comparison of the professions on 
this matter, as it is acknowledged that different personalities and communication 
styles also vary between individuals, which may impact on the implementation 
rates. 
A cost-effectiveness analysis of the pharmacist intervention has shown that it was 
cost-effective [148]. However, a more recent cost-effectiveness analysis indicates 
that the physician intervention was unlikely to be cost-effective [328], even though 
it was associated with a greater absolute risk reduction in patients with ADRs 
compared to the pharmacist intervention. The present study suggests that a higher 
prescriber implementation rate of STOPP recommendations in particular is 
associated with lower rates of incident ADRs in hospitalised older adults. Therefore, 
it could be argued that the lower implementation rate of some of the pharmacist’s 
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recommendations resulted in a higher rate of incident ADRs in the pharmacist RCT 
intervention cohort. Studies have consistently shown that pharmacists contribute 
to reductions in healthcare costs in the hospital setting [188]. If physicians are less 
likely to be cost-effective in conducting interventions of this type, it is important 
that other ways to enhance the implementation of pharmacist recommendations 
are identified, which reliably lead to further reductions in ADRs, and subsequently 
lower healthcare costs. 
  
5.7 Conclusions 
This study has shown that the methods of communication and the medium through 
which the STOPP/START recommendations are provided may have a significant 
impact on their implementation. Qualitative research is necessary to identify the 
key factors affecting prescriber implementation of hospital pharmacists’ medication 
appropriateness recommendations, along with possible ideas for future 
intervention, as non-implementation of these recommendations may be 





Chapter 6: Factors affecting prescriber 
implementation of hospital pharmacists’ 
medication appropriateness recommendations 
in older adults 
 
 
6.1 Chapter description 
In Chapter 5, a significant difference was shown between the prescriber 
implementation rates of STOPP/START recommendations between one pharmacist 
approach and one physician approach in an acute hospital setting. It was 
highlighted that the method of communication may have been one of the primary 
reasons for this difference in STOPP/START recommendation implementation. 
However, the high uptake rate of the pharmacist’s medication reconciliation 
recommendations suggests that there were other important factors influencing 
prescriber implementation of the pharmacist’s STOPP/START recommendations 
other than the method of communication. In this chapter, I describe semi-
structured interviews with hospital pharmacists and physicians which aimed to 
explore the principal factors affecting prescriber implementation of pharmacist 





Non-implementation of pharmacist recommendations by prescribers may prolong 
PIP in hospitalised older adults, increasing the risk of adverse clinical outcomes. The 
aim of this study was to ascertain the key factors influencing physician prescriber 
implementation of pharmacists’ medication appropriateness recommendations in 
hospitalised older adults.  
6.2.2 Methods 
Semi-structured interviews were conducted with hospital pharmacists and 
physicians who provided care to older adults (≥ 65 years) in two acute university 
teaching hospitals in the Republic of Ireland. Content analysis was employed to 
identify the key themes that influence physician prescriber implementation of 
pharmacist recommendations.  
6.2.3 Results 
Fourteen interviews were conducted with six hospital pharmacists and eight 
hospital physicians between August 2018 and August 2019. Five key factors were 
found to affect physician implementation of pharmacist recommendations: 
i) The clinical relevance and complexity of the recommendation: 
recommendations of higher priority and those that do not require complex 
decision-making are implemented more readily.   
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ii) Interprofessional communication: recommendations provided verbally, 
particularly those communicated face to face with confidence and assertion, 
are more likely to be implemented than written recommendations.   
iii) Prescriber role and identity: the grade, specialty, and personality of the 
prescriber significantly affect implementation.  
iv) Knowing each other and developing trusting relationships: personal 
acquaintance and the development of interprofessional trust and rapport 
greatly facilitate recommendation implementation.  
v) The hospital environment: organisational issues such as documentation in 
the patient notes, having the opportunity to intervene, and the clinical 
pharmacy model all affect implementation. 
6.2.4 Conclusions 
This study provides a deeper understanding of the underlying behavioural 
determinants affecting prescriber implementation of pharmacist recommendations 
and will aid in the development of theoretically-informed interventions to improve 









With their expertise in medications, pharmacists can play a vital role in recognising 
and resolving instances of PIP in multimorbid older patients with polypharmacy 
[147]. Hospital pharmacists’ interventions to improve medication appropriateness 
in older adults have been shown in RCT studies to significantly reduce PIP, ADRs, 
and hospital attendances, including both emergency department visits and 
medication-related readmissions [147, 187, 329]. Pharmacist interventions to 
minimise PIP are often in the form of a recommendation, usually provided to the 
prescriber after reviewing patients’ prescriptions. The prescriber implementation 
rate of these recommendations is commonly used as an indicator to measure the 
success of pharmacist interventions [330]. However, in order for process measures 
such as the rate of prescriber implementation to be clinically valid, it is essential 
that they correlate with positive patient outcomes [331]. Pharmacist interventions 
with a high proportion of medication appropriateness recommendations 
implemented by prescribers are more likely to result in significant improvements in 
patient outcomes compared to those with lower rates of implementation, which 
typically result in non-significant patient outcomes [186, 187, 207, 208].  
It was shown in Chapter 5 that prescribers in an Irish hospital implemented a 
significantly greater proportion of physician-provided STOPP/START 
recommendations in comparison to those provided by a pharmacist (83.4% versus 
37.8%; p < 0.0001) [280]. The physician’s intervention was also associated with a 
greater absolute risk reduction in ADRs (9.3% versus 6.8%). This suggests that 
prescriber non-implementation of pharmacist recommendations may be prolonging 
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PIP in older adults and contributing to preventable ADRs and other adverse patient 
outcomes. However, only very limited qualitative research has been conducted to 
explore the underlying reasons for prescriber non-implementation of pharmacist 
recommendations. Therefore, the aim of the present study was to conduct semi-
structured interviews with pharmacists and physicians in order to determine the 
key factors affecting prescriber implementation of pharmacist recommendations 
that target medication appropriateness in hospitalised older adults. 
 
6.4 Methods 
6.4.1 Context and study setting 
The semi-structured interviews in this qualitative study were conducted in two 
acute university teaching hospitals in the Munster region of the Republic of Ireland. 
At the time of the interviews, pharmacists in both hospitals worked primarily 
according to a ward-based clinical pharmacy model, with pharmacists based on one 
or more assigned wards, reviewing patients under the care of multiple consultant 
physicians. Clinical pharmacy services in both hospitals primarily involved 
pharmacists performing medication reconciliation at admission and conducting 
prescription review throughout patients’ hospital stay, without routine involvement 
at the time of discharge. At the time of the study, pharmacists did not have 




6.4.2 Study design and recruitment 
Ethical approval for this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Cork, Republic of Ireland (Appendix 19). 
This study is reported in accordance with the COREQ checklist (Appendix 20) [258]. 
Semi-structured interviews were chosen as the preferred method of data collection 
in this study as they tend to evoke more in-depth accounts of participants’ 
experiences and perspectives [259]. A sampling matrix was designed to ensure that 
semi-structured interviews were conducted with medical physicians and 
pharmacists with various levels of experience in both hospitals (as shown in Table 
6.1). Previous studies have suggested that the level of experience of the pharmacist 
and the physician are important factors affecting physician implementation of 
pharmacist recommendations [332, 333]. Physicians were ineligible for inclusion if 
they had a pharmacy degree or had previously trained to be a pharmacist. 
Participants were recruited using a combination of convenience sampling and 
snowballing, and the study’s information sheet and consent form were both 









Table 6.1: Sampling Matrix 
Interview participant type 




- Pharmacist < 3 years of hospital pharmacy experience 1 1 
- Pharmacist ≥ 3 years of hospital pharmacy experience 1 1 
- Pharmacist ≥ 5 years of experience with a postgraduate 
qualification in pharmacy 
1 1 
        
Physician   
- Intern* 1 1 
- Senior House Officer+ 1 1 
- Registrar 1 1 




* < 1 year post-qualification experience.    
+
 ≥ 1 year post-qualification experience (usually 2 years in duration after internship).                                
 ≥ 3 years post-qualification experience (the final stage of specialist training prior to eligibility for consultancy). 
 
6.4.3 Data collection 
Separate topic guides with a similar line of questioning were formulated for 
pharmacists and physicians based on the TDF [217], a literature review, and my 
own and my supervisors’ knowledge of the research area (Appendix 21). Each topic 
guide was pilot tested with one participant each, and both were iteratively refined 
during the study where appropriate. All semi-structured interviews were conducted 
by the primary researcher (KD) between August 2018 and August 2019. One 
interview was conducted in a private room at the interviewer’s workplace as this 
was the preference of the interviewee. However, all other interviews were 
conducted in a private room at the participants’ respective hospital sites to 
minimise disruption to their work day. All participants provided written informed 
consent prior to participation. The interviews were audio-recorded and transcribed 
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verbatim. Field notes were documented after each interview so as to inform data 
analysis and topic guide refinement. Data analysis was done in tandem with data 
collection. It was planned in advance that if no new themes emerged in the 
additional three interviews after the eleventh interview (i.e. to complete the 14-
participant sampling matrix), then this would confirm that data saturation had been 
reached [260]. 
6.4.4 Data analysis 
All transcripts were entered into QSR NVivo® Version 11 to facilitate data analysis, 
which consisted of four stages. In Phase 1, transcripts were repeatedly read to 
ensure familiarisation with the data. Phase 2 comprised conventional content 
analysis, whereby open coding was utilised to inductively generate non-hierarchical 
codes [261]. Thereafter, these initial codes were categorised to develop the 
evolving themes. In Phase 3, the TDF was applied to deductively code the 
transcripts and identify the domains present as part of directed content analysis 
[261]. The predominant domains were determined by consensus agreement 
between two researchers (KD and AF), with three elements examined to decide 
this: i) the frequency of beliefs in each domain, ii) the existence of contrasting 
beliefs, and iii) the perceived strengths of the beliefs affecting implementation, as 
per Patey et al. [262]. 
Finally, the evolving themes (from Phase 2) and predominant TDF domains (from 
Phase 3) were evaluated further to subsequently identify the main themes, which 
indicate the key factors that influence prescriber implementation of pharmacists’ 
medication appropriateness recommendations for hospitalised older adults. To 
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ensure validity and reliability in the data analysis, six transcripts were coded by a 
second researcher (AF). All members of the research group were involved in 
refining the final themes presented. 
 
6.5 Results 
A total of 14 interviews were conducted, as per the sampling matrix (Table 6.1). 
Both pilot interviews were included in the data analysis. With regard to hospital-
based experience, half the participants had less than 5 years’ experience, four 
participants had ≥ 5 years’ experience but less than 10 years’ experience, and three 
participants had over 10 years’ experience. Ten participants were female, and the 
mean interview length was 33 minutes (range 18 – 47 minutes).  
6.5.1 Main themes 
Five main themes emerged as the key factors influencing prescriber 
implementation of hospital pharmacists’ medication appropriateness 
recommendations, as described in detail below. Subthemes and quotations have 
been displayed under each main theme to help explain these findings, with 
supplementary quotations available in Appendix 22 to provide further evidence 








Theme 1 – Clinical relevance and complexity of the recommendation  
Clinical relevance in the hospital setting 
Put simply, if it is a relevant recommendation that either clearly benefits the patient 
or prevents patient harm, it will be implemented. 
“...if it’s an implementation that’s going to affect the patient’s acute inpatient 
care, it’ll be implemented”. [Pharmacist 6] 
Priority  
Participants emphasised that physicians’ priorities are primarily to manage patients’ 
acute issues. Depending on how salient the pharmacist recommendation is, and the 
urgency with which it must be addressed, physicians will prioritise the 
recommendations relative to their other work commitments. 
“…it’s probably something that mightn’t be deemed particularly important or 
it’s not going to cause any adverse effect, at least in the short term. You know, 
those kind of things would be slower to be acted upon, maybe because people 
would have graded it in their head as to how important that particular 
intervention is based on other jobs that they have to do that day”.  
[Pharmacist 3] 
Complexity of decision-making 
Recommendations which are not straightforward or not supported by clear 
evidence-based guidelines require greater knowledge and decision-making, thus 
hindering implementation.  
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“...maybe grey areas or where maybe more thought is needed, that’s probably 
where the recommendations mightn’t be followed”. [Pharmacist 3] 
 
Theme 2 – Interprofessional communication 
Route of communication 
Recommendations provided verbally, particularly those delivered face to face, are 
much more likely to be implemented than those that are written. In addition, verbal 
reminders are often required to reinforce the implementation of written 
recommendations, which may not be seen or could even be ignored on their own.  
“I think verbal is better, I think it’s easier to ignore something that’s in the 
chart, as opposed to if you are face to face with someone, I think you take it 
on board more…” [Physician 7] 
Providing recommendations verbally allows for bidirectional discussion, affording 
both the pharmacist an opportunity to clearly explain the rationale for their 
recommendation, and for the physician to clarify their reason for implementation 
or not, facilitating closure of the communication loop. 
“I mean I think the face-to-face stuff can be useful regarding again…because 
there might be a bit more rationalising around why something should be 





Pharmacist manner and language 
Implementation is facilitated by pharmacists displaying confidence, assertiveness, 
and a clear rationale for the recommendation. 
“...if they were to be more assertive in why they have made that 
recommendation or not then we on the medic side might be more inclined to 
take notice, like sit up and take notice of kind of what they’re saying”. 
[Physician 7] 
Participants highlighted that pharmacists often play a ‘corrective role’. While most 
prescribers welcome this input, others may perceive this critiquing to be a 
challenge to their authority. For this assertiveness to not be misconstrued as 
arrogance, pharmacists often adjust their language to avoid conflict with or causing 
offence to physician prescribers, in order to facilitate implementation.  
“...we don’t want to be arrogant either by coming in and saying ‘you are 
wrong’. My recommendations are always ‘consider doing this’, because the 
recommendations I have made are based on this guideline”. [Pharmacist 2] 
 
Theme 3 – Prescriber role and identity  
Personality 
Participants expressed that the physician’s personality may be a factor affecting 
implementation, attesting that some may be open-minded and accepting of 
pharmacists’ recommendations, while others are less receptive to pharmacist 
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advice as it may be perceived as a challenge to their judgement or impingement on 
their prescribing role. 
“We have very supportive physicians, they’re very supportive of pharmacy and 
are very happy to take your recommendations on board and would always 
thank us for flagging things. And then we would have physicians who don't 
like to be questioned on their treatment decisions”. [Pharmacist 2] 
Grade and experience of prescriber 
Most interviewees asserted that junior prescribers would be more likely to 
implement pharmacists’ recommendations. However, it was implied that this may 
be on the basis of blind trust if they are following the recommendation simply due 
to hierarchical influences.  
“I remember back when I was an intern and I would have trusted everybody 
more senior than me, which would have been everyone. So, I might have just 
done it without thinking about it too much...” [Physician 6] 
Conversely, with more complex issues, participants emphasised that junior 
prescribers may be less likely to implement pharmacists’ recommendations, either 
due to a lack of knowledge or skills, or because they are not in a position to decide 
on the patients’ pharmacotherapy, thus deferring responsibility to their senior 
colleagues.  
“I feel like I don’t have the power to make the pharmacy decisions really. So, 




Participants indicated that senior physicians may be more likely to resist pharmacist 
input. Two participants highlighted that this viewpoint among some senior 
physicians may have a ‘trickle-down effect’ influencing their junior colleagues to 
also be dismissive of pharmacist recommendations. 
“...there’ll be a trickle-down effect as well, like if a top manager is going ‘Oh, 
pharmacy who? What are they for?’ Then the intern is going to think ‘Oh well, 
I’m fine without them. I don’t need an opinion from them at all’”. [Pharmacist 
4] 
Specialty 
There was no unanimous agreement on how physician specialty affected 
implementation. Interviewees stated that some physicians were more likely to 
implement such recommendations as they welcomed pharmacists’ expertise 
concerning medications outside of their specialist knowledge. Conversely, it was 
outlined that other specialists felt less comfortable with implementing 
recommendations perceived to be beyond their scope of practice, particularly when 
this may encroach on other prescribers’ areas of expertise.  
“I think they just don’t want to step on people’s toes, or it may be something 







Theme 4 – Knowing each other and developing trusting relationships 
Knowing each other 
Participants indicated that although a physician knowing the pharmacist is not 
essential for implementation, it was strongly emphasised that familiarity enhances 
pharmacist-physician interactions, supports the development of collaborative 
relationships, and ultimately facilitates the routine implementation of pharmacist 
recommendations. However, it was clear from the interviews that pharmacists 
placed a greater importance on knowing each other than the physicians: 
“…it’s definitely important that…they know you I suppose, that they’ve seen 
you around, they know who you are, they know that, you know…they’ve had 
positive interactions with you before definitely I think improves the likelihood 
that they’ll take on board what you have to say”. [Pharmacist 5] 
Relationship-building 
Interviewees conveyed that greater rapport enhances the likelihood of pharmacist 
recommendations being implemented by physicians.  
“…when you have an interpersonal relationship with someone, you’re more 
likely to take on board their opinion, and subsequently maybe implement their 
recommendations”. [Physician 5] 
However, the recurrent medical staff changeovers hinder the longevity of 
pharmacists’ relationships, particularly with more junior physicians. This frequent 
change in personnel necessitates the continual establishment of new pharmacist-
physician relationships.  
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“…the teams change then every two or three months, and you have a whole 
host of new interns and SHOs and things like that but…you’re kind of starting 
from scratch again then maybe with the medical teams a little bit…” 
[Pharmacist 5] 
Trusting pharmacists’ recommendations 
It was indicated that physicians may not be that aware of pharmacists’ training, 
skills, or roles in optimising older adults’ medications, all of which influences trust in 
pharmacists’ recommendations. Building trust usually takes substantial time; this 
can be achieved by pharmacists consistently providing high-quality 
recommendations. 
“I think once you prove yourself to them a bit, they warm to you a bit. I 
suppose it would be the same as any new doctor. They’d be slow to trust you 
until there’s trust there”. [Pharmacist 1] 
In addition, participants affirmed that when trust has been established the 
physician may be more likely to approach pharmacists for advice and implement 
their recommendations. 
“…and then over time, I think, as you’re there and you get to know people 
more that they come to you with questions…” [Pharmacist 6] 
Theme 5 – The hospital environment 
Timing and opportunity 
Even though most participants expressed that face-to-face discussion was their 
preferred method of communication, this is not always possible in the busy hospital 
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environment. There can be challenges with meeting physicians in person due to 
busy schedules, and there is not always a clear opportunity for pharmacists to 
discuss recommendations face to face, thus often relying on impromptu 
encounters. Furthermore, many pharmacists indicated that implementation would 
be facilitated by pharmacists having a prescheduled time to discuss their 
recommendations, such as a ward round or multidisciplinary team meeting. 
“…unless you’re on a round with them, it’s difficult to find [an opportunity to 
meet] afterwards. You’re running around bleeping people, nosing into 
doctors’ rooms to see if someone is in there…so it can be…it can make it 
difficult”. [Pharmacist 4]  
Documentation in the medical records 
The medical case notes may not always contain sufficient information about the 
physicians’ plan for the patient – this can result in pharmacists making 
recommendations that are of lower relevance or not in line with the physicians’ 
treatment plan. 
“…the pharmacist may be recommending or fairly concerned with things 
whereas we may not be concerned with things because our goal of care may 
have changed, and that sometimes doesn’t come across that well in the chart. 
You know, it may not be clearly flagged as…we don’t always write down that 





Working as a team 
Participants indicated that the pharmacist may often be perceived as an ‘outsider’, 
and stated that pharmacists who work closely with physicians as part of a team 
would have more recommendations implemented as physicians know these 
pharmacists better and have had time to build trusting relationships. 
“You know it’s so much better to work with the physicians as a team rather 
than work with them in isolation on the ward. They don’t get to know you. 
They don’t build a relationship”. [Pharmacist 6] 
Staffing levels and pharmacist presence 
A common thread throughout the transcripts was pharmacist staffing levels; a 
greater pharmacist presence would increase accessibility to physicians and face-to-
face discussions, and allow more time for collaborative teamwork.   
“Also, the fact that we’re not fully resourced; if we had more presence on the 
wards and more presence with teams, I think the likelihood is that we would 
have…recommendations would be taken up probably much more quickly and 
much more easily because you would be more readily available to the team to 
discuss matters” [Pharmacist 3] 
6.5.2 Predominant TDF domains 
Six domains were identified as predominant in affecting physician prescriber 
implementation of pharmacist recommendations (Table 6.2), and these were 
pervasive in the five main themes depicted. Some of the supporting quotations may 
illustrate more than one TDF domain due to overlap between the constructs.
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Table 6.2: Behavioural determinants affecting implementation of pharmacist 


















“But if it was a risk, so if there were an interaction that puts 









“…I think meeting as opposed to opportunistically trying to 
find the team on the ward…” [Physician 2] 
 
“I think the fact that a lot of our recommendations are made 
retrospectively or they are very reactive, I think if you were 
there at the point of prescribing, the likelihood is that you 






“Oh, face to face, they’ll do it, they get your point. They’ll do 
it straight away, and leaving a note - it can just fall by the 










“Good rapport always helps. If you know the same 
pharmacist and you are working with them all the time, I 
think that benefits, like that definitely helps”. [Physician 1] 
 
 
Alienation –  
‘outsider’ 
 
“A lot of the time the team isn’t around when you’re 
reviewing the chart so you’re leaving notes and that kind of, 
the communication isn’t there, they might not actually 
recognise you when you do come up to them, so you’re just, 






“I think everything is like top-down approach like. If juniors 
don't see kind of their superior buying into it, if they almost 
see them ignoring it totally – ‘oh we’ll disregard that’. I'm 
sure that has a knock-on effect…” [Physician 4] 
 
“I think any of the consultants I have worked with have been 
very open to pharmacist intervention and discussion with 
them as well. So, I would have no problem ever discussing 




Table 6.2 (continued): Behavioural determinants affecting implementation of 














Role and Identity 
 




“That may be around grade too often; a lot of this is 
consultant-driven. So, a registrar and SHO may not feel 








“…it depends then individually, if they might be very 
willing to listen or they might just be a little bit like ‘No, 
you don’t, this is my patient, it’s nothing to do with you’ 






“I would imagine personality may come into it here and 
our self-belief may come into it a bit. And you know, look 
I’ve certainly worked with doctors who pay lip service to 











“I think physicians are so busy, they…it’s not something 
that’s on their radar when a patient presents to an acute 






“So I think the more straightforward ones where the 
guidelines are very clear are acted on probably quicker 
and it’s easier for people to make a decision around 








“I think someone with experience would be more able to 
actually be making an informed decision” [Physician 3] 
 
“I think it’s probably the lack of experience is twofold: they 
can take on recommendations quite readily, but other 
times with more difficult decisions that have to be made 
that may be a little bit more difficult, they might need to 




Table 6.2 (continued): Behavioural determinants affecting implementation of 

















“I think the more knowledge that you have, in terms of 
pharmacology, you’d be more likely to make your own 






“…the pharmacy had flagged it [i.e. the potentially 
inappropriate medication] and suggested maybe we start 
to wean her off it but I suppose I wasn’t sure how to go 
about weaning [the older patient] off it. So, in that case I 
kind of held off until I had spoken to somebody more 






“I think that, say, if you were a cardiologist, they know 
lots and lots about cardiology drugs but outside of that, 





Goal of care 
 
“I think people are too busy, too busy to [examine older 
patients’ medications]…just focusing on getting…treating 
the presenting complaint and getting the patient in and 




“…sometimes it’s very minor discrepancies, like for 
example do you know like a half or a full dose PPI or 
something like that, that you might, you know, just put at 
the end of your to-do list because you’re busy and you 
might…you know, so you don’t prioritise it”.  [Physician 3] 
 
 






Even though interprofessional relationships and communication between 
pharmacists and physicians have been widely investigated by previous researchers 
[323-325], limited qualitative research has been conducted in the hospital setting, 
particularly when it comes to investigating the behavioural determinants underlying 
physicians’ implementation of pharmacist recommendations. The present study is 
the first to explore the views of pharmacists and physicians regarding the key 
factors affecting physician implementation of pharmacists’ medication 
appropriateness recommendations for hospitalised older adults.  
These findings echo those of previous studies which have shown that face-to-face 
communication is a key facilitator to physician implementation of pharmacist 
recommendations [207, 334, 335]. Synchronous bidirectional discussion and face-
to-face contact have been shown to be important components in developing 
collaborative working relationships between pharmacists and physicians [183, 336, 
337]. Conversely, written communication lacks synchronicity, and is infrequently 
bidirectional between pharmacists and physicians, and may contribute to further 
ambiguity [338, 339]. This study reiterates that written recommendations from 
pharmacists are less likely to be implemented by prescribers [317]. However, this 
may be confounded by the fact that less urgent recommendations are often 
communicated in written form, and therefore may not be implemented as readily 
[340].  
In line with previous research, most participants expressed a preference for face-to-
face delivery of pharmacist recommendations [339]. However, this method of 
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communication is hampered by the difficulty in finding prescribers and speaking 
face to face in the busy hospital environment. Previous research has shown that 
interprofessional discussions in hospitals are most commonly brief, unstructured, 
and opportunistic interactions [341-343]. However, many of our participants 
emphasised the value of having scheduled times to meet (e.g. at ward rounds or 
multidisciplinary team meetings), rather than solely relying on spontaneous 
interactions, which may interrupt workflow and increase the risk of error [339, 
344]. Involvement with ward rounds affords pharmacists the opportunity to 
proactively minimise or prevent PIP rather than the traditional reactive role, 
whereby pharmacists retrospectively review patients’ prescriptions after the initial 
prescribing decisions have been made [345]. Pharmacist involvement in ward 
rounds has been shown to increase medication appropriateness and reduce 
preventable ADEs [346, 347]. However, even with face-to-face communication, 
implementation may be hindered if the receiver of the recommendation is not a 
‘decision-maker’ on the attending medical team [300].  
Previous research has suggested that pharmacists’ grade significantly affects 
physician implementation of hospital pharmacist recommendations [332]. 
However, the present study did not find this to be a key determinant of 
implementation, but it was clear from the interviews that this may be influenced by 
physicians’ lack of awareness of the specific aspects of pharmacist training and 
experience [348]. In contrast, these findings have reemphasised that a physician’s 
experience and grade, as well as some physicians’ ingrained sense of the traditional 
hierarchy, significantly affect the implementation of pharmacist recommendations 
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[183, 333]. Thus, it is not surprising that ‘Social Influences’ appeared as one of the 
predominant TDF domains throughout the interviews. Senior physicians are less 
likely to be interested in developing collaborative relationships with others who 
they perceive to be subordinate or challenging their prescribing decisions [323, 
324]. In order to facilitate implementation, pharmacists often employ indirect 
communication strategies (e.g. gentle reminders, suggestions, questions) to avoid 
conflict or embarrassment and to prevent provoking defensive behaviour from 
physicians [183]. A hierarchical culture such as this impedes teamwork in 
healthcare [349]. Interprofessional education has been suggested as one strategy to 
enhance collaboration between healthcare professionals. However, further 
evidence is required to demonstrate its effectiveness in fostering the development 
of effective interprofessional healthcare teams with improved patient outcomes 
[350-352].  
Participants affirmed that pharmacists working in close collaboration with 
physicians as part of a team would facilitate implementation of pharmacist 
recommendations. Successful interventions of this nature commonly involve 
pharmacists working closely with medical staff [182, 329, 353]. A previous study in 
an Irish hospital has shown that a team-based pharmacist approach was associated 
with a significantly higher proportion of recommendations being implemented 
compared with standard ward-based pharmaceutical care (95.9% versus 69.3%), 
and the same study also resulted in a significant improvement in medication 
appropriateness for the team-based pharmacist interventions only [204]. 
Moreover, the team-based pharmacist recommendations were also implemented 
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earlier compared to ward-based pharmacist recommendations, which may be vital 
in the prevention of ADRs [204]. However, team-based models can be less efficient 
with pharmacist time as in these models pharmacists may not be able to review the 
same number of patients, and also may affect collaboration with other healthcare 
professionals, such as nurses [354]. 
Working together as a team allows for pharmacists and physicians to get to know 
each other and their professional roles, to develop rapport, and to build up mutual 
trust in clinical judgement [326, 355]. Trust is fundamental to successful 
pharmacist-physician relationships [356]. The present findings reaffirm that 
physicians’ trust in pharmacists may be developed through the consistent delivery 
of useful recommendations [355]. Evidence of this trust may be exhibited by 
physicians asking pharmacists for their particular input to patient management. 
However, this advice-seeking behaviour may also be facilitated by ready 
accessibility to pharmacists [357]. 
In the present study, it was reemphasised that the recurrent staff changeover in 
hospitals can make it challenging to develop and maintain long-lasting relationships 
between pharmacists and physicians [358]. Therefore, it would seem prudent for 
pharmacists to develop strong relationships with senior physicians who usually 
have a long residence time in the hospital. Senior prescribers modelling trust with 
pharmacists should have a ‘trickle-down effect’, as two interviewees described, to 
influence junior prescribers to trust pharmacists and implement their 
recommendations [358].  
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Identification of the predominant TDF domains in this study has provided a greater 
understanding of the underlying behavioural determinants related to prescriber 
implementation of pharmacist recommendations. Further research is required to 
develop theoretically-informed interventions that aim to change the behaviour of 
pharmacists and physicians in order to enhance implementation of pharmacist 
recommendations to improve prescribing appropriateness. 
6.6.1 Strengths and limitations 
The TDF was utilised in formulating the topic guides and in analysing the transcripts; 
it has been shown that interview studies based on this framework can reveal 
additional themes compared to those without a theoretical basis [284, 285]. All 
interviews were conducted by the same researcher, which allowed for consistency 
in both data collection and analysis. Participants were aware that the interviewer 
was a pharmacist, but it was emphasised to physician participants that they should 
strive to see the interviewer in his role as a researcher aiming to gain a greater 
understanding of their views. While the risk of social desirability bias must be 
acknowledged, it did not seem to appear as a significant issue given the honest 
views and opinions provided, describing both positive and negative experiences 
with hospital pharmacists. 
The transferability of the study findings may be questioned given that the 
interviews were conducted in just two acute university teaching hospitals in one 
geographical area of the Republic of Ireland. Given that different clinical pharmacy 
models or different practices exist, these findings may not necessarily reflect all the 
key factors affecting prescriber implementation of pharmacist recommendations in 
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other hospital settings in the Republic of Ireland or in other similar countries. 
Future work should aim to  investigate this issue in settings with other clinical 
pharmacy models and, with the increasing prevalence of computerised systems in 
hospitals, further qualitative research is necessary to explore the factors affecting 
implementation of pharmacist recommendations communicated via electronic 
means [359].  
 
6.7 Conclusion 
There are a number of barriers to prescriber implementation of hospital pharmacist 
recommendations aiming to improve medication appropriateness in older adults. It 
is imperative that a high proportion of such recommendations is implemented in 
order to achieve better patient outcomes. This study has generated a greater 
understanding of the key factors affecting prescriber implementation of pharmacist 
recommendations, and will help inform both the design of future pharmacist 
interventions aimed at improving the appropriateness of prescribing in hospitalised 








                     
Chapter 7: Discussion 
 
7.1 Chapter description 
This chapter firstly presents a summary of the thesis findings, focusing on the novel 
aspects of the research. Following this, an overview is provided of the key factors 
affecting prescriber implementation of medication appropriateness 
recommendations in hospitalised older adults, with a discussion of these findings in 
the context of the published literature. Thereafter, the overall strengths and 
limitations associated with this body of work will be described. Finally, the 











7.2 Summary of findings 
In the introduction to this thesis, it was highlighted that there is no accepted 
optimal strategy to minimise PIP in hospitalised older adults. Consequently, the 
prevalence of PIP remains unacceptably high, placing these older patients at 
significant risk of adverse outcomes. A large number of intervention studies have 
been conducted which involved the provision of recommendations to hospital 
prescribers aiming to reduce PIP in older adults. From these studies, it is evident 
that interventions with higher prescriber implementation rates of these 
recommendations are more likely to result in significant improvements in both 
medication appropriateness and patient outcomes [186, 187, 207, 208]. 
Irrespective of the impact of these interventions, most studies with low prescriber 
implementation rates have not investigated the reasons underlying the reduced 
uptake of recommendations with any rigour [207, 208]. With this gap in the 
literature, this doctoral research investigated the key determinants underlying 
prescriber implementation of medication appropriateness recommendations 
related to older patients’ pharmacotherapy, focusing primarily on the 
implementation of pharmacist-provided and computer-generated 
recommendations. 
The first novel outcome of this thesis was the production of a systematic literature 
review and meta-analysis on the effectiveness of computerised interventions 
designed to minimise PIP in hospitalised older adults [251]. Previous reviews had 
gathered evidence across different healthcare settings [198, 199], but the 
systematic review described in Chapter 2 has filled an important knowledge gap in 
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the literature as it was the first conducted specifically related to interventions in the 
hospital setting. The main finding was that these interventions can significantly 
reduce PIP in hospitalised older adults compared to control (p < 0.05). However, the 
systematic review also showed that computerised interventions do not routinely 
result in significantly improved patient outcomes. Three of the nine included 
studies assessed the intervention’s impact on patient outcomes, with statistically 
significant improvements in two of seventeen patient outcomes assessed – one 
study showing a reduction in ADEs and the other a reduction in inpatient falls.  
Five studies reported the prescriber implementation rates of the computer-
generated recommendations, ranging widely from 22.5% to 95%. Interestingly, it 
was more common for interventions that targeted fewer PIMs to have higher 
implementation rates. Although not extensively investigated in any of the included 
studies, three articles provided reasons for prescriber non-implementation of 
recommendations to discontinue PIMs, including:  
i) patient was tolerating the PIM,  
ii) PIM was clinically indicated, or 
iii) no suitable alternative available (to the PIM).  
This systematic review allowed for a greater understanding of the particular 
research area in advance of conducting the studies related to computer-generated 
recommendations, as described in Chapters 3 and 4. In particular, the description of 
the computerised interventions and the reasons for prescriber non-implementation 
of computer-generated recommendations helped inform the development of the 
topic guides for the semi-structured interview study described in Chapter 3. This 
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qualitative study utilised the TDF to help ascertain the key factors that affected 
prescriber implementation of the SENATOR trial intervention’s recommendations. 
In Chapter 3, interview participants revealed that implementation of 
recommendations depended on some individual prescriber characteristics, such as 
prescriber experience, specialty, and the prescriber’s attitude towards research 
studies. Implementation was facilitated by provision of the recommendations to a 
‘decision-maker’ in the prescribing team. In addition, the interviewees asserted that 
the hospital environment played a role in the low implementation rates. 
Recommendations were often not acted upon due to the patient’s acutely ill status 
in the hospital setting, and that it may be preferable to make changes in a non-
acute setting when the patient is more stable. Furthermore, the recommendations 
were mostly not provided to prescribers at the time of patient review, thus 
hindering their implementation. 
The most pervasive perception among the interviewees was that the clinical 
relevance of the computer-generated SENATOR recommendations was a key factor 
affecting their implementation. Quite simply, if recommendations were not 
considered relevant, they would not be implemented. Furthermore, 
recommendations of low relevance contributed to prescriber fatigue with the 
intervention. This meant that even recommendations of greater relevance may 
have been ignored, preventing their implementation. 
In comparison to the other key factors affecting implementation of the SENATOR 
recommendations, the clinical relevance of recommendations can be measured. 
Thus, the findings from Chapter 3 led us to conduct a retrospective evaluation of 
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the clinical relevance of computer-generated STOPP/START recommendations from 
the SENATOR intervention, and thereafter assess for any association between 
relevance and the rate of implementation. As part of this study, as described in 
Chapter 4, the clinical relevance of all STOPP/START recommendations that were 
provided to prescribers caring for the 204 intervention patients in Cork University 
Hospital, the lead site in the SENATOR trial, were evaluated. This study was novel in 
that it was the first study to: 
i) evaluate the clinical relevance of computer-generated STOPP/START 
recommendations, and  
ii) use a validated scale to assess the clinical relevance of computer-generated 
medication appropriateness recommendations for hospitalised older adults.  
In this study, it was found that nearly three quarters of the recommendations were 
clinically relevant (73.6%), with the remainder judged to be either of ‘no clinical 
relevance’ (21.5%) or of potential ‘adverse significance’ (4.9%) if implemented. 
However, of the clinically relevant recommendations, nearly half of these were of 
‘possibly low relevance’ (47%). Furthermore, when examining the association 
between clinical relevance and implementation, it was found that 
recommendations of higher clinical relevance were significantly more likely to be 
implemented than those of lower clinical relevance (p < 0.05). Therefore, this 
chapter corroborated the qualitative findings from Chapter 3, whereby the clinical 




The second aim of this thesis (as shown in Figure 1.1) was to identify the key 
determinants influencing prescriber implementation of pharmacist-provided 
recommendations to improve medication appropriateness in hospitalised older 
adults. Prior to undertaking qualitative research to investigate this issue (as detailed 
in Chapter 6), I compared two similar interventions – one pharmacist-led and the 
other physician-led – that involved the provision of STOPP/START 
recommendations to prescribers aiming to reduce PIP and associated ADRs in 
hospitalised older patients. This study, as described in Chapter 5, was the first to 
compare implementation rates of STOPP/START recommendations between a 
pharmacist and a physician [280]. 
Prescriber implementation of physician-provided STOPP/START recommendations 
was found to be significantly higher than those provided by a pharmacist (83.4% 
versus 37.8%; p < 0.0001). Furthermore, these results suggested that higher 
implementation rates of recommendations may be associated with better patient 
outcomes – the physician’s intervention had a higher proportion of STOPP/START 
recommendations implemented and resulted in a greater absolute risk reduction in 
patients with ADRs in comparison to the pharmacist’s intervention (9.3% versus 
6.8%). This study also identified intervention components that may have influenced 
the prescriber implementation rates of pharmacist recommendations, namely the 
method of communication utilised, the type of the recommendation made, and 
personal acquaintance with the prescriber. These findings were used to inform the 
topic guide development for the semi-structured interviews with hospital 
pharmacists and physicians conducted in Chapter 6.  
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Although several studies have explored interprofessional relationships between 
pharmacists and physicians [323-325], the final research chapter is novel in that it 
describes the first study to explicitly elucidate the factors affecting prescriber 
implementation of hospital pharmacist medication appropriateness 
recommendations. The findings in this study echo some of those described in 
Chapter 3, reaffirming that environmental barriers (e.g. communications methods 
utilised and intervention timing), individual prescriber characteristics (e.g. 
experience, specialty, and personality), and the clinical relevance of the prescribing 
advice all significantly affect the implementation of medication appropriateness 
recommendations by hospital physician prescribers. 
It was suggested in Chapter 5 that one reason contributing to non-implementation 
of pharmacist recommendations was lack of personal acquaintance with the 
physician. This hypothesis was supported by interviewees in Chapter 6, who 
indicated that although knowing each other is not essential, it does however greatly 
enhance rapport and the likelihood of recommendation uptake. In addition, the 
findings in Chapter 6 emphasised the important influence that the medical 
hierarchy has on implementation of pharmacist recommendations. Junior 
physicians are likely to seek advice from their senior physician colleagues as part of 
the decision-making process to implement pharmacist recommendations. This 
implies that physicians often trust their colleagues’ advice over that of pharmacists, 
which perhaps further explains the significantly lower implementation rate of 
pharmacist-provided recommendations in comparison to physician-provided 
recommendations found in Chapter 5.  
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Six TDF domains appeared as predominant in influencing prescriber 
implementation of medication appropriateness recommendations in each of the 
qualitative studies (Chapters 3 and 6). Five of these predominant domains were 
common to both studies, namely: ‘Environmental Context and Resources’, 
‘Social/Professional Role and Identity’, ‘Memory, Attention and Decision Processes’, 
‘Knowledge’, and ‘Goals’. By mapping these predominant domains to the BCW, this 
may help identify intervention functions that could be utilised to enhance 
prescriber implementation of recommendations to improve medication 
appropriateness.   
The ‘Social Influences’ domain appeared as predominant in influencing prescriber 
implementation of pharmacist recommendations, but this was not the case for the 
computer-generated SENATOR recommendations. This is perhaps unsurprising due 
to the importance that has been previously attributed to the interpersonal 
processes between pharmacists and physician prescribers [360, 361]. Conversely, 
the ‘Intentions’ domain appeared as predominant in affecting prescriber 
implementation of the SENATOR recommendations, but not for the pharmacist 
recommendations in Chapter 6. As highlighted in Chapter 3, this may be due to 
prescribers’ lack of intrinsic motivation to engage with a research trial intervention, 
whereas there may be greater intentions to engage with pharmacist interventions 
as they have been proven to be effective in improving the appropriateness of 




                     
7.3 Key factors affecting prescriber implementation of 
medication appropriateness recommendations in 
hospitalised older adults 
The factors identified by this body of doctoral research to be key in affecting 
prescriber implementation of medication appropriateness recommendations are as 
follows:  
i) Clinical relevance of the recommendation.  
ii) Method of communication and integration into prescriber workflow. 
iii) The hospital environment.  
iv) Prescriber identity.  
v) Source of the recommendation.  
Whilst the quantitative research components of this thesis allowed us to make 
statistical inferences on specific factors affecting implementation, the deeper 
insights into these issues are primarily underpinned by the two qualitative 
studies described in Chapters 3 and 6. Given the complexity associated with 
prescribing for older adults in the hospital setting, this thesis aimed to robustly 
identify the salient factors affecting implementation of these recommendations, as 
it would be impossible to detail each underlying determinant of this issue. The 
factors outlined above contain elements that are inextricably interlinked, and will 




7.3.1 Clinical relevance of the recommendation 
Participants in both qualitative studies (Chapters 3 and 6) emphasised that the 
clinical relevance of the recommendations was key to implementation. 
Recommendations that are important in the clinical context of the patient are more 
likely to be implemented; for example, if they are related to the acute admission 
and/or would undoubtedly prevent or ameliorate medication-related harm. 
Similarly, it was suggested that the low implementation rate observed in the 
pharmacist intervention described in Chapter 5 may have been due to 
recommendations that were of low relevance at the time of the intervention [169]. 
Whilst previous studies have assessed the clinical relevance of pharmacist 
recommendations or computer-generated recommendations [289, 293-295, 307], 
very few studies actually prove that clinical relevance is the likely reason for non-
implementation. However, in this thesis, the participant insights from the interview 
studies have been corroborated by the novel quantitative findings in Chapter 4, 
whereby the clinical relevance was shown to significantly influence the 
implementation rate, i.e. recommendations of higher clinical relevance were 
significantly more likely to be implemented than those of lower clinical relevance  
(p < 0.05).   
However, recommendations of low clinical relevance can also have an effect on the 
implementation of recommendations of high clinical relevance. Large numbers of 
recommendations of low relevance may cause prescribers to experience fatigue 
with the intervention – for computerised interventions, this is a well-documented 
phenomenon called ‘alert fatigue’ [194], possibly resulting in clinically important 
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recommendations being ignored. This may have been the case with the findings in 
Chapter 4, as it was observed that even recommendations judged to be of ‘possibly 
very important relevance’ were still not implemented approximately 30% of the 
time. 
7.3.2 Method of communication and integration into prescriber 
workflow 
As indicated above, these factors affecting implementation are often 
interconnected. With regard to pharmacist interventions, it should be noted that 
the clinical relevance of the recommendation often dictates the method of 
communication used to contact the prescriber [317]. Recommendations of high 
importance that require urgent resolution will necessitate swift communication, 
usually using verbal methods – via telephone, or preferably face to face if the 
prescriber is present. There is less urgency to resolve issues of lower relevance; this 
may result in the pharmacist providing the recommendation in writing or delaying 
the recommendation until the next opportunity to discuss with the prescriber. As 
written recommendations usually have lower implementation rates than verbal 
recommendations [317, 318], this may be a confounding factor affecting the 
implementation of recommendations of lower relevance. Thus, one reason 
postulated for significantly reduced implementation rates for recommendations of 
lower relevance may be the method of communication used. 
In Chapter 5, it was suggested that the proportion of the pharmacist’s 
recommendations implemented was significantly lower than the physician’s due to 
the method of communication used. Only one third of the pharmacist’s 
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recommendations were communicated verbally, whereas all the physician’s 
recommendations were communicated in this manner. This theory was supported 
by interviewees in Chapter 6, who affirmed that not only did face-to-face 
communication enhance the rate of implementation, but it was also the preferred 
method of communication by both pharmacists and physicians as it facilitated 
synchronous bidirectional discussion [111, 355, 362-364]. Face-to-face 
communication is usually deemed the most effective method to facilitate 
implementation of these recommendations [360, 365].  
Whilst the method of communication used appears to be important, it is also 
paramount that provision of prescribing recommendations is integrated into 
prescriber routine workflow. In Chapter 6, interviewees emphasised that better 
integration of pharmacists’ recommendations into prescribers’ workflow may 
require the organisation of scheduled discussions between pharmacists and 
physicians (e.g. as part of multidisciplinary team meetings) or pharmacist 
involvement in physicians’ ward rounds. Research has shown that pharmacist 
participation in consultant physician-led ward rounds can significantly add to the 
implementation rates of pharmacist recommendations [366]. Furthermore, the 
findings in Chapter 3 emphasised the importance of the timing of the 
recommendations – those provided to prescribers at a time when they are not 
reviewing the patient are much less likely to be implemented [333]. Thus, 
computer-generated pharmacotherapy recommendations within an EHR should 
ideally be provided at the point of prescribing or at the time of patient review to 
facilitate implementation [367].  
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7.3.3 The hospital environment 
Environmental barriers within the hospital setting can prevent the review and 
implementation of recommendations to optimise medication appropriateness. As 
previously mentioned, face-to-face communication usually achieves the highest 
implementation rates, but this is not always possible in busy acute hospital wards 
[368]. Pharmacists and physicians may not be physically present on the ward at the 
same time to discuss recommendations face to face. Furthermore, there can be 
difficulties in contacting prescribers via telephone, and written recommendations in 
the patients’ clinical notes may be overlooked [369].  
The implementation of pharmacist recommendations can be influenced by the type 
of pharmaceutical care model that exists in individual hospital settings. In Chapter 
6, it was clear that both pharmacists and physicians felt that pharmaceutical care 
models with pharmacists and physicians working together on the same clinical care 
team were likely to have higher implementation rates of pharmacist 
recommendations compared to those without pharmacists integrated into the 
team. Previous research has shown that this team-based pharmacist approach not 
only increases the implementation rate significantly, but it can also result in earlier 
implementation of recommendations [204]; swifter implementation may be vital in 
the prevention of particular ADRs.  
Participants in Chapters 3 and 6 questioned whether the hospital environment was 
the right place to optimise the appropriateness of prescribing for older adults, as 
the acute setting does not always facilitate the review of patients’ chronic 
medications [76]. Certain types of recommendations may be less likely to be 
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implemented in hospital; for example, recommendations to discontinue or taper 
benzodiazepines may be more appropriate for a setting where the patient is 
clinically stable, e.g. in primary care. In the qualitative studies, patient preference 
did not appear as one of the key factors affecting implementation. However, in a 
non-acute environment, such as the general practice setting, patient preference 
and involvement are likely to be much more influential [370, 371]. 
From this doctoral research, it is evident that prescribers do not always view 
recommendations addressing medication appropriateness as a priority in the acute 
hospital setting. Hospital prescribers’ busy workload, which is often characterised 
by severe time constraints, may prevent a thorough medication review being 
performed for every patient [111]. In addition, many indicated that there is a 
culture within hospital settings for prescribers to primarily focus on the patients’ 
acute illness and/or issues related to their own particular specialty [372, 373]. In 
Chapter 6, participants indicated that senior prescribers’ compliance with such 
prescribing norms has a substantial influence on junior prescribers’ behaviour 
[374]. Junior prescribers are less likely to implement recommendations that 
contravene the prescribing norms within their specialty team or within their 
hospital setting [375]. This lack of a holistic approach to older patients’ care in 
hospital settings is a fundamental barrier to implementing these recommendations 
and optimising pharmacotherapy.  
7.3.4 Prescriber identity 
In this thesis, it was clear that that the roles of individual prescribers and their 
professional identity have a significant effect on the implementation of medication 
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appropriateness recommendations. Interview participants in Chapters 3 and 6 
asserted that prescriber specialty is an important determinant of implementation; 
specialists who do not have specific expertise in geriatric pharmacotherapy may be 
hesitant to make changes to medications that are outside their specialist field of 
knowledge. Similar to previous research, participants stated that some prescribers 
believe that they are responsible for managing medications solely within their 
specialty, and that dealing with other prescribing issues is not within their remit 
[376]. Furthermore, interviewees described specialists’ reluctance to interfere with 
medications that had been prescribed by a colleague or other specialist [377, 378].  
It was clearly evident that prescriber experience is an important factor affecting the 
implementation rate of recommendations aimed at optimising medication in older 
adults, which concurs with previous research [379]. However, conflicting views 
were expressed by interviewees regarding this issue. Some participants suggested 
that higher implementation rates may be seen amongst junior prescribers as they 
are more likely to trust the source of the recommendations to be reliable – a lack of 
clinical knowledge may prevent them from distinguishing between clearly correct 
and incorrect recommendations [375]. Contrastingly, another common belief was 
that junior prescribers were less likely to implement recommendations. Irrespective 
of their knowledge or skills, it was indicated that junior prescribers may be more 
hesitant to change pharmacotherapy independently – either because they do not 
accept the role as the ‘decision-maker’, or because of fear of negative patient 
consequences or criticism from their senior colleagues, often resulting in no action 
being taken in response to particular recommendations [273].  
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This sense of clinical inertia was also indicated in the systematic review (Chapter 2), 
whereby the most common reason for non-implementation of computer-generated 
recommendations was that the patient was already tolerating the PIM [251]. 
Previous qualitative research has conveyed this ‘don’t rock the boat’ approach 
when it comes to making changes to older patients’ pharmacotherapy [380, 381]. 
Furthermore, in accordance with existing research, my findings accentuate the 
importance of providing medication recommendations to a ‘decision-maker’ [271], 
i.e. usually a senior member of the prescribing team. However, this ‘decision-maker’ 
status is not simply a function of experience and hierarchy [375]; it is also a 
reflection of prescriber knowledge, training, and self-efficacy [273]. 
7.3.5 Source of the recommendation 
It was evident from this thesis that the source of medication appropriateness 
recommendations has a substantial impact on the implementation rate. This was 
distinctly conveyed by the marked contrast in implementation rates of physician-
provided recommendations and pharmacist-provided recommendations 
demonstrated in Chapter 5. A previous study by Axon et al. has indicated that junior 
physicians are more likely to follow senior physicians’ prescribing recommendations 
rather than those from pharmacists [333]; as highlighted in Chapter 6, this is likely 
influenced by the medical hierarchy within hospital settings [375].  
Prescribers having trust in the recommendation source is of paramount 
importance. A major theme from Chapter 6 was that knowing and trusting the 
pharmacist was a key facilitator to prescribers implementing the recommendations, 
which is commonly reported in the literature [326, 360, 361]. Trust is vital to 
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collaborative pharmacist-physician relationships [355, 382], as with any 
professional relationship [383]. Building trust can take time [384, 385], and some 
pharmacists in the interviews felt that they had to prove their competence to some 
physicians before they were trusted and their recommendations implemented. The 
need for trust has previously been explained by physicians’ lack of awareness of the 
pharmacists’ knowledge, skill set, and role within the healthcare team [323, 324]. 
Building and maintaining interprofessional trust can be achieved by the provision of 
valued recommendations consistently over time [355]. However, the findings in 
Chapter 6 are in line with previous published research in suggesting that high staff 
turnover may affect collaboration, and thus impact negatively on maintaining these 
trusting relationships between pharmacists and physicians over time [336, 341].  
Similarly, trust in computerised interventions emerged as a subtheme in Chapter 3, 
whereby interviewees stressed that whilst they regarded computer-generated 
recommendations to be a potential aid to better quality prescribing, they would not 
trust them unquestionably. Previous research has shown that prescribers with 
higher levels of trust in CDSSs are significantly more likely to implement computer-
generated recommendations [386]. However, as shown in Chapter 4, some CDSS-
generated recommendations may be of potential adverse significance if 
implemented. Therefore, it is important that prescribers do not implicitly trust all 




7.4 Strengths and limitations 
The specific strengths and limitations of each study have already been described in 
the individual research chapters (Chapters 2 – 6). However, the main overall 
strengths and limitations of this work will be discussed below.  
One particular strength of this thesis was the complementary use of quantitative 
and qualitative research, whereby the results of one study either helped explain 
findings from previous studies or contributed to the development of research 
questions in subsequent investigations. For example, the quantitative results from 
Chapter 4 provided data to substantiate the qualitative findings from Chapter 3, 
supporting the argument that the clinical relevance of computer-generated 
recommendations was a significant factor affecting their implementation.  
Using the TDF as a robust framework in the directed content analysis phase of both 
qualitative interview studies allowed me to make comparisons between the 
findings in Chapters 3 and 6, and subsequently to ascertain the key factors affecting 
prescriber implementation common to both studies [217, 261]. In addition, the 
interview transcripts in both qualitative studies also underwent conventional 
content analysis [261]. Using these methods in tandem was more time-consuming 
compared to standard approaches of qualitative analysis. However, this allowed me 
to convey the themes openly without the constraints of specifically reporting 
according to the TDF, whilst still identifying the predominant TDF domains which 
can be mapped to suitable intervention functions [226].  
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Where possible, the studies in this thesis were reported in accordance with best-
practice guidelines. The PRISMA Statement was used to report the conduct of the 
systematic review and meta-analysis described in Chapter 2 [236]. Furthermore, the 
COREQ checklist guided reporting of the semi-structured interview studies in 
Chapters 3 and 6 [258]. It is important to emphasise that all five research chapters 
in this thesis are novel and have either been published in peer-reviewed journals, 
are currently under review, or are in preparation for submission for publication. 
Finally, the findings within this thesis have been presented at conferences locally, 
nationally, and internationally – indicating substantial interest in this body of work 
and the quality of the research conducted. Further endeavours shall be made to 
disseminate these findings and to use them to develop interventions which can 
sustainably minimise PIP in hospitalised older adults. 
There are also a number of limitations within this thesis that must be 
acknowledged. Although the qualitative study in Chapter 3 included participants 
from six countries, it is acknowledged that the interviews were based around one 
single computerised intervention (i.e. the CDSS intervention in the SENATOR RCT) 
[202]. Therefore, some of the findings specific to this intervention may not be as 
transferable to other hospital settings with different software systems. Additionally, 
whilst the qualitative study described in Chapter 6 did assess the views of 
pharmacists and physician prescribers from two hospital sites, it is likely that some 
findings may not be generalisable across all hospital settings in the Republic of 
Ireland or in other countries. However, I contend that the context of the study sites 
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has been described in sufficient detail to allow readers to decide if the findings are 
transferable to their own setting.  
Lastly, this thesis did not involve the development of a novel intervention. 
However, design and testing of a theoretically-informed intervention was beyond 
the scope of this body of work. It was deemed more important to firstly gain a 
greater understanding of the underlying factors that prevent medication 
optimisation for older adults in the hospital setting. Nonetheless, the findings in this 
thesis will inform the design of interventions targeting prescriber behaviour aimed 
at reduction of PIP in hospitalised older adults in future. 
  
7.5 Implications of findings 
The findings in this thesis have provided evidence to inform changes to practice 
that facilitate the implementation of recommendations to improve medication 
appropriateness in hospitalised older adults. Furthermore, the research described 
in this thesis has created a foundation to build on the evidence provided as well as 
yielding directions for new research. 
7.5.1 Implications for practice 
These findings suggest that a change to the specialty culture in hospitals is required. 
With the growing proportion of older adults in secondary care, many specialists will 
have responsibility for increasing numbers of these patients more frequently [387]. 
Specialists taking a more holistic approach to optimising medications for older 
adults must become the norm in hospital practice [388]. If PIP is identified and a 
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recommendation is made, the onus is on these specialists to ensure that PIP is 
reviewed promptly and implemented if deemed appropriate, rather than clinical 
inertia which perpetuates PIP, thereby potentially increasing the risk of patient 
harm [272].  
The findings from this thesis concur with previous research in demonstrating that 
prescribers perceive their knowledge to be suboptimal with regard to prescribing in 
older adults [111], emphasising that further education and training in geriatric 
pharmacotherapy is required at both undergraduate and postgraduate level [389, 
390]. These educational interventions have been shown to be acceptable to 
implement and effective in improving prescriber knowledge [143], and may 
therefore be one solution to overcome prescribing inertia and low self-efficacy with 
optimising geriatric pharmacotherapy when PIP issues are identified [391].  
A key component for interventions to improve medication appropriateness is how 
the recommendations are provided, who receives them, and at what time during 
the hospitalisation of an older person. In line with several previous research 
studies, the research described in this thesis indicates that pharmacists should 
strive to deliver their recommendations face to face, where possible, in order to 
facilitate higher implementation rates. It is important to reiterate this point as 
suboptimal communication methods continue to prevail, which can contribute to 
adverse patient outcomes [339]. Furthermore, rather than relying on impromptu 
discussions with prescribers, hospital pharmacists should be afforded opportunities 
for regular structured face-to-face communication with attending physician 
prescribers when the patient’s case is being reviewed, e.g. such as on ward rounds 
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or at multidisciplinary team meetings. In addition, when pharmacists are confident 
that their recommendations can reduce PIP, they can show appropriate 
assertiveness with regard to proposed medication changes [392]. Previous studies 
have shown that a lack of pharmacist assertiveness results in medication errors 
going uncorrected [363]. 
It was evident from the interviews in Chapter 6 that physicians’ awareness of 
pharmacists’ training was an issue [323]. Increased interprofessional education 
between pharmacists and physicians is warranted to facilitate greater 
understanding of each profession’s knowledge and skills, as well as to promote 
collaboration [393, 394]. As with previous research, the findings in this thesis 
advocate greater use of pharmacist-physician collaborative practice models to 
facilitate implementation of pharmacists’ medication recommendations [187, 204, 
353]. Team-based pharmacist models may not be feasible in all institutions [204], 
but it is advisable that pharmacists have good engagement with other 
multidisciplinary team members, and, where possible, integrate with the attending 
physician’s team.  
Pharmacist-physician team-based collaborations should begin with defined 
introductions – either formal or informal – to open the channels of communication 
and clarify roles [316, 395]. Given the high turnover of junior medical staff in 
hospitals, it would seem prudent for future collaborative models to have strong 
trust-based relationships between pharmacists and senior physician prescribers, 
particularly consultants. Having senior prescribers collaborating with pharmacists to 
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optimise pharmacotherapy in multimorbid older adults should serve as role models 
to junior prescribers and improve their prescribing habits [396].  
With the advancement of technology, it is likely that computerised interventions 
will become much more widely used for prescribing optimisation in the coming 
decades [88]. Concerns have been expressed about their integration into hospital 
settings, including being costly to design and integrate into hospital settings, and 
the possibility of new types of clinical error [249]. However, most computerised 
systems designed to reduce medication errors are both clinically effective and cost-
effective [250, 397, 398]. The systematic review in this thesis established that 
computerised interventions can significantly reduce PIP in hospitalised older adults. 
As systematic reviews are widely viewed as the ‘gold standard’ in evidence 
synthesis to inform practice [399], this systematic review adds justification for their 
use in hospitals, where possible, to reduce PIP and improve patient outcomes. In 
Chapter 3, it was highlighted that the timing and location of the computer-
generated SENATOR recommendations was a key barrier to implementation. 
Provision of these recommendations in future must be seamlessly integrated into 
prescriber workflow, ideally in EHRs or EPRs.  
Lastly, my findings indicate that the hospital environment may not always be 
conducive to making changes to long-term medications in acutely unwell older 
adults [76], and that it may be preferable to do this in primary care post-
hospitalisation. However, for this to be achieved, better information exchange is 
required between primary and secondary healthcare settings in order to facilitate 
comprehensive medication reviews by GPs and pharmacists [400, 401]. As 
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described by the interview participants in Chapter 3, prescriber implementation of 
recommendations may be hindered by patient resistance to deprescribing certain 
medications, which is commonly reported in the literature for medications such as 
hypnotics and PPIs [402-404]. Therefore, better patient education is necessary to 
explain the harms of PIP; previous RCTs with patient education interventions have 
been proven to significantly reduce PIP in older adults [275, 276].  
7.5.2 Implications for future research 
Future research into this area should consider the measurement of ‘prescriber 
implementation’ rather than the commonly used term ‘prescriber acceptance’, as 
prescribers may agree with the recommendation at face value but not necessarily 
act on the recommendation. Nonetheless, prescriber implementation is merely a 
process measure (i.e. it assesses what prescribers do). To be valid in a clinical 
setting, process measures must correlate with important patient outcomes [331]. In 
Chapter 5, the physician-driven intervention was associated with a higher 
implementation rate for STOPP/START recommendations and a greater absolute 
risk reduction in ADRs in comparison to the pharmacist’s intervention. This prompts 
two further research questions. Firstly, future studies should examine if improved 
prescriber implementation of STOPP/START recommendations, as a process 
measure, correlates with improved patient outcomes (e.g. reduced ADRs). This may 
have ultimately proved to be a key shortcoming of the SENATOR intervention, 
whereby low implementation of the recommendations resulted in no difference in 
the proportion of patients with ADRs between the intervention and control groups 
[281]. Secondly, future research should aim to test in a multi-centre RCT setting if 
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there are statistically significant differences in prescriber implementation between 
physicians’ recommendations and pharmacists’ recommendations with a larger 
sample size of pharmacists and physicians to help account for interindividual 
differences. 
This thesis underlines the importance of using qualitative research alongside RCTs 
in future – not only to explain the quantitative results associated with the trial, but 
also to help inform the research and development of future interventions [256, 
257]. The qualitative findings in Chapter 3 and quantitative findings in Chapter 4 
have together confirmed that the clinical relevance of the computer-generated 
recommendations in the SENATOR RCT significantly affected their implementation. 
Therefore, this body of work has reaffirmed that future researchers should consider 
mixed-methods approaches to answer complex research questions.  
This thesis shows that meticulous software refinement is required for future 
computerised interventions to minimise inappropriate or irrelevant 
recommendations [304, 405], thus increasing the proportion of clinically relevant 
recommendations. In addition, it was suggested by interviewees that it is 
fundamentally important to provide the most clinically relevant recommendations 
first to reduce prescriber fatigue with these types of interventions [194]. Therefore, 
it is imperative for future researchers to consider developing an in-built ranking 
system within the software algorithms to prioritise prescribing recommendations 
with the highest clinical relevance. Furthermore, given the low inter-rater reliability 
with the scale used in Chapter 4, it would be worthwhile for future researchers to 
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consider developing a new validated scale to assess the clinical relevance of 
computer-generated pharmacotherapy recommendations. 
As highlighted throughout this thesis, there is an urgent need to develop 
theoretically-informed interventions with enhanced prescriber implementation of 
recommendations to optimise medication appropriateness in older adults. Of the 
fourteen possible TDF domains, five appeared predominant in both qualitative 
studies in this thesis. As demonstrated in Chapters 3 and 6, mapping these 
predominant TDF domains to the BCW helped identify what intervention types may 
be successful in enhancing prescriber implementation rates. However, even though 
all nine intervention functions described in the BCW may be suitable in theory, all 
options may not be feasible in routine clinical practice. When designing future 
intervention strategies, it may be warranted to employ the APEASE criteria 
(Acceptability, Practicability, Effectiveness/cost-effectiveness, Affordability, 
Safety/side effects, Equity) [227]. This set of criteria can be used to help decide on 
the intervention content and delivery in a particular context, but should be applied 
in a systematic manner in combination with expert judgment. Even though the 
research in this thesis has been focused on secondary care, there is a clear need for 
further research to determine the best way to integrate these types of 
interventions into clinical workflows not only in hospitals but also in other settings, 
such as general practice, ambulatory care clinics, long-term care facilities, as well as 






Optimising pharmacotherapy for multimorbid older adults is a complex process. 
The research described in this thesis was conducted in the context of a continuing 
high prevalence of PIP in hospitalised older adults. Prescriber implementation rates 
of recommendations to reduce PIP vary widely between interventions. Non-
implementation increases the risk of medication-related harm, but the reasons for 
non-implementation in individual studies are often not clear or not reported.  
This thesis has made a substantial contribution to the literature by achieving its aim 
of providing a comprehensive and detailed body of research exploring the key 
factors affecting prescriber implementation of recommendations to improve 
medication appropriateness in hospitalised older adults. 
This work has provided evidence that prescriber implementation is primarily 
influenced by the clinical relevance of the recommendations, the method of 
communication, the identity of the prescriber, the source of the recommendation, 
and the acute hospital environment. Therefore, prescriber implementation of these 
recommendations is not attributable to one easily identifiable cause, and it is likely 
that a multi-faceted approach will be required in future interventions. The studies 
described in this thesis have laid the groundwork for the development of 
theoretically-informed interventions that could result in enhanced prescriber 
implementation of these recommendations, ultimately assisting with the aim of 
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Appendix 1: STOPP/START criteria version 2 
 
Screening Tool of Older People’s Prescriptions (STOPP) version 2. 
The following prescriptions are potentially inappropriate to use in patients aged 65 
years and older. 
Section A: Indication of medication 
1. Any drug prescribed without an evidence-based clinical indication. 
2. Any drug prescribed beyond the recommended duration, where treatment 
duration is well defined. 
3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop 
diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a 
single drug class should be observed prior to considering a new agent). 
 
Section B: Cardiovascular System 
1. Digoxin for heart failure with normal systolic ventricular function (no clear 
evidence of benefit). 
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart 
failure). 
3. β-blocker in combination with verapamil or diltiazem (risk of heart block). 
4. β-blocker with bradycardia (< 50/min), type II heart block or complete heart 
block (risk of complete heart block, asystole). 
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular 
tachyarrhythmias (higher risk of side effects than β-blockers, digoxin, verapamil 
or diltiazem) 
6. Loop diuretic as first-line treatment for hypertension (safer, more effective 
alternatives available). 
7. Loop diuretic for dependent ankle oedema without clinical, biochemical 
evidence or radiological evidence of heart failure, liver failure, nephrotic 
syndrome or renal failure (leg elevation and /or compression hosiery usually 
more appropriate). 
8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 
mmol/l), hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. 
corrected serum calcium > 2.65 mmol/l) or with a history of gout 




9. Loop diuretic for treatment of hypertension with concurrent urinary 
incontinence (may exacerbate incontinence). 
10. Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, 
rilmenidine, guanfacine), unless clear intolerance of, or lack of efficacy with, 
other classes of antihypertensives (centrally-active antihypertensives are 
generally less well  tolerated by older people than younger people). 
11. ACE inhibitors or Angiotensin Receptor Blockers (ARBs) in patients with 
hyperkalaemia. 
12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent 
potassium-conserving drugs (e.g. ACE inhibitors, ARBs, amiloride, triamterene) 
without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e.    
> 6.0 mmol/l – serum K+ should be monitored regularly, i.e. at least every 6 
months). 
13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in 
severe heart failure characterised by hypotension i.e. systolic blood pressure     
< 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular 
collapse). 
 
Section C: Antiplatelet/Anticoagulant Drugs 
1. Long-term aspirin at doses greater than 160mg per day (increased risk of 
bleeding, no evidence for increased efficacy). 
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk 
of recurrent peptic ulcer). 
3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin 
inhibitors, or factor Xa inhibitors with concurrent significant  bleeding risk, i.e. 
uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a 
coronary stent(s) inserted in the previous 12 months or concurrent acute 
coronary syndrome or has a high grade symptomatic carotid arterial stenosis 
(no evidence of added benefit over clopidogrel monotherapy). 
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor, or 
factor Xa inhibitors in patients with chronic atrial fibrillation (no added benefit 
from aspirin). 
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor, or 
factor Xa inhibitors in patients with stable coronary, cerebrovascular, or 
peripheral arterial disease (No added benefit from dual therapy). 
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar 
efficacy, stronger evidence and fewer side effects). 
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8. Vitamin K antagonist, direct thrombin inhibitor, or factor Xa inhibitors for first 
deep venous thrombosis without continuing provoking risk factors (e.g. 
thrombophilia) for > 6 months, (no proven added benefit). 
9. Vitamin K antagonist, direct thrombin inhibitor, or factor Xa inhibitors for first 
pulmonary embolus without continuing provoking risk factors (e.g. 
thrombophilia) for > 12 months (no proven added benefit). 
10. NSAID and vitamin K antagonist, direct thrombin inhibitor, or factor Xa 
inhibitors in combination (risk of major gastrointestinal bleeding). 
11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased 
risk of peptic ulcer disease). 
 
Section D: Central Nervous System and Psychotropic Drugs 
1. Tricyclic antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac 
conduction abnormalities, prostatism, or prior history of urinary retention (risk 
of worsening these conditions). 
2. Initiation of TCAs as first-line antidepressant treatment (higher risk of adverse 
drug reactions with TCAs than with SSRIs or SNRIs). 
3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects 
(chlorpromazine, clozapine, flupenthixol, fluphenzine, pipothiazine, promazine, 
zuclopenthixol) with a history of prostatism or previous urinary retention (high 
risk of urinary retention). 
4. Selective serotonin re-uptake inhibitors (SSRIs) with current or recent significant 
hyponatraemia i.e. serum Na+ < 130 mmol/l (risk of exacerbating or 
precipitating hyponatraemia). 
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of 
prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all 
benzodiazepines should be withdrawn gradually if taken for more than  4  
weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if 
stopped abruptly). 
6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with 
parkinsonism or Lewy Body Disease (risk of severe extra-pyramidal symptoms). 
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side effects of 
neuroleptic medications (risk of anticholinergic toxicity). 
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of 
exacerbation of cognitive impairment). 
9. Neuroleptic antipsychotic in patients with behavioural and psychological 
symptoms of dementia (BPSD) unless symptoms are severe and other non-
pharmacological treatments have failed (increased risk of stroke). 
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10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia 
(risk of confusion, hypotension, extra-pyramidal side effects, falls). 
11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia 
(< 60 beats/minute), heart block or recurrent unexplained syncope or 
concurrent treatment with drugs that reduce heart rate such as β-blockers, 
digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and 
injury). 
12. Phenothiazines as  first-line treatment, since safer and more efficacious 
alternatives exist (phenothiazines are sedative, have significant antimuscarinic 
toxicity in older people, with the exception of prochlorperazine for 
nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and 
levomepromazine as an anti-emetic in  palliative care). 
13. Levodopa or dopamine agonists for benign essential tremor (no evidence of 
efficacy). 
14. First-generation antihistamines (safer, less toxic antihistamines now widely 
available). 
 
Section E: Renal System. The following drugs are potentially inappropriate in 
older people with acute or chronic kidney disease with renal function below 
particular levels of eGFR (refer to summary of product characteristics datasheets 
and local formulary guidelines) 
1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 
ml/min/1.73m2 (risk of digoxin toxicity if plasma levels not measured).  
2. Direct thrombin inhibitors (e.g. dabigatran)  if eGFR < 30 ml/min/1.73m2 (risk of 
bleeding). 
3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 
(risk of bleeding). 
4. NSAIDs if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
Section F: Gastrointestinal System 
1. Prochlorperazine or metoclopramide with parkinsonism (risk of exacerbating 
parkinsonian symptoms). 
2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full 




3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, 
oral iron, opioids, verapamil, aluminium antacids) in patients with chronic 
constipation where non-constipating alternatives are available (risk of 
exacerbation of constipation). 
4. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate         
> 600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate > 1800 
mg/day; no evidence of enhanced iron absorption above these doses). 
 
Section G: Respiratory System 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of 
adverse effects due to narrow therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance 
therapy in moderate-severe COPD (unnecessary exposure to long-term side 
effects of systemic corticosteroids and effective inhaled therapies are available). 
3. Antimuscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of 
narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow 
obstruction (may cause urinary retention). 
4. Non-selective β-blocker (whether oral or topical for glaucoma) with a history of 
asthma requiring treatment (risk of increased bronchospasm). 
5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± 
pCO2 > 6.5 kPa (risk of exacerbation of respiratory failure). 
 
Section H: Musculoskeletal System 
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective 
agents with history of peptic ulcer disease or gastrointestinal bleeding, unless 
with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse). 
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe 
heart failure (risk of exacerbation of heart failure). 
3. Long-term use of NSAID (> 3 months) for symptom relief of osteoarthritis pain 
where paracetamol has not been tried (simple analgesics preferable and usually 
as effective for pain relief). 
4. Long-term corticosteroids (> 3 months) as monotherapy for rheumatoid arthritis 
(risk of systemic corticosteroid side effects). 
5. Corticosteroids (other than periodic intra-articular injections for mono-articular 




6. Long-term NSAID or colchicine (> 3 months) for chronic treatment of gout 
where there is no contraindication to a xanthine-oxidase inhibitor (e.g. 
allopurinol, febuxostat) (xanthine-oxidase inhibitors are first choice prophylactic 
drugs in gout). 
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk 
of myocardial infarction and stroke). 
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of 
peptic ulcer disease). 
9. Oral bisphosphonates in patients with a current or recent history of upper 
gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or 
peptic ulcer disease, or upper gastrointestinal bleeding (risk of 
relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal 
stricture). 
 
Section I: Urogenital System 
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of 
increased confusion, agitation) or narrow-angle glaucoma (risk of acute 
exacerbation of glaucoma), or chronic prostatism (risk of urinary retention). 
2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic 
hypotension or micturition syncope (risk of precipitating recurrent syncope). 
 
Section J. Endocrine System 
1. Sulphonylureas with a long duration of action (e.g. glibenclamide, 
chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged 
hypoglycaemia). 
2. Thiazolidinediones (e.g. rosiglitazone, pioglitazone) in patients with heart failure 
(risk of exacerbation of heart failure). 
3. β-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of 
suppressing hypoglycaemic symptoms). 
4. Oestrogens with a history of breast cancer or venous thromboembolism 
(increased risk of recurrence). 
5. Oral oestrogens without progestogen in patients with intact uterus (risk of 
endometrial cancer). 
6. Androgens (male sex hormones) in the absence of primary or secondary 





Section K: Drugs that predictably increase the risk of falls in older people 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, parkinsonism). 
3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, 
long-acting nitrates, ACE inhibitors, ARBs) with persistent postural hypotension 
i.e. recurrent drop in systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted 
daytime sedation, ataxia). 
 
Section L: Analgesic Drugs 
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, 
buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as 
first-line therapy for mild pain (WHO analgesic ladder not observed). 
2. Use of regular (as distinct from prn) opioids without concomitant laxative (risk 
of severe constipation). 
3. Long-acting opioids without short-acting opioids for break-through pain (risk of 
persistence of severe pain). 
 
Section N: Antimuscarinic/Anticholinergic Drug Burden 
Concomitant use of two or more drugs with antimuscarinic/anticholinergic 
properties (e.g. bladder antispasmodics, intestinal antispasmodics, TCAs, first-









                     
Screening Tool to Alert to Right Treatment (START) version 2. 
Unless an elderly patient’s clinical status is end-of-life and therefore requiring a 
more palliative focus of pharmacotherapy, the following drug therapies should be 
considered where omitted for no valid clinical reason(s). It is assumed that the 
prescriber observes all the specific contraindications to these drug therapies prior 
to recommending them to older patients. 
 
Section A: Cardiovascular System 
1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the 
presence of chronic atrial fibrillation. 
2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, 
where Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors 
are contraindicated. 
3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a 
documented history of coronary, cerebral, or peripheral vascular disease. 
4. Antihypertensive therapy where systolic blood pressure consistently > 160 
mmHg and/or diastolic blood pressure consistently > 90 mmHg; if systolic blood 
pressure > 140 mmHg and /or diastolic blood pressure > 90 mmHg, if diabetic. 
5. Statin therapy with a documented history of coronary, cerebral, or peripheral 
vascular disease, unless the patient’s status is end-of-life or age is > 85 years. 
6. ACE inhibitor with systolic heart failure and/or documented coronary artery 
disease. 
7. β-blocker with ischaemic heart disease. 
8. Appropriate β-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with 
stable systolic heart failure. 
 
Section B: Respiratory System 
1. Regular inhaled β2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, 
tiotropium) for mild to moderate asthma or COPD. 
2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where 
FEV1 < 50% of predicted value and repeated exacerbations requiring treatment 
with oral corticosteroids. 
3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 





Section C: Central Nervous System & Eyes 
1. Levodopa or a dopamine agonist in idiopathic Parkinson’s disease with 
functional impairment and resultant disability. 
2. Non-TCA antidepressant drug in the presence of persistent major depressive 
symptoms. 
3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for 
mild-moderate Alzheimer’s dementia or Lewy Body dementia (rivastigmine). 
4. Topical prostaglandin, prostamide, or β-blocker for primary open-angle 
glaucoma. 
5. SSRI (or SNRI or pregabalin if SSRI contraindicated) for persistent severe anxiety 
that interferes with independent functioning. 
6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs 
Syndrome, once iron deficiency and severe renal failure have been excluded. 
 
Section D: Gastrointestinal System 
1. PPI with severe gastro-oesophageal reflux disease or peptic stricture requiring 
dilatation. 
2. Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) for 
diverticulosis with a history of constipation. 
 
Section E: Musculoskeletal System 
1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling 
rheumatoid disease. 
2. Bisphosphonates and vitamin D and calcium in patients taking long-term 
systemic corticosteroid therapy. 
3. Vitamin D and calcium supplement in patients with known osteoporosis and/or 
previous fragility fracture(s) and/or (Bone Mineral Density T-scores more than   
-2.5 in multiple sites). 
4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium 
ranelate, teriparatide, denosumab) in patients with documented osteoporosis, 
where no pharmacological or clinical status contraindication exists (Bone 
Mineral Density T-scores more than -2.5 in multiple sites) and/or previous 
history of fragility fracture(s). 
5. Vitamin D supplement in older people who are housebound or experiencing 




(Reproduced with the permission of Prof. Denis O’Mahony, August 2019) 
 
6. Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history of 
recurrent episodes of gout. 
7. Folic acid supplement in patients taking methotrexate. 
 
Section F: Endocrine System 
1. ACE inhibitor or ARB (if intolerant of ACE inhibitor) in diabetes with evidence of 
renal disease i.e. dipstick proteinuria or microalbuminuria (> 30mg/24 hours) 
with or without serum biochemical renal impairment. 
 
Section G: Urogenital System 
1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is 
not considered necessary. 
2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy 
is not considered necessary. 
3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic 
atrophic vaginitis. 
 
Section H: Analgesics 
1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or 
low-potency opioids are not appropriate to the pain severity or have been 
ineffective. 
2. Laxatives in patients receiving opioids regularly. 
 
Section I: Vaccines 
1. Seasonal trivalent influenza vaccine annually. 
2. Pneumococcal vaccine at least once after age 65 according to national 
guidelines. 
 
Reference:  O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. 
STOPP/START criteria for potentially inappropriate prescribing in older people: 
version 2. Age Ageing. 2015 Mar;44(2):213-8. 
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Appendix 2: Theoretical Domains Framework (version 2) 
 
 
Domain (definition) Constructs 
1. Knowledge Knowledge (including knowledge of condition /scientific rationale) 
(An awareness of the existence of something) Procedural knowledge 
 Knowledge of task environment 
2. Skills Skills 
(An ability or proficiency acquired through practice) Skills development 
 Competence 
 Ability 
 Interpersonal skills 
 Practice 
 Skill assessment 
3. Social/Professional Role and Identity Professional identity 
(A coherent set of behaviours and displayed personal qualities of an  Professional role 
individual in a social or work setting) Social identity 
 Identity 
 Professional boundaries 
 Professional confidence 
 Group Identity 
 Leadership 
 Organisational commitment 
4. Beliefs about Capabilities Self-confidence 
(Acceptance of the truth, reality, or validity about an ability, talent, or  Perceived competence 
facility that a person can put to constructive use) Self-efficacy 




 Professional confidence 
5. Optimism Optimism 
 Pessimism 
 Unrealistic optimism 
 Identity 
6. Beliefs about Consequences Beliefs 
 Outcome expectancies 
 Characteristics of outcome expectancies 
 Anticipated regret 
 Consequents 
7. Reinforcement Rewards (proximal / distal, valued / not valued, probable / improbable) 
(Increasing the probability of a response by arranging a dependent 












Domain (definition) Constructs 
8. Intentions Stability of Intentions  
(A conscious decision to perform a behaviour or a resolve to act in a  Stages of change model 
certain way) Transtheoretical model and stages of change 
9. Goals Goals (distal / proximal) 
(Mental representations of outcomes or end states that an individual wants  Goal priority 
to achieve) Goal / target setting 
 Goals (autonomous /controlled) 
 Action planning 
 Implementation intention 
10. Memory, Attention and Decision Processes Memory 
(The ability to retain information, focus selectively on aspects of the  Attention 
environment and choose between two or more alternatives) Attention control 
 Decision making 
 Cognitive overload / tiredness 
11. Environmental Context and Resources Environmental stressors 
(Any circumstance of a person’s situation or environment that  Resources / material resources 
discourages, or encourages the development of skills and abilities,  Organisational culture / climate 
independence, social competence, and adaptive behaviour) Salient events / critical incidents 
 Person x environment interaction 
 Barriers and facilitators 
12. Social Influences Social pressure 
(Those interpersonal processes that can cause individuals to change their  Social norms 
thoughts, feelings, or behaviours) Group conformity 
 Social comparisons 
 Group norms 
 Social support 
 Power 
 Intergroup conflict 
 Alienation 
 Group Identity 
 Modelling 
13. Emotion Fear 
(A complex reaction pattern, involving experiential, behavioural, and  Anxiety 
physiological elements, by which the individual attempts to deal with a  Affect 
personally significant matter or event)  Stress 
 Depression 
 Positive / negative affect 
 Burn-out 
14. Behavioural Regulation Self-monitoring 
(Anything aimed at managing or changing objectively observed or  Breaking habit 
measured actions) Action planning 
 
 
Reference:  Cane J, O'Connor D, Michie S. Validation of the theoretical domains 
framework for use in behaviour change and implementation research. Implement 
Sci. 2012 Apr 24;7:37. 
(Reproduced with the permission of Prof. Susan Michie, August 2019)
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The domains of the TDF are presented in yellow here. Depending on which domains 
are identified, they can be mapped to intervention functions, shown here in red, 
which may be suitable components in the design of future interventions. 
 
Reference: Michie S, Atkins L, West R. The behaviour change wheel: a guide to 
designing interventions: London: Silverback Publishing; 2014. 
(Reproduced with permission from Prof. Susan Michie, August 2019)  
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Appendix 4: PRISMA checklist for systematic review 
 
Section/topic  # Checklist item  
Reported on 
page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  48 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  51 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
51/52 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g. web address), and, if available, provide 
registration information including registration number.  
52 
Eligibility criteria  6 Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
53 
Information sources  7 Describe all information sources (e.g. databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
52/53 




Section/topic  # Checklist item  
Reported on 
page # 
Study selection  9 State the process for selecting studies (i.e. screening, eligibility, included in systematic review, and, if applicable, included 
in the meta-analysis).  
53 
Data collection process  10 Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
53 
Data items  11 List and define all variables for which data were sought (e.g. PICOS, funding sources) and any assumptions and 
simplifications made.  
53 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be used in any data synthesis.  
54 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  54 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g. 
I
2
) for each meta-analysis.  
54 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias, selective reporting 
within studies).  
54 
Additional analyses  16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
N/A 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
54/55 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g. study size, PICOS, follow-up period) and 
provide the citations.  
57-59 
Appendix 6 





Section/topic  # Checklist item  
Reported on 
page # 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with a forest plot.  
57-59,       
62-63 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  62 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  60-61 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION  
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g. healthcare providers, users, and policy makers).  
67-70 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g. incomplete retrieval of 
identified research, reporting bias).  
68-69 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  70 
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other support (e.g. supply of data); role of funders for the 




                     
 
Appendix 5: Search strategy for systematic review 
 
  
Inappropriate prescribing  OR  potentially inappropriate prescribing  OR 
inappropriate prescription*  OR  overprescribing  OR  underprescribing  OR  
inappropriate polypharmacy  OR  inappropriate medicine*  OR  inappropriate 
medication*  OR inappropriate drug*  OR  optimize prescribing  OR improve 









Computer*  OR  software  OR  software intervention  OR  clinical decision support 
OR  CDSS OR  CDS   
  
Note: This search strategy was developed in the PubMed database. For each of the 
remaining databases, the search strategy was modified to suit their specific search 
capabilities if necessary. 
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C: 12,356  
I: 12,153          
Total: 
24,509 
The sedative hypnotics diazepam 
and diphenhydramine. 
Patients aged ≥ 65 years admitted 
to the adult inpatient service.    
Physician Computerised reminder in a CPOE system aiming 
to minimise use of diphenhydramine and 
diazepam, and directing physicians to either a 
non-pharmacological sleep protocol or to an 










Total: 424  
Eighteen medications with 
moderate to severe centrally-acting 
anticholinergic properties, selected 
by an interdisciplinary team (which 
included a geriatrician, a geriatric 
nurse practitioner, a pharmacist, a 
social worker, a physical therapist, 
an occupational therapist, and an 
administrative assistant). 
 
English-speaking patients ≥ 65 
years hospitalised on a medical 
ward, with cognitive impairment at 
the time of hospital admission. 
Patients excluded if they had 
previously been enrolled in the 
study, were aphasic, or 
unresponsive at the time of 
screening. 
 
Physician If a physician ordered any one of 18 
inappropriate anticholinergic medications in a 
CPOE system, a CDSS interruptive alert 
recommended to discontinue the medicine, dose 
modification, or suggested an alternative. 
 










Total: 134  
PIMs according to the 2003 Beers 
criteria, as these were the explicit 
criteria in INTERcheck®. 
Inpatients ≥ 65 years – only 
exclusion criteria were severe 
malignancy (life expectancy less 
than 6 months) or terminal illness. 
Physician The physician utilised a computerised 
prescription support system (INTERcheck®) to 
identify PIMs and potential drug-drug 
interactions, as well as aiming to reduce 
anticholinergic load and adjust doses in patients 



























OFF, ON, OFF, 
ON. First two 
blocks were 6 
weeks long 
and last two 
blocks were 7 
weeks long.  
C: 668 
I: 739  
Total 1,407 
Benzodiazepines, NSAIDs, opiates, 
sedative-hypnotics. These were 
selected by an expert panel 
including a geriatrician, a general 
psychiatrist, a pharmacist, two 
general internists, and an 
anaesthesiologist specialising in 
pain management, as had 
previously been done in Peterson 
et al. [200]. 
All persons aged ≥ 65 years who 
had an order for a medication in 
one of the targeted drug classes 
during the study period. The study 
excluded patient orders in which 
qualifying medication orders were 
subsequently cancelled and any 
orders with missing data. 
Physician When one of the study medications was ordered 
in a CPOE system for patients ≥ 65 years, a 
clinical decision support tool modified one or 
more of the following parameters: medication 
selection, default dosage, or default frequency. 
The physician could then choose to accept or 
override the recommendation. The tool was 
alternated ‘OFF’ and ‘ON’ in consecutive blocks 
during the study period.  
 

















metoclopramide, and all 
antipsychotics. 
Patients aged ≥ 65 years. Prescribers – 
doesn’t 
specify.   
Informational alerts popped up when a PIM was 
ordered in the CPOE system. The physician was 
required to acknowledge the alert, before 
deciding on whether to cancel their order or 















A list of Beers 2003 criteria 
medications selected by a 
geriatrician and pharmacist, and 
then revised by the hospital’s 
Pharmacy and Therapeutics 
Committee. 
 
All hospitalised inpatients aged       
≥ 65 years. 
Physicians  The CPOE system alerted prescribers when a PIM 
was ordered by providing a medication-specific 
warning that advised alternative medication or 

















































medications decided on by a panel 
of experts, including a geriatrician, 
a geriatric psychiatrist, a 
pharmacist, 2 internists, and an 
anaesthesiologist specialising in 
pain management. 
 
All patients ≥ 65 years prescribed 
one of the targeted medications 
and admitted to any of the 
medical, surgical, neurology, and 
gynaecology services were 
evaluated. General ward and 
intensive care patients were 
eligible for analysis. Only those 
patients whose admission was 
entirely contained within 1 of the 
6-week study periods were 
included. 
Physicians A decision support tool altered the default dose 
and frequency for psychotropic medications for 
patients ≥ 65 years, and suggested an alternative 
medication when prescribers ordered one of 12 
psychotropic medications known to be poorly 
tolerated in older patients. The support tool was 
activated for 2 of 4 six-week study periods in an 
off-on-off-on pattern. 
 





C: 1,925       
I: 1,793  
Total: 3,718 
Nine high-use and high impact 
PIMs, selected by an expert panel 
consisting of two doctors of 
pharmacy, two physician 
information technology 
experts, three geriatricians, and 
three emergency physicians. 
The intervention was aimed at 
emergency department physicians. 
C: 31 physicians 
I: 32 physicians 
 
Physicians Physicians in the intervention group were 
provided decision support when they attempted 
to prescribe a PIM for patients ≥ 65 years who 
were being discharged from the emergency 
department. The computerised reminder 
provided recommendations for alternatives 
which the physician could accept or reject.   
 
 
USA: United States of America C: Control group; I: Intervention group; CPOE: Computerised physician order entry; RCT: Randomised controlled trial; CDSS: Clinical decision support system; PIM: Potentially 
inappropriate medication; NSAID: Non-steroidal anti-inflammatory drug. 
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Appendix 8: COREQ checklist for qualitative interview study from Chapter 3 
 
    
   Domain 1: Research Team and Reflexivity 
 
   
Personal characteristics   
1. Interviewer/facilitator Which author/s conducted the interview or focus group? KD conducted the interviews. 
2. Credentials What were the researcher’s credentials (e.g. PhD, MD)? At the time of undertaking the interviews, KD’s credentials were BPharm, MPharm, MPSI. 
3. Occupation What was their occupation at the time of the study? KD is an Irish registered pharmacist who was undertaking a PhD in Clinical Pharmacy 
research when this study was conducted. 
4. Sex Was the researcher male or female? Male. 
5. Experience and training What experience or training did the researcher have? KD completed training in utilisation of QSR NVivo® software, and received training in 
analysis of qualitative interviews at Oxford University, United Kingdom. 
    
Relationship with participants   
6. Relationship established Was a relationship established prior to study  
commencement? 
The interviewer had established a rapport with some of the primary researchers prior to 
the qualitative study due to trial commitments (i.e. annual general meetings, 
teleconferences, communication via email), but no relationship between the interviewer 
and prescriber participants was established prior to study commencement. 
7. Participant knowledge of the 
interviewer 
What did the participants know about the researcher           
(e.g. personal goals, reasons for doing the research)? 
KD had disclosed to all participants that he was a pharmacist undertaking this study as part 
of his PhD, prior to conducting the interviews. 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? (e.g. bias, assumptions, reasons      
and interests in the research topic) 
KD is a registered pharmacist who was working as a primary researcher as part of the 
SENATOR trial, and was conducting this study as part of his PhD exploring factors affecting 
prescriber implementation of medication recommendations in hospitalised older adults. 
This information was disclosed to participants ahead of the interview. 
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   Domain 2: Study Design   
   
Theoretical framework   
9. Methodological orientation  
and Theory 
What methodological orientation was stated to underpin 
the study (e.g. grounded theory, discourse analysis, 
ethnography, phenomenology, content analysis)? 
Content analysis was used in this study to analyse the data from the interview transcripts.  
Conventional content analysis was used to identify the conventional themes, which were 
attributed as factors that influenced implementation of the SENATOR recommendations. 
The Theoretical Domains Framework (TDF) was used to structure the interview topic 
guides, and directed content analysis was used to identify the relevant TDF domains.  
   
     Participant selection   
10. Sampling How were participants selected (e.g. purposive,   
convenience, consecutive, snowball)? 
Primary researchers involved with the SENATOR trial were recruited using purposive 
sampling as there were limited numbers of primary researchers at each site. Snowball 
sampling was used to recruit prescribers, whereby the SENATOR primary researchers and 
their colleagues referred the interviewer to prescribers in their site who would participate 
in the study. 
11. Method of approach How were participants approached                                                         
(e.g. face-to-face, telephone, mail, email)? 
Participants were contacted via email, and were provided with an information sheet and 
consent form in their native language in advance of the interview. 
12. Sample size How many participants were in the study? 24. 
13. Nonparticipation How many people refused to participate or dropped out? 
Reasons? 
None. 
    
     Setting    
14. Setting of data collection Where was the data collected (e.g. home, clinic,    
workplace)? 
All interviews took place in the participant’s workplace, or in their workplace when 
previously working as part of the SENATOR trial. 
15. Presence of nonparticipants Was anyone else present besides the participants and 
researchers? 
No. 
16. Description of sample What are the important characteristics of the sample          
(e.g. demographic data, date)? 
Table 3.1 provides details of where the participants were sampled from, whilst Table 3.2 
provides demographic details of the participants. The interviews took place between 






     Data collection   
17. Interview guide Were questions, prompts, guides provided by the authors? 
Was it pilot tested? 
Two separate topic guides comprising a similar line of questioning (with prompts where 
appropriate) were formulated for both prescribers and primary researchers, and these 
were based on a review of the literature, the TDF, and my own and my supervisors’ 
knowledge of the research area of the randomised controlled trial and research area. 
Careful consideration was given to the language used, knowing that English would not be 
the first language for all participants. Interviewees were provided with a sample of a 
SENATOR report in their native language during the interview as a reminder of the report 
design and the types of recommendations provided. The topic guide for interviewing 
prescribers was piloted with a prescriber who had received SENATOR recommendations in 
the lead trial site, and this interview was included in the data analysis. The topic guide for 
interviewing primary researchers was piloted with a primary researcher working with a 
similar randomised controlled trial (OPERAM study), who was very familiar with the 
SENATOR trial procedures. The topic guides were iteratively refined during the study to 
ensure that emerging themes were explored in subsequent interviews. 
18. Repeat interviews Were repeat interviews carried out? If yes, how many? No. 
19. Audio/visual recording Did the research use audio or visual recording to collect      
the data? 
All interviews were audio-recorded. 
20. Field notes Were field notes made during and/or after the interview        
or focus group? 
Field notes were recorded after each interview, and were used to refine topic guides and 
inform data analysis. 
21. Duration What was the duration of the interviews or focus group? The average interview length was 24 minutes (range 18 – 64 minutes). 
22. Data saturation Was data saturation discussed? Data analysis coincided with data collection, and sampling continued until no new themes 
emerged. As per the Francis et al. method, an additional three interviews were conducted 
without any new themes appearing to confirm that data saturation had been reached. 
23. Transcripts returned Were transcripts returned to participants for comment    
and/or correction? 
No. 
   
256 
 
   Domain 3: Analysis and Findings   
   
     Data analysis   
24. Number of data coders How many data coders coded the data? Two (KD and SC). 
25. Description of the coding      
tree 
Did authors provide a description of the coding tree? A description of the process is provided, whereby initial, non-hierarchical codes were 
categorised, and subsequently developed to generate themes and subthemes as part of 
conventional content analysis. 
The TDF was the chosen framework for directed content analysis, and was used as the basis 
for a coding tree here. 
26. Derivation of themes Were themes identified in advance or derived from                            
the data? 
Conventional content analysis comprised open coding to inductively create initial, non-
hierarchical codes. These initial codes were subsequently categorised to generate the 
evolving themes and subthemes. 
Directed content analysis was then employed whereby the transcripts were deductively 
coded using the TDF to identify the domains present. 
27. Software What software, if applicable, was used to manage the data? QSR NVivo
®
 Version 11 
28. Participant checking Did participants provide feedback on the findings? No.  
   
     Reporting   
29. Quotations presented Were participant quotations presented to illustrate the Yes. 
  themes/findings? Was each quotation identified?  
  e.g. participant number  
30. Data and findings Was there consistency between the data presented and Quotations are presented in a manner consistent with findings. 
 consistent the findings?  
31. Clarity of major themes Were major themes clearly presented in the findings? Major themes are clearly presented in the results section. 
32. Clarity of minor themes Is there a description of diverse cases or discussion Subthemes are presented under each of the major themes. 
  of minor themes? 
 
 
SENATOR: Software ENgine for the Assessment & optimization of drug and non-drug Therapy in Older peRsons         OPERAM: Optimising Therapy to prevent avoidable hospital admissions in the Multi-morbid elderly                                                                                                                                                                                                                                                                                                                                                                
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Appendix 9: Final version of topic guides for Chapter 3 
 
Topic guide for SENATOR primary researchers 
 
1. As we know, the SENATOR engine analysed patients’ information and made 
recommendations to optimise patients’ medications. Here is an example of a 
report that was generated. What are your thoughts on the design of the 
report? 
 Structure, layout, colours, font size, information provided 
 Location of report 
2. When a prescriber was looking at a SENATOR report for the first time, what do 
you think they would have thought of it? 
 Do you think that they knew what the report was asking them to do? 
3. What are your thoughts on the quality of the recommendations? 
 Thoughts on the relevance of the recommendations? 
 Would you change anything about the recommendations/report? 
4. What are your thoughts on the timing of the intervention?  
 Would it have been better to have the report at the original point of 
prescribing/admission? 
5. What are your thoughts on conducting this intervention in the hospital setting? 
 Do you think there is a more appropriate setting this could take place? 
6. Whose role is it to make recommendations to optimise older patients’ 
medications in your hospital?  
 How would these recommendations be communicated (do you know)? 
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7. How do you communicate the presence of the report and the 
recommendations?  
 Were there any barriers to this communication? 
8. What are your thoughts on the methods of communication of the report’s 
recommendations in this hospital?  
 What method of communication did you find most successful when 
providing the recommendations to the prescribing team, e.g. face-to-face or 
via telephone? 
9. Given your professional background, how do you feel your role may affect the 
number of recommendations implemented? 
 The role/status of the primary researcher 
10. How do you feel when discussing the report with the prescribing team? 
11. Did you have any particular rewarding or negative experiences in your role in 
carrying out the intervention? 
12. What was the reaction of prescribers in your hospital to the SENATOR 
report/recommendations? 
 Was there a positive or negative reaction? 
 Do you think that prescribers saw it as a priority to review the SENATOR 
report recommendations? 
13. In your opinion, whose role should it be to review computer-generated 
recommendations like this in the hospital setting? 
 Do you think there should be someone to screen the recommendations 
before reaching the prescriber? 
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14. The prescriber implementation rates for the SENATOR recommendations were 
lower than expected – why do you think that may be? 
15. How do you think that we could achieve higher implementation rates of the 
recommendations? 
16. Do you foresee any problems for implementing an intervention like this 
routinely in future? 
 Resources (money, electronic prescribing)         
 Having a defined role for someone to lead/deliver the intervention  
17. Do you think there is anything more you could have done to enhance the 
acceptance rates of the recommendations? 
 Anything more that your Principal Investigator could have done? 
 Anything more that the lead site (Cork) could have done? 
18. How could SENATOR (or a similar intervention) be done better in future? 
 What resources would be required?  
 What information would you want to be provided by the computer?  
 How should the information to be provided? 
 
That brings us to the end of the interview. Do you have any additional comments 




                     
Topic guide for prescribers 
 
The SENATOR trial involves a computer programme analysing older patients’ 
medications, medical conditions, and other information with the aim of optimising 
prescribing. The programme then generates a report for the prescribing team to 
review with recommendations to address potentially inappropriate medications or 
potential prescribing omissions.   
1. Firstly, what are your thoughts on the SENATOR intervention overall?  
2. Do you think that automated programmes can help reduce potential 
inappropriately prescribing in hospitalised older adults?  
 Why? / Why not?   
3. What is your role in reviewing the appropriateness of medications an older 
patient is prescribed during their hospital stay?  
 Is this a priority of yours on a daily basis?  
4. How confident do you feel in prescribing for this patient group?  
 Do you think that your prescribing decisions would benefit from regular 
automated support/feedback/advice?  
 How do you feel about trusting recommendations from an automated 
programme?  
As I said, the SENATOR intervention produced a report highlighting potentially 
inappropriate medications or potential prescribing omissions. Here is an example of 




5. How did you receive the report or how were you made aware of the 
recommendations?  
 What are your thoughts on the method of communication for this 
intervention?  
 What about the timing of the intervention?  
6. When you looked at the SENATOR report for the first time, what did you think 
of it?  
 Did you understand what the report was aiming to do or what it asked of 
you?  
 What do you think of the design of the report? (e.g. layout, font size, length, 
colours, data / information contained within the report etc.)  
7. When looking at the report, how easy or difficult was it for you to identify 
which of the recommendations were relevant for each patient?  
 Do you think all of the recommendations that you have reviewed have been 
relevant for your patients’ needs?   
 If you saw irrelevant recommendations, would it make you question the 
validity / relevance of the other recommendations?  
8. What influence, if any, did the SENATOR report have on your decision-making?   
9. Is there anything that may have prevented you from acting upon the SENATOR 
recommendations?  
 Patient’s acute medical presentation / Lack of information to hand /       




10. In your opinion, whose role should it be to review these computer-generated 
recommendations in the hospital setting?  
 Do you think someone should screen the recommendations before reaching 
the prescriber (e.g. doctor, pharmacist, nurse)?  
11. The prescriber implementation rates for the recommendations were lower 
than anticipated – what do you think are the reasons for this?  
 How do you think that we could achieve higher implementation rates of the 
computer-generated recommendations?  
12. What problems, if any, do you foresee in implementing this intervention into 
routine clinical practice?  
 Resources (e.g. money to cover the cost, electronic prescribing, having a 
person to review the recommendations)  
13. Do you have any suggestions for how we could enhance the implementation 
of this type of intervention in future?  
 What resources would be required? Electronic prescribing?  
 What information would you want to be provided by the computer?  
 How would you like this information to be provided? Information 
box/report/alert?  
 
That brings us to the end of the interview. Do you have any additional comments 
that you would like to make, or any points you would like to expand on? 
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(Reproduced with the permission of Prof. Denis O’Mahony, Principal Investigator of 




                     
Appendix 11: Supplementary quotations for Chapter 3 
 
 






Aid to prescribing, 




“…essentially what they’re doing is giving us guidance and as 
clinicians it’s up to us to decide what we do about it”. Surgical 
Prescriber 1 
“I think they can be very helpful. They can’t do it automatically but I 
think they can give very good hints, so I think in general they’re 
helpful as assisting”. Medical Prescriber 3 
“I think it’s a useful resource. Also, I think that we make mistakes 
when we’re prescribing because there’s too much information we 
have to attend to and sometimes we just can’t handle everything, 
and so I think it’s a very good thing that we can have a computer or 
someone who can supervise what we are doing. So it’s like, it helps 
us to do our job better”. Medical Prescriber 10 
 “I don’t think you can look at the advice alone. Em…like I said 
sometimes there are a bit of errors, which I think is normal. Em…you 
have to think about it yourself and not just read like the advice and 
put it into eh…put it into practice but really think about it as well”. 
Medical Prescriber 2 
 “I think…the human intelligence, at least as it is today, computers 
haven’t taken that over…that we use them as assisting us but not 
relying on it completely so if there comes, you know if there’s 
something that we think sounds funny we can always take over and 
correct that”. Medical Prescriber 12 
“If it comes out with something that is completely opposed to my 
views then I would also then be looking into that to find out then, 
okay, I wouldn’t have perceived that as an interaction. Is there other 
stuff to back it up? I don’t think I would be blindly led by a 
computer”. Medical Prescriber 6 
“I wouldn’t implicitly trust automated recommendations I suppose is 
what I’m trying to get at”. Medical Prescriber 8 
“…you cannot trust the programme blindly, i.e. you have to still think 
about the medication”. Medical Prescriber 4 
“I mean I wouldn’t ever rely solely on a computer, but I think it’s kind 
of helpful to have that, that initial maybe…em…notification from a 
computer programme, and you can work with that then”. Medical 
Prescriber 1 
 
Lack of specificity “…it’s not specific to the particular patient because it does…it did not 
take into account the complexity of that particular patient”.  Primary 
Researcher 9 
“…the decision support software says that for a thousand people, 
that’s the right thing to do. It may not be the right thing to do for 
that person”. Surgical Prescriber 2 
“…the computer cannot take into context the human aspect of the 
patient and therefore they cannot they cannot advise on the 




















“I think absolutely for sure, em, the fact that a lot of the 
recommendations were simply not relevant or appropriate, I think 
that’s very very very very important. Em, and…obviously explains 
part…at least partly explains the low uptake”. Primary Researcher 7 
“I had recommendations that were irrelevant and even, even 
dangerous.” Medical Prescriber 4 
“So I think there’s potential for benefit, but you need to make sure it’s 
not information overload and people aren’t just getting dismissive of 
it”. Medical Prescriber 6 
“…if we could filter out the irrelevant or inappropriate 
recommendations, I think that the whole value of the report would 
go upwards very significantly. Because undoubtedly there is a fatigue 
as well when you get lots and lots of recommendations”.   Primary 
Researcher  7 
“…it seems that if there’s been a negative one then they’re not so 
receptive the next time”.  Primary Researcher 4 
“Well if you have some not very specific recommendations, you can 
see that they are…the second time you go they are…or the third time 
they are less interested in the study. So I already had physicians who 
start laughing when I go there again. So it’s definitely a barrier to the 
adherence”. Primary Researcher 1  
“…some consultants were really interested and over time when I 
repeatedly met the same consultant, they kind of lost interest 
because some of the recommendations were too broad, too generic. 
They were not tailored to that particular patient”. Primary 
Researcher 9 
 
Provision of the 
recommendations: 
Report Layout and 
Length 
“…well this is rather clear. Stop these. Start these. So em I don’t know 
if you can get any more clearer than that”. Medical Prescriber 12 
“There’s a lot of text in it so if people are very busy, they might think 
it’s too big, too big a file. But having this in colour – STOPP and START 
– this is very good, very clear yeah”. Primary Researcher 8 
“I’d try and keep it a little bit shorter, so make sure the report (you 
know) only has recommendations that really are relevant to the 
setting”. Primary Researcher 2 
“…if it could be a one-page document I think that would be better 
because I think we all have short attention spans…” Primary 
Researcher 7 
“…it’s probably a little bit too long and a bit too detailed (you know), 
and that maybe just focusing on the smaller number of maybe 
significant…significant STOPP or START recommendations might 
make more sense”. Medical Prescriber 1 
 
Provision of the 
recommendations 
by the primary 
researcher 
“…if you’ve had a chance to speak to the researchers, you’ve 
get…you’ve got a better understanding”. Medical Prescriber 6 
“…their interest would be higher if I was a doctor who would give the 
















Right setting for 
the intervention 
 
“It’s the right place to do it, absolutely. Here we are starting a lot of 
new drugs. Here we have the possibility to monitor the response and 
the side effects”. Medical Prescriber 12 
“…the inpatient services are very specialty-driven. And probably the 
only people who’ve really got a whole overview of the person, to me, 
is the general practitioners and they’re the ones who are having to, 
who are being asked to, continue prescriptions”. Medical Prescriber 
6 
“I mean they, these recommendations are relevant to the patient, but 
they’re not particularly relevant to a patient in hospital at that 
particular time”. Primary Researcher 2 
“In the ward, I’m often just dealing with the acute issues. And I 
probably don’t see it so much as my role to start stopping what other 
people have done. I think when the SENATOR trial first came out I 





intervention in a 
busy environment 
 
“So unless they actually become part of the fabric of a health service, 
then you’re gonna have a situation where you’re gonna have a few 
enthusiastic early uptakers, and then you’re gonna have everyone 
else who kind of (you know) will uptake, take them up for a period of 
time and then will drift out of consciousness”. Surgical Prescriber 2 
“I think just by repeating this I think people will get more eh…yeah 
familiar with this kind of program”. Medical Prescriber 4 
“I think so yeah, and also (you know) this is something new. People 
are not used to this”. Medical Prescriber 12 
“…any trial would probably suffer from similar…you know similar 
challenges in a really busy hospital where people just are kind of too 
busy to give an awful lot of time to a research project”. Primary 
Researcher 2 
“…they were rushed, they were busy doing something else, and the 
recommendations that I would have highlighted to them would not 
have been seen as a priority, it would have been something that they 
would have come back to at a later stage”. Primary Researcher 7 
“…it’s very busy busy mornings we have here but so it is easy to get 
lost.  So in order for it to be used in the everyday rounds, it has to 
become more established so that (you know) it’s a part of that, that 
everyday work, not just something that (you know) you hear about 
once a week, or every other week, or something like that, then you 














Timing of the 
intervention and 
location of the 
recommendations 
 
“…if it was present right at the time where they’re dealing with the 
patient, where they’re focused on the patient, I think that could 
absolutely have improved uptake of the recommendations”. Primary 
Researcher 7 
“The intervention of getting the information may not have been the 
best time. The patient isn’t on your mind - you’re not thinking about 
the patient, you’re not doing a chart review”. Medical Prescriber 8 
“I’d say it was more the timing and…you know it was hit or miss if 
you got somebody who was in the middle of doing a hundred things 
and you’re interrupting them to tell them about this report you’ve 
placed, they’re not going to be very receptive to…to hearing about 
it”. Primary Researcher 2 
“…certainly from me the big issue was just the timing of getting the 
report versus when I saw the patient, when I was probably most 
invested in (you know) their, their care pathway”. Medical Prescriber 
1 
“…it is a little bit of an interruption and especially you may be dealing 
with another patient’s case and so to to to sort of think back on…on a 
different patient and their prescription I think it’s hard to really grasp 
and take in the recommendations at that particular time”. Primary 
Researcher 7 
“…it might just be around kind of timing actually more than anything 
else, and that maybe the route of the information just being a bit 
disconnected. You know a patient’s in one place, you get your 
information in a different place…” Medical Prescriber 8 
“I think it’s location. I think simply if we saw it we’d have gone ‘oh 
yeah, that’s sensible’. So, putting it physically in where we’re writing 
our notes”. Medical Prescriber 11 
“If instead having it inside the history, it was em…it appeared with 
the programme, with the prescription programme, because you have 
to use it - there’s no other way, and probably they would pay more 
attention”.  Medical Prescriber 10 
“I suppose one of the other things is that this came into me by email, 
and em…it, it, it maybe wasn’t immediate enough in terms of the 
patient interaction to take it on board, you know that you 
would…probably the best time to get this is actually the first time you 
see the patient on the ward round”. Medical Prescriber 1 
“I find the eh, the email a bit better for me personally, because eh if 
it’s filed in the notes it can get lost amongst all the pages and I 
wouldn’t necessary know that the patient would have that type of 
recommendations”. Medical Prescriber 9 
“Ill often the time when you’ll come, when you’ll actually open this 
email will be a couple of days later after you’ve gotten it and at that 
stage the patient is well gone home and that window is kinda missed 





Theme Descriptor  Illustrative Quotations 
 
3. Prescriber 




“But I’m not the prescribing clinician. You know because a lot of the 
time, and you can say it well yes you are because they’ve come into 
hospital and you’ve, you or a member of your team have physically 
prescribed them, but really you’re not. You’re, you’re carrying on a 
prescription on a decision that’s been made by somebody else. You’re 
honouring their decision”. Surgical Prescriber 2 
“Well I think it’s my responsibility to do so as a doctor and I’m the 
one who has to decide which medicines I give to someone”. Medical 
Prescriber 10 
“They don’t feel it’s their place. They feel it’s a GP’s job so they don’t 
want to get involved or they’re not confident enough to get 
involved”.  Primary Researcher 4  
 “…really it needs to be targeted at the people who are making the 
decisions to initiate the medications in the first place rather than me, 
who is seeing them on a very casual basis. I might see somebody’s 
prescription chart once in their entire relationship with me (you 
know), whereas you’re talking about a general practitioner who is 





“…if it’s related, if someone’s come in with a fall and then it’s related 
to the admission, I’d be much more likely to look at the SENATOR 
recommendations in detail. So if they’ve come in with something 
which I perceive to be something completely unrelated, and they’re 
on lots of complex cardiac medicines for heart failure which is stable, 
I’ll be much more reluctant to fiddle around with things, and I 
suppose in sort of the thought process is: well if it’s not broken, 
don’t…don’t try to fix it…” Medical Prescriber 6 
“…the doctors that don’t want to make a change, they’re not going 
to make a change…” Primary Researcher 4 
“I’m not gonna start interfering with somebody’s medications unless 
there’s a glaring danger in them or I see something that’s absolutely 







“…so when the doctors are enthusiastic about the study, they will 
read it, and they will take it…they will see it more as a priority but if 
the doctor isn’t interested in the study, they will not see it as a 
priority”. Primary Researcher 6 
“I think it depends on the person itself if they are open-minded for 
studies. Sometimes physicians are not really…they can have the 
impression that not all the physicians are very open-minded to 
studies, and others are…eh…open-minded so I think it also depends 
on it”. Primary Researcher 1 
“So I guess while it’s part of a study, we’ll take on that 
responsibility”. Medical Prescriber 6 
“I appreciated the work they did so I was receptive to em…doing this 
and receiving the information because I think it’s important, and I 
think that before they did it I already thought that we needed 
something like this so I was very ready to have it and I wanted to see 
it and I don’t know if the rest of the people who participated had the 













specialty and fear 
of encroachment  
 
“…we would kind of just, probably just intervene on the ones that are 
within our area of specialty. We leave the other ones generally 
alone”.  Surgical Prescriber 2 
“One thing you’ll find I suppose with consultants is their kind of, their 
particular area is what they would focus on, so if they’re admitted 
under cardiology, they may look at cardiology meds, and you know if 
they’re on a high dose of a PPI it’s not something they’re really 
gonna review”. Primary Researcher 2 
“…a number of the recommendations would be out of my comfort 
zone of what I manage”.  Surgical Prescriber 1  
“…it comes down to what I’m prescribing…em…and I suppose your 
confidence with prescribing certain medications wanes the longer 
you’re away from a certain specialty”. Medical Prescriber 8 
“They have conditions that are out of my range of knowledge, and 
their treatment often…their treatment of one condition might collide 
with another condition that I’m not an expert in”. Medical Prescriber 
12 
“I clearly understand that there are certain specialist fields that I’m 
capable of dealing with, and that’s that acute surgical problem”.  
Surgical Prescriber 1 
“I probably don’t see it so much as my role to start stopping what 
other people have done”. Medical Prescriber 6   
“So medications started by one specialist doctor, the other specialist 
doctor is a bit reluctant to change em…or is not happy to deal with 
this medication. It looks like instead of holistic treatment of the 
patient, each consultant is treating their part”. Primary Researcher 9 
“…you may have a patient admitted under you or you see the patient 
but you’re not the only person involved in their care so you may be 
reluctant to stop a medication that somebody else started. You may 
not have all the information why the medication was started”. 
Medical Prescriber 1 
“I think especially if you’re meeting a patient for the first time and 
they’re on a number of different medications em…you will not want 
to interfere with medications that you didn’t start or certainly 
medications that are outside of your own specialty”. Primary     
Researcher 7  
“…you’re carrying on a prescription on a decision that’s been made 
by somebody else. You’re honouring their decision. So, in honouring 
their decision, you’re dishonouring their decision by changing that, 







“I think the team has to be given a…a real nudge – ‘read the STOPP 
medications!’ – not because they won’t, because I think we just 
forget”. Medical Prescriber 11 
“I think it was usually something that they would put on the long 
finger, that they would intend to come back to”. Primary Researcher 
7 
“…it’s all about reminders. I think people are well-intentioned, I think 














the need for a 
‘decision-maker’ 
 
“…if you’re just started as a doctor…em I think you’re also a bit 
hesitant to, to stop certain medications than if you’ve years of 
experience”. Medical Prescriber 12 
“…if you have a lot of years of work, it’s possible that you tend to 
consolidate your ideas so SENATOR could be less effective in 
changing your prescription”. Medical Prescriber 7 
“I mean it definitely has to be somebody with senior clinical decision-
making power. Em…most interns won’t really have the kind of 
experience to go tinkering with people’s medications and they 
shouldn’t be”. Medical Prescriber 8 
“The junior doctors, like interns – they are maybe…do not have the 
eh…they’re not that independent or they (you know) don’t take 
many decisions without consulting their seniors”. Medical Prescriber 
12 
“I think it’s probably more important that it’s targeted at the actual 




4. The patient  
 
Acute status of the 
patient 
 
“The primary reason is I think they are not (the physicians here) are 
not worried about the chronic medications, they focus on the acute 
conditions”.  Primary Researcher 5 
“…when the patients are admitted in secondary care in hospital, the 
clinical team only deals with the acute problem. They are not 
interested in looking into the other medications…” Primary 
Researcher 9 
“I think the mindset on a busy clinical job is to sort out the acute 
issue and the long term medications oftentimes I would imagine 
physicians don’t feel that they’re the ones that should have to 
em…em…change or interfere or sort of adjust the long term 
medications”. Primary Researcher 7 
“…the priority to that patient may have been focused on, on more 
acute issues around that you know, you know do I need to operate or 
not? So that’s probably why there’s been a slight, a lower em 
acceptance of some of the recommendations”. Surgical Prescriber 1 
“…personally my focus would be on the acute pathology, which shall 
be the abdominal pain and...and it’s rare that we have in the past 
made any meaningful alterations to certain medication”. Surgical 
Prescriber 1 
“…from a surgery point of view, it’s a...(you know)…you’re very much 
focused on an interventional situation”. Surgical Prescriber 2 
“…we know when they’re surgical if it is a…like fracture, the focus is 
on the fracture, not all the other medication, so they are not willing 
to change many things”. Primary Researcher 8 
“…surgeons most of the time don’t care about these things, well 
some of them at least, because they are really focused on the 
surgery, and it’s like this is someone else’s job”. Medical Prescriber 
10 
“The benzodiazepine one - again if the patient’s unwell and they’ve 
been on a long-term sleeping tablet, my impression would be let’s 
sort the acute issue. If they’re drowsy or something like that, then 











Theme Descriptor  Illustrative Quotations 
 
 






“I’m not sure the grade is affected, it’s more who is in charge of the 
patient and who knows the patient best”. Primary Researcher 8 
“I think doctors that meet the patient for the first time at the 
hospital admission, they don’t know…they don’t know him so much. 
Eh…and maybe they don’t investigate any more than what they need 
for the acute problem”. Primary Researcher 10 
“…they didn’t have a complete picture of the patient when I 
discussed the recommendation. So, I’m thinking that also is one of 
the reasons why they don’t adapt the change”. Primary Researcher 
9 
“They don’t want to get involved…em…you know making big 
changes. They think that’s a job for the GP that knows the patient 
better and knows what they’ve been taking long-term and the 





“…give more information to the patient itself, like go to the patients 
and then say like “this medication we can stop, this medication we 
can stop”, like we inform the patients as well and then em…maybe it 
would work a bit better”. Medical Prescriber 2 
“The patient in theory could affect the number of recommendations. 
I think that good communication between prescriber, pharmacist, 
and patient is the good way, is the good way to…because, because, 
because patients should be, should be the centre role, centre role. In 
my experience, patient have in part, a little part in influencing the 





“So, eh…and then there’s of course patient preference factors. Some 
of them really prefer to have some drugs”. Medical Prescriber 3  
"I think, again, if a patient is very positive and keen for changes to be 
made, and speaks to the doctor then that seems to help". Primary 
Researcher 4 
“A lot of the recommendations involved taking patients off sleeping 
tablets and benzos and things, which you’re gonna get resistance 
to”.  Primary Researcher 2 
“I wouldn’t stop some things, someone’s medications, without 




STOPP:  Screening Tool of Older People's Prescriptions    START:  Screening Tool to Alert to Right Treatment 
 
SENATOR:  Software ENgine for the Assessment & optimization of drug and non-drug Therapy in Older peRsons    GP: General practitioner 
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Appendix 12: Reasons for criterion exclusion in evaluation of 
clinical relevance 
As part of the intervention, recommendations START I1 and START I2 (suggesting to 
ensure patients received influenza and pneumococcal vaccinations) appeared on all 
SENATOR reports. These recommendations were excluded from the assessment of 
clinical relevance and implementation as it was not documented if all these patients 
had been vaccinated or not. STOPP A1 (a recommendation suggesting to stop “Any 
drug prescribed without an evidence-based clinical indication”) was also written on 
the report but this too could not be assessed for clinical relevance or 
implementation, as the indication was not clear for all medications. Therefore, of 
the 114 STOPP/START criteria (version 2), recommendations based on 3 criteria 
were excluded from the analysis.   
However, it should also be noted that two slight software modifications were made 
a few weeks into patient recruitment:  
i) START A2 (“Aspirin [75 mg – 160 mg once daily] in the presence of chronic 
atrial fibrillation, where Vitamin K antagonists or direct thrombin inhibitors or 
factor Xa inhibitors are contraindicated”) was initially triggering as a stand-
alone recommendation, but later appeared as a joint recommendation along 
with START A1 (“Vitamin K antagonists or direct thrombin inhibitors or factor 
Xa inhibitors in the presence of chronic atrial fibrillation”). Therefore, 
relevance and implementation data are only available for START A1 from that 
point on.   
275 
 
ii) STOPP A3 (a recommendation to stop “Any duplicate drug class prescription”) 
was initially appearing on reports. However, due to high numbers of STOPP 
A3 recommendations being produced that were not clinically relevant, this 






















Appendix 13: Inter-rater reliability assessment 
 
A convenience sample of three pharmacists and three physicians (one consultant 
geriatrician, and two specialist registrars – i.e. senior residents – in geriatric 
medicine) were invited to participate. Raters were purposively selected on the basis 
of their involvement with the SENATOR project and/or the OPERAM project. 
Twenty intervention cases were selected at random, representing approximately 
10% of intervention patients recruited at Cork University Hospital. Details of this 
random selection can be found below. The study’s objectives were explained to 
each rater, and all raters were supplied with instructions on how to assess the 
clinical relevance of the recommendations, whereby the rater had to independently 
assign a code of 0 – 5 for each SENATOR-generated STOPP/START recommendation 
based on the clinical relevance categories. Three sample cases (all based on real 
intervention patients) were provided with the clinical relevance codes already 
assigned to the recommendations, and with a rationale given as to why each code 
was chosen by the pharmacist-physician pair for each patient. The twenty clinical 
cases were presented in a standardised format (Appendix 14) to include age, sex, 
comorbidities, medications prescribed at the time of randomisation, laboratory test 
results, and any other important information required to facilitate the raters in 
evaluating the clinical relevance of the STOPP/START recommendations.  
For the random selection of the twenty intervention cases, a list of all intervention 
patients in the study site was divided into four according to the date of recruitment 
to ensure patient cases were obtained from different times during the RCT.   
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An independent researcher (external to the study) rearranged the four lists of 
patient numbers into a random order. The first five patients with at least three 
STOPP/START recommendations in each list were chosen as the cases in the inter-
















                     
Appendix 14: Standardised case format for inter-rater 
reliability assessment 
 
Age:      80  
Sex:      Female  
Date of recruitment:   11/2017 
Presenting Condition:  Patient presenting with urosepsis. Patient fell during the 
   night before admission to hospital when on her way to the  




3. Chronic ischaemic heart disease 
4. Osteoarthritis 
5. Osteoporosis 
6. Neck of femur fracture 2014 
Medications:   
1. Tinzaparin 3500 units od SC        On since admission 
2. Piperacillin/Tazobactam 4.5g tds IV        On since admission  
3. Aspirin 75mg od po 
4. Ramipril 2.5mg od po 
5. Atorvastatin 20mg od po 
6. Zolpidem 10mg nocte po        On for 6 – 12 months 
7. Paracetamol 1g qds po/IV prn    






Sodium (mmol/L) 140 
Potassium (mmol/L) 4.1 
Corrected calcium (mmol/L) 2.31 
Creatinine (µmoles/L) 63 
eGFR (MDRD) ml/min/1.73m2 113 
Haemoglobin (g/dl) - 
Platelets x 109 370 
INR - 
 Blood Pressure: 124/79 mmHg. 
 Heart Rate: 76 beats/minute. 
 Patient does not have a history of 
recurrent falls. 
 On at home but not charted:                                 
Calcium/Vitamin D3 500mg/400 units  
1 tablet bd po and Risedronate 






Drug Recommendation Clinical 
Relevance 
Zolpidem 
Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon 
(may cause protracted daytime sedation, ataxia). 
 
 
Any drug prescribed beyond the recommended 








β-blocker with ischaemic heart disease. 
 
 
Vitamin D and calcium supplement in patients with known 
osteoporosis and/or previous fragility fracture(s) and/or (Bone 
Mineral Density T-scores more than -2.5 in multiple sites). 
 
 
Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, 
strontium ranelate, teriparatide, denosumab) in patients with 
documented osteoporosis, where no pharmacological or clinical 
status contraindication exists (Bone Mineral Density T-scores more 
than -2.5 in multiple sites) and/or previous history of fragility 
fracture(s). 






























STOPP A2 1 8 104 17 4 134 
STOPP A3 - 20 - - - 20 
STOPP B1 - 2 - - - 2 
STOPP B3 - 2 - 1 - 3 
STOPP B5 - 5 1 - - 6 
STOPP B6 2 2 - 1 - 5 
STOPP B7 7 10 6 3 - 26 
STOPP B8 - - 3 2 1 6 
STOPP B9 - 1 - - - 1 
STOPP B11 - - 2 1 1 4 
STOPP B12 - - 2 - - 2 
STOPP C3 3 8 1 5 - 17 
STOPP C5 2 - - 2 - 4 
STOPP C6 1 4 - 1 - 6 
STOPP C10 - - - 1 5 6 
STOPP C11 - - - - 1 1 
STOPP D2 - 1 1 1 - 3 
STOPP D4 - 1 1 - - 2 
STOPP D5 - - 13 9 2 24 
STOPP D8 - - 5 13 - 18 
STOPP D9 - 1 - - - 1 
STOPP D10 - 2 1 1 1 5 
STOPP D11 - 4 - - - 4 
STOPP D12 - - - 9 - 9 
STOPP D14 - - 1 20 - 21 
STOPP E3 - 1 1 - - 2 
STOPP E6 - - - - 1 1 
STOPP F2 1 - 15 - - 16 
STOPP F3 - - 3 2 3 8 
STOPP G1 - 1 - - - 1 
STOPP G2 - - 1 - - 1 




























STOPP H4 - 2 1 - - 3 
STOPP H5 - 2 - 1 - 3 
STOPP H6 - - 1 - - 1 
STOPP H7 - - - 1 - 1 
STOPP H8 - - - 7 - 7 
STOPP H9 - - - 2 - 2 
STOPP I1 - - - 10 - 10 
STOPP I2 - 1 - 4 - 5 
STOPP J3 - 40 1 - - 41 
STOPP K1 - - 13 10 8 31 
STOPP K2  - 1 2 3 1 7 
STOPP K3 1 1 3 11 - 16 
STOPP K4 - - 10 5 1 16 
STOPP L1 - 4 5 2 - 11 
STOPP L2 1 2 4 10 2 19 
STOPP L3 - 2 6 4 1 13 
STOPP N - 1 4 12 - 17 
START A1 1 - 1 12 13 27 
START A2 - 1 - 1 1 3 
START A3 22 15 3 4 3 47 
START A4 - 5 4 4 3 16 
START A5 - 6 12 11 4 33 
START A6 - 2 21 24 3 50 
START A7 2 1 5 5 - 13 
START A8 - - 8 5 1 14 
START B1 - 1 1 - 2 4 
START B2 - 1 1 2 2 6 
START B3 - 5 - - - 5 
START C1 - - - - 1 1 
START D2 - - 1 - - 1 
START E1 - 3 3 1 - 7 
START E2 - - - - 1 1 
START E3 - - - 5 2 7 





























STOPP E4 - - - 8 3 11 
START E6 - - 1 2 - 3 
START F1 - 1 1 10 1 13 
START G1 - 8 - 1 - 9 
START G2 - 12 8 1 - 21 
START H1 - 4 3 - 1 8 
START H2 1 3 29 13 2 48 

















                     
Appendix 16: Clinical relevance of recommendations based 






































PPIs 2 8 96 - - 106 
Benzodiazepines - - 37 27 11 75 
ACE inhibitors 
and/or ARBs 
1 3 25 38 5 72 
β-blockers 2 41 14 10 1 68 
Opioids 1 13 19 16 7 56 
Laxatives 1 5 29 13 2 50 
Diuretics 9 13 11 6 1 40 
Antihistamines - - 3 35 - 38 
Statins - 6 12 11 4 33 
Antipsychotics - 4 3 21 2 30 




- 2 7 11 2 22 
5-alpha reductase 
inhibitors 
- 12 8 1 - 21 
Alpha-1 Receptor 
blockers 
- 10 - 9 - 19 
Vitamin D +/- 
Calcium 




- 9 2 2 4 17 
Antihypertensives 
(START A4) 
- 5 4 4 3 16 
Anticholinergics - 1 3 11 - 15 
Miscellaneous 
cardiac drugs 













































Antidepressants - 3 4 1 - 8 
Corticosteroids - 4 3 1 - 8 
NSAIDs - - - 2 6 8 
Calcium channel 
blockers 
- 2 2 3 - 7 
DMARDs - 3 3 1 - 7 
Anti-diabetic drugs - 4 - - 1 5 
Drugs to treat gout 
or hyperuricaemia 
- - 3 2 - 5 
Oxygen - 5 - - - 5 
Anti-dementia 
drugs  
- 4 - - - 4 
Drugs for urinary 
frequency or 
incontinence 
- - 2 2 - 4 




PPI: Proton pump inhibitor        ACE: Angiotensin Converting Enzyme        ARB: Angiotensin Receptor Blocker     







                     
Appendix 17: STOPP/START criteria version 1 
 
STOPP (Screening Tool of Older People’s potentially inappropriate 
Prescriptions). 
The following prescriptions are potentially inappropriate in persons aged ≥ 65 years 
of age.  
A. Cardiovascular System 
1. Digoxin at a long-term dose > 125µg/day with impaired renal function∗ 
(increased risk of toxicity). 
2. Loop diuretic for dependent ankle oedema only i.e. no clinical signs of heart 
failure (no evidence of efficacy, compression hosiery usually more appropriate). 
3. Loop diuretic as first-line monotherapy for hypertension (safer, more effective 
alternatives available). 
4. Thiazide diuretic with a history of gout (may exacerbate gout). 
5. Non-cardioselective β-blocker with chronic obstructive pulmonary disease 
(COPD) (risk of bronchospasm). 
6. β-blocker in combination with verapamil (risk of symptomatic heart block). 
7. Use of diltiazem or verapamil with NYHA Class III or IV heart failure (may worsen 
heart failure). 
8. Calcium channel blockers with chronic constipation (may exacerbate 
constipation). 
9. Use of aspirin and warfarin in combination without histamine H2 receptor 
antagonist (except cimetidine because of interaction with warfarin) or proton 
pump inhibitor (PPI) (high risk of gastrointestinal bleeding). 
10. Dipyridamole as monotherapy for cardiovascular secondary prevention (no 
evidence for efficacy). 
11. Aspirin with a past history of peptic ulcer disease without histamine H2 receptor 
antagonist or PPI (risk of bleeding). 
12. Aspirin at dose > 150mg day (increased bleeding risk, no evidence for increased 
efficacy). 
13. Aspirin with no history of coronary, cerebral, or peripheral arterial symptoms or 
occlusive arterial event (not indicated). 
14. Aspirin to treat dizziness not clearly attributable to cerebrovascular disease (not 
indicated). 
15. Warfarin for first, uncomplicated deep venous thrombosis for longer than 6 
months duration (no proven added benefit). 
16. Warfarin for first uncomplicated pulmonary embolus for longer than 12 months 
duration (no proven benefit). 
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17. Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent bleeding 
disorder (high risk of bleeding).  
      ∗ GFR < 50ml/min. 
 
 
B. Central Nervous System and Psychotropic Drugs 
1. Tricyclic antidepressants (TCAs) with dementia (risk of worsening cognitive 
impairment). 
2. TCAs with glaucoma (likely to exacerbate glaucoma). 
3. TCAs with cardiac conductive abnormalities (pro-arrhythmic effects). 
4. TCAs with constipation (likely to worsen constipation). 
5. TCAs with an opiate or calcium channel blocker (risk of severe constipation). 
6. TCAs with prostatism or prior history of urinary retention (risk of urinary 
retention). 
7. Long-term (i.e. > 1 month), long-acting benzodiazepines, e.g. chlordiazepoxide, 
flurazepam, nitrazepam, chlorazepate and benzodiazepines with long-acting 
metabolites e.g. diazepam (risk of prolonged sedation, confusion, impaired 
balance, falls). 
8. Long-term (i.e. > 1 month) neuroleptics as long-term hypnotics (risk of 
confusion, hypotension, extra-pyramidal side effects, falls). 
9. Long-term neuroleptics (> 1 month) in those with parkinsonism (likely to 
worsen extra-pyramidal symptoms). 
10. Phenothiazines in patients with epilepsy (may lower seizure threshold).  
11. Anticholinergics to treat extra-pyramidal side effects of neuroleptic medications 
(risk of anticholinergic toxicity). 
12. Selective serotonin re-uptake inhibitors (SSRIs) with a history of clinically 
significant hyponatraemia (non-iatrogenic hyponatraemia < 130mmol/l within 
the previous 2 months). 
13. Prolonged use (> 1 week) of first-generation antihistamines, i.e. 
diphenydramine, chlorpheniramine, cyclizine, promethazine (risk of sedation 
and anti-cholinergic side effects). 
 
C. Gastrointestinal System 
1. Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhoea of 
unknown cause (risk of delayed diagnosis, may exacerbate constipation with 
overflow diarrhoea, may precipitate toxic megacolon in inflammatory bowel 
disease, may delay recovery in unrecognised gastroenteritis). 
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2. Diphenoxylate, loperamide or codeine phosphate for treatment of severe 
infective gastroenteritis i.e. bloody diarrhoea, high fever or severe systemic 
toxicity (risk of exacerbation or protraction of infection). 
3. Prochlorperazine or metoclopramide with parkinsonism (risk of exacerbating 
parkinsonism). 
4. PPI for peptic ulcer disease at full therapeutic dosage for > 8 weeks (earlier 
discontinuation or dose reduction for maintenance/prophylactic treatment of 
peptic ulcer disease, oesophagitis or GORD indicated). 
5. Anticholinergic antispasmodic drugs with chronic constipation (risk of 
exacerbation of constipation). 
 
D. Respiratory System 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of 
adverse effects due to narrow therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance 
therapy in moderate-severe COPD (unnecessary exposure to long-term side 
effects of systemic steroids). 
3. Nebulised ipratropium with glaucoma (may exacerbate glaucoma). 
 
E. Musculoskeletal System 
1. Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer 
disease or gastrointestinal bleeding, unless with concurrent histamine H2 
receptor antagonist, PPI, or misoprostol (risk of peptic ulcer relapse). 
2. NSAID with moderate-severe hypertension (moderate: 160/100mmHg – 
179/109mmHg; severe: ≥ 180/110mmHg) (risk of exacerbation of hypertension). 
3. NSAID with heart failure (risk of exacerbation of heart failure). 
4. Long-term use of NSAID (> 3 months) for relief of mild joint pain in osteoarthtitis 
(simple analgesics preferable and usually as effective for pain relief). 
5. Warfarin and NSAID together (risk of gastrointestinal bleeding). 
6. NSAID with chronic renal failure∗ (risk of deterioration in renal function).                     
∗ estimated GFR 20 – 50ml/min. 
7. Long-term corticosteroids (> 3 months) as monotherapy for rheumatoid 
arthrtitis or osterarthritis (risk of major systemic corticosteroid side effects). 
8. Long-term NSAID or colchicine for chronic treatment of gout where there is no 






F. Urogenital System 
1. Bladder antimuscarinic drugs with dementia (risk of increased confusion, 
agitation). 
2. Bladder antimuscarinic drugs with chronic glaucoma (risk of acute exacerbation 
of glaucoma). 
3. Bladder antimuscarinic drugs with chronic constipation (risk of exacerbation of 
constipation). 
4. Bladder antimuscarinic drugs with chronic prostatism (risk of urinary retention). 
5. Alpha-blockers in males with frequent incontinence i.e. one or more episodes of 
incontinence daily (risk of urinary frequency and worsening of incontinence). 
6. Alpha-blockers with long-term urinary catheter in situ, i.e. more than 2 months 
(drug not indicated). 
 
 
G. Endocrine System 
1. Glibenclamide or chlorpropamide with type 2 diabetes mellitus (risk of 
prolonged hypoglycaemia). 
2. β-blockers in those with diabetes mellitus and frequent hypoglycaemic episodes 
i.e. ≥ 1 episode per month (risk of masking hypoglycaemic symptoms). 
3. Oestrogens with a history of breast cancer or venous thromboembolism 
(increased risk of recurrence). 
4. Oestrogens without progestogen in patients with intact uterus (risk of 
endometrial cancer). 
 
H. Drugs that adversely affect those prone to falls (≥ 1 fall in past three months) 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, parkinsonism). 
3. First generation antihistamines (sedative, may impair sensorium). 
4. Vasodilator drugs known to cause hypotension in those with persistent postural 
hypotension i.e. recurrent > 20mmHg drop in systolic blood pressure (risk of 
syncope, falls). 










I. Analgesic Drugs 
1. Use of long-term powerful opiates e.g. morphine or fentanyl as first line therapy 
for mild-moderate pain (WHO analgesic ladder not observed). 
2. Regular opiates for more than 2 weeks in those with chronic constipation 
without concurrent use of laxatives (risk of severe constipation). 
3. Long-term opiates in those with dementia unless indicted for palliative care or 
management of moderate/severe chronic pain syndrome (risk of exacerbation 
of cognitive impairment). 
 
 
J. Duplicate Drug Classes 
Any regular duplicate drug class prescription e.g. two concurrent opiates, NSAIDs, 
SSRIs, loop diuretics, Angiotensin Converting Enzyme (ACE) inhibitors (optimisation 
of monotherapy within a single drug class should be observed prior to considering a 
new class of drug). This excludes duplicate prescribing of drugs that may be 
required on a prn basis e.g. inhaled β2 agonists (long and short acting) for asthma or 

















START: Screening Tool to Alert doctors to Right i.e. appropriate, 
indicated Treatment. 
These medications should be considered for people ≥ 65 years of age with 
the following conditions, where no contraindication to prescription exists. 
 
A. Cardiovascular System 
1. Warfarin in the presence of chronic atrial fibrillation. 
2. Aspirin in the presence of chronic atrial fibrillation, where warfarin is 
contraindicated, but not aspirin. 
3. Aspirin or clopidogrel with a documented history of atherosclerotic coronary, 
cerebral, or peripheral vascular disease in patients with sinus rhythm. 
4. Antihypertensive therapy where systolic blood pressure consistently > 160 
mmHg. 
5. Statin therapy with a documented history of coronary, cerebral, or peripheral 
vascular disease, where the patient’s functional status remains independent for 
activities of daily living and life expectancy is > 5 years. 
6. ACE inhibitor with chronic heart failure. 
7. ACE inhibitor following acute myocardial infarction. 
8. β-blocker with chronic stable angina. 
 
B. Respiratory System 
1. Regular inhaled β2 agonist or anticholinergic agent for mild to moderate asthma 
or COPD. 
2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where 
predicted FEV1 < 50%. 
3. Home continuous oxygen with documented chronic type 1 respiratory failure 
(pO2 < 8.0kPa, pCO2 < 6.5kPa) or type 2 respiratory failure (pO2 < 8.0kPa, pCO2   
> 6.5kPa). 
 
C. Central Nervous System 
1. Levodopa in idiopathic Parkinson’s disease with definite functional impairment 
and resultant disability. 
2. Antidepressant drug in the presence of moderate-severe depressive symptoms 




D. Gastrointestinal System 
1. Proton Pump Inhibitor with severe gastro-oesophageal acid reflux disease or 
peptic stricture requiring dilatation. 
2. Fibre supplement for chronic, symptomatic diverticular disease with 
constipation. 
 
E. Musculoskeletal System 
1. Disease-modifying anti-rheumatic drug (DMARD) with active moderate-severe 
rheumatoid disease lasting > 12 weeks. 
2. Bisphosphonates in patients taking maintenance oral corticosteroid therapy. 
3. Calcium and Vitamin D supplement in patients with known osteoporosis 
(radiological evidence or previous fragility fracture or acquired dorsal kyphosis). 
 
F. Endocrine System 
1. Metformin with type 2 diabetes +/- metabolic syndrome (in the absence of renal 
impairment∗). 
2. ACE inhibitor or Angiotensin Receptor Blocker in diabetes with nephropathy i.e. 
overt urinalysis proteinuria or microalbuminuria (> 30mg/24 hours) +/- serum 
biochemical renal impairment∗. 
3. Antiplatelet therapy in diabetes mellitus if one or more co-existing major 
cardiovascular risk factor present (hypertension, hypercholesterolaemia, 
smoking history). 
4. Statin therapy in diabetes mellitus if one or more co-existing major 
cardiovascular risk factor present. 
∗ GFR < 50ml/min 
 
Reference:  Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening 
Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to 
Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008 
Feb;46(2):72-83. 
(Reproduced with the permission of Prof. Denis O’Mahony, August 2019) 
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Appendix 18: Prescriber implementation rates for START 
recommendations (including START-based recommendations 







START-based Recommendations Physician Pharmacist p-value† 
Cardiovascular System 29/37 26/42 0.1121 
Warfarin with chronic atrial fibrillation 15/18 2/3  
Aspirin with chronic atrial fibrillation where warfarin is 
contraindicated 
2/3 4/5  
Aspirin or clopidogrel with a documented history of 
atherosclerotic coronary, cerebral, or peripheral 
vascular disease in patients with sinus rhythm 
0/2 9/14  
Antihypertensive therapy where systolic blood pressure 
consistently > 160 mmHg 
1/1 -  
Statin therapy with history of coronary, cerebral, or 
peripheral artery disease without contraindication 
8/9 9/12  
ACE inhibitor with chronic heart failure 3/4 1/5  
ACE inhibitor following acute myocardial infarction - 0/1  
β-blocker with chronic stable angina. - 1/2  
Respiratory System - 16/20 - 
Regular inhaled  β2 agonist or anticholinergic agent for 
mild to moderate asthma or COPD 
- 5/7  
Regular inhaled corticosteroid for moderate-severe 
asthma or COPD, where predicted FEV1 < 50%. 
- 11/13  
Central Nervous System - 4/4 - 
Antidepressant drug in the presence of moderate-
severe depressive symptoms lasting at least three 
months. 
- 4/4  
Gastrointestinal System 1/1 - - 
Proton Pump Inhibitor with severe gastro-oesophageal 
acid reflux disease or peptic stricture requiring 
dilatation. 











START-based Recommendations Physician Pharmacist p-value† 
Musculoskeletal System 97/109 14/31 < 0.0001* 
Disease-modifying anti-rheumatic drug (DMARD) with 
active moderate-severe rheumatoid disease lasting > 12 
weeks 
- 0/1    
Bisphosphonates in patients taking maintenance oral 
corticosteroid therapy 
14/18 2/12    
Calcium and vitamin D supplementation in patients with 
known osteoporosis, fragility fracture or dorsal kyphosis 
83/91 12/18     
Endocrine System 12/12 11/18   0.0136* 
Metformin with type 2 diabetes mellitus +/- metabolic 
syndrome 
1/1 2/2  
ACE inhibitor or Angiotensin Receptor Blocker in 
patients with diabetes and nephropathy 
7/7 1/1  
Antiplatelet therapy in those with diabetes mellitus and 
one or more major cardiovascular risk factors 
2/2 2/2  
Statin therapy in patients with diabetes mellitus and one 
or more major cardiovascular risk factors 
2/2 6/13  
Total START Recommendations 139/159 71/115 < 0.0001* 
Total STOPP/START Recommendations 376/451 171/370 < 0.0001* 
ACE: Angiotensin Converting Enzyme   COPD: Chronic obstructive pulmonary disease   FEV1: Forced expiratory volume in 1 second 
†p-value calculated using chi-squared test.     * Statistically significant difference observed (p < 0.05).         
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Appendix 20: COREQ checklist for qualitative interview study from Chapter 6 
 
    
   Domain 1: Research Team and Reflexivity 
 
   
Personal characteristics   
1. Interviewer/facilitator Which author/s conducted the interview or focus group? KD conducted the interviews. 
2. Credentials What were the researcher’s credentials (e.g. PhD, MD)? At the time of undertaking the interviews, KD’s credentials were BPharm, MPharm, MPSI. 
3. Occupation What was their occupation at the time of the study? KD is an Irish registered pharmacist, who was undertaking a PhD in Clinical Pharmacy 
research when this study was conducted. 
4. Sex Was the researcher male or female? Male. 
5. Experience and training What experience or training did the researcher have? KD completed training in utilisation of NVivo software, and received training in analysis of 
qualitative interviews at Oxford University, United Kingdom. 
    
Relationship with participants   
6. Relationship established Was a relationship established prior to study  
commencement? 
The interviewer had no previous relationship or established rapport with any of the 
interviewees prior to study commencement. 
7. Participant knowledge of the 
interviewer 
What did the participants know about the researcher           
(e.g. personal goals, reasons for doing the research)? 
KD had disclosed to all participants that he was a pharmacist undertaking this study as part 
of his PhD, prior to conducting the interviews. 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? (e.g. bias, assumptions, reasons      
and interests in the research topic) 
KD is a registered pharmacist who was conducting this study as part of his PhD exploring 
factors affecting physician prescriber implementation of medication appropriateness 
recommendations in hospitalised older adults. This information was disclosed to 






   Domain 2: Study Design   
   
Theoretical framework   
9. Methodological orientation  
and Theory 
What methodological orientation was stated to underpin 
the study (e.g. grounded theory, discourse analysis, 
ethnography, phenomenology, content analysis)? 
Content analysis was used in this study to analyse the data from the interview transcripts.  
Conventional content analysis was used to identify the conventional themes, which were 
attributed as factors that influence physician prescriber implementation of hospital 
pharmacist recommendations. The Theoretical Domains Framework (TDF) was used to 
structure the interview topic guides, and directed content analysis was used to identify the 
relevant TDF domains from the interview transcripts.  
   
     Participant selection   
10. Sampling How were participants selected (e.g. purposive,   
convenience, consecutive, snowball)? 
Participants were identified and recruited through a combination of convenience sampling 
and purposive sampling. Of the pharmacists, the pilot participant was recruited face to face 
by KD at their place of work, three were identified via a colleague of KD, and two were 
recruited via snowballing (i.e. identified from a pharmacist who had already participated in 
the study). Of the physicians, two were identified through a colleague of KD, three via 
snowballing, and three were identified via pharmacists who had not already participated in 
the study (note: these pharmacists were identified through a colleague of KD). 
11. Method of approach How were participants approached                                                         
(e.g. face-to-face, telephone, mail, email)? 
Nine participants were recruited via email, three participants were approached face to face 
by KD at their place of work, and two were contacted via text message. 
12. Sample size How many participants were in the study? 14. 
13. Nonparticipation How many people refused to participate or dropped out? 
Reasons? 
None. 
    
     Setting    
14. Setting of data collection Where was the data collected (e.g. home, clinic,    
workplace)? 
One interview was conducted in a private room at the interviewer’s workplace as this was 
the preference of the interviewee. However, all other interviews were conducted in a 




    
15. Presence of nonparticipants Was anyone else present besides the participants and 
researchers? 
No. 
16. Description of sample What are the important characteristics of the sample          
(e.g. demographic data, date)? 
Ten participants were female. With regard to hospital-based experience, half the 
participants had less than 5 years’ experience, four participants had ≥ 5 years’ experience 
but less than 10 years’ experience, and three participants had over 10 years’ experience. 
The interviews took place between August 2018 and August 2019.  
   
     Data collection   
17. Interview guide Were questions, prompts, guides provided by the authors? 
Was it pilot tested? 
Two separate topic guides comprising a similar line of questioning (with prompts where 
appropriate) were formulated for the pharmacist and physician participants. The topic 
guides were based on a review of the literature, the TDF, and my own and my supervisors’ 
knowledge of the research area. Each topic guide was pilot tested with one participant 
each, and both of these interviews were included in the study. The topic guides were 
iteratively refined during the study where appropriate to ensure that emerging themes 
were explored in subsequent interviews. 
18. Repeat interviews Were repeat interviews carried out? If yes, how many? No. 
19. Audio/visual recording Did the research use audio or visual recording to collect      
the data? 
All interviews were audio-recorded. 
20. Field notes Were field notes made during and/or after the interview        
or focus group? 
Field notes were recorded after each interview, and were used to refine topic guides and 
inform data analysis. 
21. Duration What was the duration of the interviews or focus group? The mean interview length was 33 minutes (range 18 – 47 minutes). 
 
22. Data saturation Was data saturation discussed? Data analysis coincided with data collection. It was as planned in advance that if no new 
themes emerged in the additional three interviews after the eleventh interview (i.e. to 
complete the 14-participant sampling matrix), then this would confirm that data saturation 
had been reached.  





   
   Domain 3: Analysis and Findings   
   
     Data analysis   
24. Number of data coders How many data coders coded the data? Two (KD and AF). 
25. Description of the coding      
tree 
Did authors provide a description of the coding tree? A description of the process is provided, whereby initial, non-hierarchical codes were 
categorised, and subsequently developed to generate themes and subthemes as part of 
conventional content analysis. 
The TDF was the chosen framework for directed content analysis, and was used as the basis 
for a coding tree here. 
26. Derivation of themes Were themes identified in advance or derived from                            
the data? 
Conventional content analysis comprised open coding to inductively create initial, non-
hierarchical codes. These initial codes were subsequently categorised to generate the 
evolving themes and subthemes. 
Directed content analysis was then employed whereby the transcripts were deductively 
coded using the TDF to identify the domains present. 
27. Software What software, if applicable, was used to manage the data? QSR NVivo
®
 Version 11. 
28. Participant checking Did participants provide feedback on the findings? No.  
   
     Reporting   
29. Quotations presented Were participant quotations presented to illustrate the Yes. 
  themes/findings? Was each quotation identified?  
  e.g. participant number  
30. Data and findings Was there consistency between the data presented and Quotations are presented in a manner consistent with findings. 
 consistent the findings?  
31. Clarity of major themes Were major themes clearly presented in the findings? Major themes are clearly presented in the results section. 
32. Clarity of minor themes Is there a description of diverse cases or discussion Subthemes are presented under each of the major themes. 




                     
Appendix 21: Final version of topic guides for Chapter 6 
 
Topic guide for pharmacists 
1. What do you see as the main roles that pharmacists have in the 
multidisciplinary care of older adults in the hospital setting?  
2. How aware do you think physicians are of the pharmacist’s role in the hospital 
setting?   
 What do you think doctors’ opinions are of hospital pharmacists’ roles?   
3. How would you compare your knowledge and skill set with that of a physician 
when it comes to medication appropriateness in hospitalised older adults?  
 Are there any gaps in the knowledge or skill set of physicians that 
pharmacists can help with in particular?  
 Are there any gaps in the knowledge or skill set of pharmacists?   
4. To what extent do pharmacists and physicians share the same goals in terms of 
reducing potentially inappropriate prescribing in older adults?  
5. How would you describe your day-to-day interactions with physicians?  
6. How do you inform physicians of medication appropriateness issues in older 
adults?  
 How do you decide what method of communication to use? 
 Do you use different communication methods for different types of 
recommendations?  
 Do you find any methods of communication more effective than others?  
 If the most effective method is not the most commonly used, ask why.  
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7. What factors might make it more likely for a physician to 
implement recommendations from a pharmacist?   
8. What factors might make it less likely for a physician to 
implement recommendations from a pharmacist?   
9. Are there any specific types of recommendations that you think are more likely 
or less likely going to be implemented by physicians?  
 e.g. recommendations regarding medication reconciliation, medication 
appropriateness, drug interactions, renal dose adjustment etc.  
10. How does the experience of a pharmacist affect the number of 
recommendations implemented by physicians?   
11. How do the characteristics of an individual pharmacist affect the 
implementation of recommendations?  
 Personality? Knowledge? Mindset? Approach from pharmacist? Confidence? 
12. How does the grade or experience of physician affect the number of 
recommendations implemented?  
13. How does the specialty of physician affect the number of recommendations 
implemented?  
 Are some specialties more likely or less likely to implement the 
recommendations?  
 How do you feel about making a recommendation to a specialist concerning 
their area of expertise?  
14. How do the characteristics of an individual physician affect the number of 
recommendations implemented?  
 Personality? Knowledge? Mindset? Approach from doctor? Confidence?  
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15. How important do you think it is for the physician to know you or be familiar 
with you when it comes to implementing your recommendations?  
16. On a scale of 1 to 10, how would you, as a pharmacist with (insert 
number) years of experience, rate your confidence in discussing medication 
appropriateness with physicians, 1 being not confident at all and 10 being very 
confident?   
17. You identify that an older patient under the care of a hospital physician has 
been prescribed a potentially inappropriate medication long-term by another 
prescriber, and make a recommendation to stop this medication. How likely is 
it that this will be implemented?   
18. What are the organisational barriers to pharmacists providing medication 
recommendations?  
19. How does the hospital environment affect the implementation rate of 
pharmacist recommendations?  
 Is there enough time/opportunity to address these issues?   
20. Does the patient have any impact on the number of pharmacist 
recommendations implemented?  
21. Are pharmacist recommendations audited or reviewed by your 
department? Any quality improvement initiatives?  
22. Do you think that the culture within this particular hospital has any impact 
on i) the relationship between pharmacists and physicians and/or ii) physicians’ 
implementation of pharmacist recommendations?  
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23. Do you have experience from another hospital that is relevant? Were the 
means of communicating with physicians different and what was the effect on 
the implementation of recommendations?  
24. If you could change how pharmacists make recommendations or interventions 
for older adults in your hospital setting, what would you suggest?  
25. In some jurisdictions, pharmacists prescribe as part of the hospital 
multidisciplinary team. How do you feel about pharmacists having some form 
of prescribing (or deprescribing) role in the care of older adults?  
26. A study by our research group has suggested that physicians are more likely to 
implement recommendations from fellow physicians than from pharmacists 
when it comes to recommendations addressing older patients’ medications. 
What are your thoughts on this?  
  
That brings us to the end of the interview. Do you have any additional comments 








Topic guide for physicians 
1. What do you see as your role in identifying and addressing issues of potentially 
inappropriate prescribing in hospitalised older adults?  
 How do you feel about making changes in older patients’ medications?  
2. What do you see as the main roles that pharmacists have in 
the multidisciplinary care of older adults in the hospital setting?  
3. How would you compare your knowledge and skill set with that of a pharmacist 
when it comes to medication appropriateness in hospitalised older adults?  
 Are there any gaps in your knowledge or skill set that pharmacists can help 
with?  
 Are there any gaps in the knowledge or skill set of pharmacists?   
4. To what extent do pharmacists and physicians share the same goals in terms of 
reducing potentially inappropriate prescribing in older adults?  
5. How would you describe your relationship or day-to-day interactions 
with pharmacists?  
6. At present, how do you receive recommendations from pharmacists in 
hospital?   
 e.g. face to face, over the telephone, written, or a combination?  
 How do you most commonly receive these recommendations?  
 What method do you find most effective? Why?  
 If the most effective method is not the most commonly used method, 
why do you think that is the case?   
7. What factors might make it more likely for you implement a recommendation 
from a pharmacist?  
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8. What factors might make it less likely for you to implement a recommendation 
from a pharmacist?  
9. Are there any specific types of recommendations from hospital pharmacists 
that you find most beneficial?  
 e.g. recommendations regarding medication reconciliation, medication 
appropriateness, drug interactions, renal dose adjustment etc.  
10. How does the experience of a pharmacist affect the number of their 
recommendations that you implement?  
11. How do the characteristics of an individual pharmacist affect the 
implementation of pharmacist recommendations?  
 Personality? Knowledge? Mindset? Approach from pharmacist? Confidence? 
12. How does the grade or experience of physician affect the number of 
pharmacist recommendations implemented, do you think?  
13. How does the specialty of physician affect the number of pharmacist 
recommendations implemented?  
 Are some specialties more likely or less likely to implement the 
recommendations?   
14. How do the characteristics of an individual physician affect the implementation 
of pharmacist recommendations?  
 Personality? Knowledge? Mindset? Approach from doctor? Confidence?  
15. How important is it for you to know or be familiar with the pharmacist you are 




16. On a scale of 1 to 10, how would you, as a(n) (insert grade of doctor) rate your 
confidence in discussing medication appropriateness with a hospital 
pharmacist, 1 being not confident at all and 10 being very confident? Why?  
17. Can you describe an instance where a pharmacist made a recommendation 
that you did not implement.  
 What are reasons you did not implement the recommendation?  
18. How does the hospital environment affect the implementation rate of 
pharmacist recommendations?  
 Is there enough time/opportunity to address these issues?   
19. Does the patient have any impact on the number of pharmacist 
recommendations implemented?   
20. A pharmacist makes a recommendation to you to stop a potentially 
inappropriate medication that an older patient has been taking long-term 
under the care of another physician. What would you do?   
21. If pharmacist recommendations are not implemented, what clinical impact (if 
any) does this have on older patients?    
22. If you could change how pharmacists make recommendations or 
interventions for older adults in your hospital setting, what would you 
suggest?   
23. In some jurisdictions, pharmacists prescribe as part of the hospital 
multidisciplinary team. How do you feel about pharmacists having some form 




24. A study by our research group has suggested that physicians are more likely 
to implement recommendations from fellow physicians than from 
pharmacists when it comes to recommendations addressing older patients’ 
medications? What are your thoughts on this? 
  
That brings us to the end of the interview. Do you have any additional comments 












                     
Appendix 22: Supplementary Quotations for Chapter 6 
 
Theme Descriptor  Illustrative Quotations 
 
 
1.  Clinical 
relevance and 




in the hospital 
setting 
 
“I don’t think they’ll really do much about long-term medicines 
because – like here’s an acute setting, so they might only have 
them for a week. But like tapering a person off like long-term 
benzos is a long-term project, so I don’t think they have the time 
for it here to be honest”. Pharmacist 1 
“I think physicians are so busy, they…it’s not something that’s on 
their radar when a patient presents to an acute hospital setting, 
and I suppose if you stand back and look at it – is it the role of a 
hospital, an acute hospital, to optimise pharmacotherapy on a, on, 
on a…in older…is that the best time to do it? Is it not the best time 
for that to be done in primary care?” Pharmacist 6 
“…maybe if they press too hard on the what we would may 
consider the less important issues, you know that might kind of 
annoy you a little bit. You might feel like, you know, that’s a minor 
issue compared to what’s actually going with the patient. We need 
to focus on the bigger things”. Physician 5 
“…I suppose is it relevant to the patient’s clinical picture at the 
time of admission? So, for example, if it’s something to do with a 
sleeping tablet and it’s not relevant to the patient’s admission at 
the moment, they might feel that the GP might be a better person, 
you know, to review those type of medications”. Pharmacist 3 
“I suppose you would grade them in some sort of way, you would 
grade them on importance as well as to if something is very minor 
or very important. So like some absolute contra-indications or 
double-prescribing of anticoagulants like things that have 
potential serious side effects would be taken very seriously”. 
Physician 3 
“I find that interactions, even especially if they’re theoretical 
interactions and they’re not going to affect the patient too much, I 
don’t think they are really considered. They’re not really intervened 
on too much”. Pharmacist 2 
“I suppose it depends on what the recommendation is, like say if 
someone had A Fib [atrial fibrillation] and a high CHA₂DS₂-VASc 
score, then if the pharmacist has recommended anticoagulation 
and they weren’t anticoagulated, that obviously has a big impact. I 
think the higher impact things tend to be implemented…” 
Physician 2 
“I suppose if it’s more urgent. Like, if they saw a patient and the 
patient was on Calcichew® D3 at home and they’re on just 
Calcichew® now, they might not think of that as a problem. But if it 
was a risk, so if there were an interaction that puts the patient at 





“…maybe they’re in a very stressful day or they’re very busy and 
they’re not that interested in hearing about medication for a 
particular patient or they might feel they have more pressing 
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“But if you’re on a completely different ward dealing with an  
emergency and like you’re going to say ‘Yeah, I’ll do it at some 
point’ and you might not actually do it. So, they’re kind of smaller 
errors that you wouldn’t pay that much attention to and I think it’s 
just how you prioritise the…like perceived problem with the 
prescription”. Physician 3  
“…things like benzos not being stopped in your older people. Like 
you know that does have an effect for sure but it’s not going to be 
a priority for a patient. You know it’s not going to be one of the 
priorities for an inpatient during their stay here…” Pharmacist 6 
“…it’s an acute setting here. So, there’s always someone more sick 
than the patient they’re at. So, maybe towards the end of a 
patient’s admission when you can actually have the time to sit 
down and review it, their medicines on discharge. There’s always 
another 10 patients that are sicker than them. So, it even might 





“…it’s the ease of doing it as well. So like if you take that example 
of a PPI: if someone tells you they’re on 15 and not 30 at home and 
give you the kardex and it’s in front of you, yeah that’s easy to do”. 
Physician 3 
“…someone comes in and they’re on glaucoma eye drops – yeah 
prescribe that. There’s no thinking about it – it’s black and white”. 
Pharmacist 6 
“I would always, unless it was something very benign, like I don’t 
know Chloromycetin® eye drops or something and their eye is fine, 
then I would be happy to cancel that, but I would usually always 
call and ask the registrar if it was appropriate to stop or not”. 
Physician 7 
“I think the experience part comes in when it’s more grey areas…” 
Pharmacist 3  
“They probably interact more with the intern and the SHO on the 
team in person, you know, with recommendations or with issues, 
who in turn may have to pass it up to me then if they’re not sure 
what to do”. Physician 5 
“I think the most junior of doctors I’d say, the interns or the SHOs, I 
think are more likely to ask for advice regarding more complex 
stuff”. Physician 8 
“So I think the more straightforward ones where the guidelines are 
very clear are acted on probably quicker and it’s easier for people 
to make a decision around that because there’s no ‘oh maybe I 
need to check with a senior member of the team’ or ‘that needs to 
be discussed maybe with the GP’…” Pharmacist 3 
“More evidence-based things, they’d be more quick to change”. 
Pharmacist 1 
“Well like if they tell us more information about why we should 
change it. Kind of like their back up info about why are they 
making that recommendation”. Physician 1 
“But I think if you can present your case and give them good 
evidence, they’ll do it. Like, don’t just say that there’s an 
interaction there. Tell them where you got the interaction and 
what kind of – like, what it could cause if you don’t change it. So, 














“…I think face-to-face communication of the changes is the easiest 
way to actually get them implemented…” Physician 3 
“I suppose to meet with the doctors is always easier, so if you can 
like face to face have a discussion when you have the information 
in front of you - so when you have the patient’s kardex or the 
patient’s notes, it’s always easier to explain something rather than 
doing it through a phone call”. Pharmacist 3 
“I think face-to-face when you’re both there and you can look at 
the drug chart if necessary and you can pull the notes and you can 
say ‘look, this is the issue’, whereas I think if you’re relying on…the 
least effective probably is like our notes that we leave on the drug 
chart, because I don’t think that a lot of the time, you know, during 
a ward round, they don’t look at the drug chart…”  Pharmacist 5 
“…other methods of communication are not as effective as face-to-
face and getting you to do it right in front of them…”             
Physician 1 
“Sometimes it could be acted upon incorrectly if you’re not there to 
look at what, you know…so I think like definitely face-to-face 
communication on a ward is the most effective”. Pharmacist 5 
“I think for serious things, face-to-face is great. You can kind of 
talk back and forth sometimes you know. Written things – you 
know, you may…people may not understand the reason 
something’s being prescribed or the reason for maybe going 
outside the license…” Physician 5 
“Oh, face to face, they’ll do it, they kind of get your point. They’ll 
do it straight away, and leaving a note - it can just fall by the 
wayside…” Pharmacist 4 
“…I guess one thing is the written recommendations on the front of 
the kardex, it’s usually on the green piece of paper. We would 
follow their recommendations but a lot of the times it can get 
missed. So, I guess that’s one factor that makes us less likely to 
implement it. If we just miss it”.  Physician 1 
“…if you talk to the person face to face, I think they’d do it. They’re 
more inclined to take up your recommendations than if you left a 
note”. Pharmacist 1 
“I think if it’s not communicated well. Like definitely the best way 
of communicating it is by saying it, whereas sometimes you can 
look at what they have written especially if it is in the notes and 
say, as I said like, are they telling us just to use it with caution or 
are they telling us to absolutely stop it? So, I think verbal is better 
than written communication”. Physician 2 
“…if I think it’s an urgent issue, I will bleep them and talk to them 
verbally, because they’ll just respond to it a lot quicker that way. If 
I leave a note, they might not see it till the next ward round or they 
might not be looked at at all”. Pharmacist 2 
“…I suppose more pharmacy time would useful, because I think the 
sort of rather cold abstracts or the way we deal with a lot of it is, 
it’s written in the notes, it’s sort of vague almost anonymous green 

















“If they just write a note in a book, in the notes, I’d say they’d be 
less likely to implement them. Possibly if they didn’t get (I 
suppose) the reasoning behind them…” Pharmacist 4 
“I find that a verbal communication is much more effective than a 
written communication regarding an intervention I want to make 
because you can explain it better verbally and I think they are 
more likely to take it on board. That’s kind of just what I found. So 
I would be inclined to bleep them and talk to them through the 
issue and I think they are more inclined to take it on board then”. 
Pharmacist 2 
“…I’ve worked in places where you get a phone call maybe after 
your ward round with the big list of recommendations verbally 
that you’d be trying to write down and like the serious potential 
for information to be lost there…” Physician 5 
“I don’t really see much difference in over the phone or face-to-
face in terms of them getting, them following through on the 
intervention I think. Yeah I think they would follow through just as 








“…the most effective way of doing, getting stuff implemented is 
both by writing in the notes, and verbally contacting them. So, if 
you just write it in the notes, it may not happen. Em…you have to 
speak to somebody. It’s really important that you speak to 
somebody”. Pharmacist 6 
“…and then both verbal and written communication because 
sometimes we need reminders”. Physician 3 
“I could say well I also put it in writing on the intervention slip, just 
to kind of have a back-up there and just in case the SHO didn’t 
discuss it with the team, that somebody might see it then written 
as well”. Pharmacist 2 
“You know, coming to meet somebody is much more difficult. So, I 
think the note is probably the most important but, like if you were 
to maybe make a verbal kind of reference to the fact that ‘I have 








“Definitely, I think if you’ve got a nice manner, and you approach 
in a less accusatory fashion, you’ll get things I think a little bit 
easier, or explain better rather than going up and saying ‘That’s 
wrong, that’s dangerous, don’t do that’. But then I’ve also seen (I 
suppose) a couple of pharmacists who might be quite reluctant to 
counteract anything that a doctor has done. Like ‘Oh, they may 
know. So, I’m not saying anything’, or ‘I don’t really write in the 
patients notes because the team might get offended’, that kind of 
way. So, I think there is kind of that still hierarchy system - can still 
be there sometimes and can affect people. But definitely, the way 
you approach it will definitely affect it”. Pharmacist 4 
“…we shouldn’t just go in and say ‘you are wrong. This is what you 
should be doing’. I would always say ‘maybe think about doing 



















“I think experience…I think you…if you have a lot of experience, 
and you’re confident in what you’re saying to physicians, they’re 
gonna trust you then, and they’re gonna trust you. I think I can say 
confidently that the doctors trust me…” Pharmacist 6 
“I guess just being friendly to be honest. Nothing much to it. As 
long as they are friendly and nice and smile and are nice to you 
about it and not condescending, like you’d do anything for anyone 
who is nice to you”. Physician 1 
“But most of the time I’ll just say ‘this is the guidance. Consider 
changing x to y’ because the guidance states this. So, again, I'm 
not telling them what to do, but just what I know and what I have 
found and to maybe review it again”. Pharmacist 2 
“I suppose if it’s more direct, like ‘please consider stopping’, as 
opposed to ‘the guidelines state…’ If it’s an actual like ‘I think you 
should consider stopping it’, as opposed to just this kind of 
abstract concept”. Physician 2 
“They’re making these decisions, but I feel like sometimes they 
think ‘Oh you know, I’m writing this as a kind of an FYI’ but no one 
pushes it to say that you know you need to…can you have a look at 
my note or, what do you think about this? I feel like the individual 
pharmacist doesn’t approach it kind of even verbally…” Physician 7 
“…you need to be assertive and confident, but not overly arrogant 
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“I feel my knowledge at intern level of pharmacology and 
therapeutics is so much less than it should be, and that 
pharmacists have this really in-depth knowledge and 
understanding of a lot of different drugs…” Physician 7 
“I find if you go to interns, they won’t change things realistically, 
especially now. They’re only about four months in now. They won’t 
change – I won’t really go to interns too often because they’ll just 
bounce it back off their SHOs and registrars”. Pharmacist 1 
“Well I suppose I'm at an SHO level, I mightn’t always be sure 
whether this can be stopped…” Physician 6 
“I think usually their clinical experience plays a huge part in their 
decision to change [referring to senior physicians]”. Physician 1 
“I suppose it’s probably twofold: when they don’t have that much 
experience, they are probably more likely to take on the advice 
that you are giving them sometimes, so you know they 
mightn’t…like a lot of the time if I was making a recommendation 
on a patient’s medications, they would probably take on face value 
what I was saying as correct because they mightn’t have the 
experience behind them or they mightn’t be familiar with the 
medication”. Pharmacist 3 
“I think you may find that as you get older you are more likely to 
say, I know it all and continue on. So I think the grade is you may 
find the lower the grade the more likely they are to take on board 
pharmacists recommendations and more open to it I think. Like 
lots of things as we get older, we are maybe a bit more sure of 
ourselves and less likely to take on advice”. Physician 8 
“…if you take someone more experienced, while you might not 
always follow the recommendation, I think someone with 
experience would be more able to actually be making an informed 
decision and not following it for a reason…” Physician 3 
“…maybe the more old school consultants would’ve been more 
dismissive of pharmacist input…” Pharmacist 5 
“…senior doctors have kind of disregarded what the pharmacist’s 
opinion has been and from like, for no valid reason that I could see 
at that point in time”. Physician 7 
“I would kind of generalise and see that kind of the younger 
generation are a lot more accepting, a lot more encouraging of 
your involvement. I think personally that’s because they, a lot of 
them would have been trained with us. The older generation would 
have been completely separate…” Pharmacist 4 
“I think when you first start off as an intern you would be scared of 
making changes by yourself even if the pharmacist tells you that it 
is the correct dose or that there's a kind of interaction - we would 
always go to our, let’s say registrar first before we make any 
changes. But as you get more experienced you become more 
comfortable making the changes on your own”. Physician 1 
“…it might be that the SHO or the registrar has charted that 
particular medication and, you know, a more junior member of the 
team mightn’t feel confident in discontinuing it on the advice of 
pharmacy or they might feel that again, it might need further 
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the basis of blind 




“I suppose the lower…I suppose they would probably be more 
likely to accept their recommendations as kind of more gospel, 
whereas we might use our own experience to weigh up the pros 
and cons of taking the advice, and you know saying what are…and 
looking at the (kind of) goals, and make our own decision on 
whether we want to follow the advice…” Physician 5 
“…when they don’t have that much experience, they are probably 
more likely to take on the advice that you are giving them 
sometimes, so you know they mightn’t…like a lot of the time if I 
was making a recommendation on a patient’s medications, they 
would probably take on face value what I was saying as correct 
because they mightn’t have the experience behind them or they 
mightn’t be familiar with the medication”. Pharmacist 3 
“I think we probably take on board what anyone senior would say. 
So, if it’s a senior pharmacist you probably take it on board, 
whereas I don’t know maybe the more senior physicians would 
have their own opinions on whether it’s appropriate or not”. 
Physician 2 
“I think that interns and SHOs, well especially interns, or less 
experienced doctors would be more likely to just do what they 
were told or what they are asked to do without taking the clinical 
context into account. So, I think they would be less able to know 







“…because medicine is quite hierarchical, you’re really…it’s 
followed by a rigid structure, so maybe they feel like going to the 
more junior person and letting them pass on the message if 
needed is the appropriate way to do it”.  Physician 5 
“That may be around grade too often, a lot of this is consultant-
driven. So, a registrar and SHO may not feel empowered to sort of 
follow a recommendation either”. Physician 8 
“…whereas if it’s something that like their registrar has told them 
to do this or the SHO did it, and they’re slower then to change the 
work that another member of their team has done, you know, 
without checking, without checking with them, or they just don’t 
know”. Pharmacist 5 
“…you’re always going to go through your consultant or the senior 
registrar to make a kind of a medication prescribing decision”. 
Physician 7 
“Maybe sometimes, they were just told ‘oh prescribe this’ or 
whatever, so they’re not really sure do they…who is correct? Is it 
their registrar or is it you?” Pharmacist 5 
“…maybe junior doctors don't change immediately if someone 
else has told them to prescribe something, but they might 
question it with the rest of the team”. Physician 4 
“I might approach maybe the SHO rather than the registrar 
because I think the SHO would be more willing to listen to me and 
would be likely to discuss it with the rest of the team, and would 
be grateful for the interaction. Whereas in my experience talking 
to registrars, if I query something, it’s…the reply that I get is ‘well 
that’s what I want, so don’t question it’ basically. They might not 
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“I feel like there is probably a bit of a ‘Well the doctor knows best’ 
kind of thing, you know”. Physician 7 
“…there can be moments of conflict and it probably is to do with a 
personality clash or that they, maybe sometimes they perceive 
that they have got more important things to be dealing with than 
answering or talking about recommendations or answering a 
query from a pharmacist”. Pharmacist 3 
“I think any of the consultants I have worked with have been very 
open to pharmacist intervention and discussion with them as well. 
So, I would have no problem ever discussing anything with the 
pharmacist”. Physician 2 
“I kind of feel sometimes that the pharmacists make comments or 
write a note about potential you know, adverse effects or have you 
considered X, Y or Z but that the like senior doctors especially tend 
to just kind of fluff that off, and they say ‘Oh well, we’re the doctor 
making the prescribing decision, we have already kind of 
considered what the pharmacist is saying’…” Physician 7 
“I suppose there's a power thing. So, do you know, like someone 
telling you something…and maybe held in a position of power, I've 
no doubt maybe has an effect, do you know. Because that’s quite 
sizeable really, and then that might be that kind of trickle-down 








“Like obviously you’re gonna have surgeons or doctors who are 
way more abrupt and not as warm, or as friendly…but at the end 
of the day, it shouldn’t matter what their characteristics are, as 
long as the recommendation is sound from an experienced 
pharmacist, and is of benefit to the patient”. Pharmacist 6 
“I feel like some characters are probably more inclined to be kind 
of open-minded about most things”. Physician 7 
“…the personality of the person will obviously dictate how well 
they take that advice up or how they perceive that or how helpful 
they perceive that advice to be”. Pharmacist 3 
“…some would be more receptive to maybe perceived criticism or 
to a perceived challenge of their own prescribing”. Physician 3 
“There are some people that would, you know, think they are 
always right and they don’t want to take advice from other 
people”.  Physician 5 
“…the reply that I got from the physician was ‘I’ve prescribed it like 
that because that’s how I want it done’. Rather than ‘okay thanks 
for your query. This is why I'm doing this way and this is the 
evidence behind it’. It was just ‘this is why I'm doing it because I 
want it this way’. So I suppose maybe arrogance might come into 
it a little bit”. Pharmacist 2 
“Probably more arrogant physicians are less likely to take up 


















“I think the specialty is hugely influential on taking up 
recommendations”. Physician 7 
“And then some would be, wouldn’t want to prescribe medicines 
that they aren’t familiar with. So I think like knowledge of the drugs 
themselves would probably be the biggest factor as to what you do 
and you don’t, and I think that some doctors will be fairly set in their 
ways of using certain medications only and then not deviating from 
that”. Physician 3 
“…if you take surgeons or like specialties that maybe aren’t very 
medical and would have a lot less pharmacology knowledge, would 
be more likely to just take up anything. I’m not saying this is good or 
bad but would be more likely to just follow any recommendation 
made by someone else because they have less knowledge about the 
subject”. Pharmacist 6 
“…especially medicines that might be outside the far, day-to-day 
prescribing practice, we may not know as much…” Physician 5 
“So, I feel like in the context of a specialty, that those physicians 
probably would be very protective of their specialty drugs whereas 
the other non-kind of specialty drugs, so non-cardiac drugs for 
example in cardiology patients, I feel like recommendations would be 
both helpful and pretty well respected in that context really”. 
Physician 7 
“If you were making a recommendation…maybe a recommendation 
about the specialty…so, a cardiology drug, the cardiologist, they 
might not listen to you as fast. But if it was about another type of 
drug, they’d probably take it up faster”. Pharmacist 1 
“…you’d be more likely to agree with recommendations outside your 
specialty, and in your specialty, you may have more knowledge or 
more of that soft knowledge…” Physician 5 
“The pharmacist can kind of look at it as a whole, whereas you’ll see 
now you go into a cardiac ward, a cardiologist will never touch a 
mental health drug, ‘That’s not - I didn’t prescribe it’”. Pharmacist 4 
“So, we would normally not, unless you get psychiatry input, we 
wouldn’t have the background of the appropriateness of 
antipsychotics in particular”. Physician 4 
“You might find cardiologists might be reluctant to fiddle around 
with respiratory drugs or respiratory physicians might be slow 
enough to fiddle around with psychiatry drugs. So I think 
geriatricians are probably a group that are sort of happy to fiddle 
around with most medications”. Physician 8 
“I think it depends on the team, you know. We’ll say your 
geriatricians probably would be quite welcoming of pharmacist 
involvement and quite aware of the roles that they play, say other 
teams, not as much…” Pharmacist 5 
“I think as geriatricians we would be more likely to want to make our 
own decisions about medication management and sort of taking the 
patient’s own like context into account”.  Physician 3 
“I think the geriatric teams are probably very supportive of 
pharmacists and there does seem to be… You do you get the feeling 
that there is a shared care there between geriatricians and 
pharmacists. Em…and I think geriatricians are trained to be very 
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“…he was involved with the patient initially, he saw me as coming 
in and almost interfering, and just being overly cautious”. 
Pharmacist 4 
“…if they’re confident in their own ability, they feel maybe that 
they don’t need the advice of a pharmacist and that they’ve made 
their decision and that it’s not our place to question their decision 
retrospectively”. Pharmacist 3 
“…if it’s something that’s very specialty-based - do you know like 
certain like, I don’t know, rheumatological drugs or cardiac drugs 
that I don’t use that frequently that they’re under someone else’s 
specialist care for, I would be a lot less likely to stop it”. Physician 3 
“…some people would be I suppose less keen to stop medications 
that they felt if they haven’t started it, sometimes they’d be less 
keen to stop it. Whereas I think geriatricians would kind of take 
ownership for just stopping it”. Physician 2 
“Again, it comes down to: does a doctor who might be only seeing 
the patient, you know, on this presentation stop the medication 
that was started by another colleague”. Pharmacist 3 
“…what importance they do place on the role of the pharmacist 
because a lot of the role of the pharmacist would overlap with 
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“I think definitely in terms of uptake of recommendations, if you 
have a very good relationship with the team, you’re more 
likely…it’s more likely because they know you”.  Pharmacist 3 
“I suppose like if you were just a random person coming 
up…because I think that’s what happens a lot. They don’t know… 
If you can’t put a face to the name, they don’t know you really”. 
Pharmacist 1 
“…if you don’t know the team or you don’t know the doctor you’re 
kind of going ‘Oh God, I have to walk up there now and approach 
this’, but yeah, I’d say I wouldn’t be meek about it anyway”. 
Pharmacist 4 
“But I suppose if you’re just leaving a note to a team that you 
don’t know, how do they even know who you are?” Pharmacist 1 
“I think it would be extremely beneficial if we knew them at a kind 
of a deeper level”. Physician 7 
“So I think it’s not essential. But I think like any bit when you are 
working as part of a team if you know somebody it probably 
makes interactions a little bit better”. Physician 8 
“…if they see an intervention from you, you know, because they 
know you, they are more likely to act on that intervention, which I 
suppose is natural”. Pharmacist 3 
 
Outsider “So you’re kind of back in the mist”.  Pharmacist 5 
“Outside the loop sometime yeah. Certainly…that probably is one 
of the main sources of miscommunication, or not picking up 
recommendations in that they may not be….yeah inside the exact 




“…when you have an interpersonal relationship with someone, 
you’re more likely to take on board their opinion, and 
subsequently maybe implement their recommendations”. 
Physician 5 
“I suppose you build up a sort of relationship with some 
pharmacists too where you know that you have worked with them 
before and you know that their advice is very good and solid. So 
sometimes when maybe newer people or younger people are in 
the ward, you may be less sure as to what their sort of experience 
is…” Physician 8 
“I think I’d have a good relationship with the SHOs and registrars 
because the interns change every three months and the SHOs kind 
of change as well, but you kind of have more exposure to them 
because they’d actually be kind of the main people you see on the 
team, so they might get used to you more as well…a lot better 
relationship with them”. Pharmacist 1 
“I think if they were like again like a cardiology pharmacist that if 
they mentioned something on the ward round, I think they would 
have built up a rapport with the consultants who were there 
obviously more long-term than we are, and it probably would be 
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“Good rapport always helps. If you know the same pharmacist and 
you are working with them all the time, I think that benefits, like 
that definitely helps. If the pharmacist was to change every single 
day, I don't think that should be a reason to not implement their 
recommendations anyway”. Physician 1 
“I think, as you’re there and you get to know people more that 
they come to you with questions and things like that. You do need 
to put in a bit of time and effort, I suppose, into building up those 







“…if you build up a relationship, a working relationship, then it 
helps massively and there’s much more trust and you even get to 
know why one person is doing one thing and one person is doing 
another”. Physician 5 
“…like any relationship, like if you build up, if you make a few 
recommendations that were good, they kind of trust you more, so I 
think it’s very important...” Pharmacist 1 
“Because you know the pharmacist, and you have a personal 
relationship with them, and you trust their opinion…”  Physician 3 
“…when you’re working in a particular area, you get to know the 
different doctors that work in that particular area and they’re 
more familiar with you, even just seeing your face kind of 
repeatedly then, I think you have more I suppose credence in their 
eyes or credibility in their eyes, because you know they’ve seen you 
at work and they’ve seen you, you know review patients’ 
medications and review patients’ charts”. Pharmacist 3 
“I suppose they’re less experienced [referring to more junior 
physicians] and they have more trust in other healthcare 
professionals that might have more experience than them. So I 
suppose the less experienced they are…the more trust they would 


























“…I think meeting as opposed to kind of opportunistically trying to 
find the team on the ward…” Physician 2 
“I suppose when I’m on the wards, it’s probably more ad hoc 
interactions…” Pharmacist 3 
“…if you miss the team when they are around on a ward round, you 
are relying on, you know, if it’s extremely urgent, you’re bleeping 
and waiting for them to ring you back”. Pharmacist 5 
“You know it was just easier when the pharmacist was there on the 
ward round to flag things with the consultant and then you’d get an 
answer straight away”. Physician 2 
“…the pharmacist went on a round once a week and that was very 
good and it helped the…again, the knowledge passing and for new 
doctors…” Physician 4 
 
 
Busy  “At the same time, they could be very busy, so they might not think 
that doing them is important as well [referring to pharmacist 
recommendations]”. Pharmacist 1 
“I think when you’re on a busy service you mightn’t necessarily do it 
straight away [the pharmacist recommendation]. So, I think that’s 
probably one of the biggest factors is if you have a long patient list 
and if it’s not something say particularly pressing, then you might 
not do it straight away”. Physician 2 
“…it is all a bit chaotic, and that doesn’t lend to safe prescribing 
really and the overall hospital environment and workload could all 
impact on it certainly, and that will also then impact on following the 
guidance”. Physician 5 
“I think time is a huge thing. I think all of the teams are very time-
poor. They don’t really have the time to look at the drug chart, they 
don’t have the time to look up what it is the issue is or why it should 





“I suppose one of the issues is that when you do bleep an intern or 
bleep an SHO about a medication issue, you know, they could be 
having a really busy incident on another ward or they could be, I 
suppose dealing with something pressing on another ward and you 
are trying to explain to them about a patient on your particular 
ward”. Pharmacist 3 
“…get a bleep, find a phone, ring the number back… You know, 
maybe that’s engaged and, you know, you can play what they call 
phone tag for all that - so that can be an issue”. Physician 5 
“…at the moment we either leave a note or we bleep the team and 
we are always kind of going ‘why have you done this?’ and ‘can you 
review it?’, rather than at the time of prescribing we could have 
discussed it and you’d already have your answers and you wouldn’t 
have to go querying it because you’d know why it has been done”. 
Pharmacist 2 
“Ideally, at the point of prescribing or at the bedside or when the 
doctors have the kardex and the medication notes, that would be the 
time to raise any issues…” Pharmacist 3 
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the medical notes 
 
“…the written notes can sometimes be a disaster, because even like 
the binding holes rip and the pages either are in the wrong position 
or they fall out or they’re shoved into the back of the chart”. 
Physician 7 
“So if you are not on a ward round, I suppose some things can be 
omitted from the notes sometimes and so I suppose when I'm 
reviewing medication, I don’t assume that I have all the information 
to hand”. Pharmacist 2 
“…I suppose you have to take into consideration that there’s other 
factors that mightn’t be, you know, maybe particularly clear in the 
notes, so you know, from a pharmacist’s point of view, I think it’s 
always very prudent to, you know, to discuss any issue you have 




Working as a team 
 
“…I think being on their team would make it [would make 
implementation more likely]. You are their team, you’re kind of in 
their specialty, they know you - I think that’s much better rather than 
random pharmacists kind of approaching them on the ward...” 
Pharmacist 4 
“…well if you’re part of the team then I feel like people know you at a 
kind of deeper, like behind the professional level you know, and you 
get to know people…” Physician 7 
“I think you’ve a better relationship with the doctors if you have a 
team-based approach and I think if you’re familiar with the team 
and you have maybe more easier methods of communication where 
you are seeing each other more frequently or you’re catching up with 
each other at certain points of the day, then I think that makes the 






“I think staffing levels is a big thing here, like we don’t have enough 
pharmacists here to cover every ward, so like I said, if you have 
screened a drug in the dispensary and you have to go up to the ward 
that you’re not familiar with - the team isn’t familiar with you. So, if 
we had more staff levels I think that, and that they actually see your 
face, they’d be more inclined to implement it…” Pharmacist 1 
“I think it may be as simple as sort of more face time, more 
pharmacists, more clearly a role and understood role among 
doctors…” Physician 8 
“I think we don’t have sufficient staff to expand our roles and really 
develop relationships. It’s all about developing relationships with the 
physicians, particularly the consultants and I don’t think we’re able 
to do that with what we have at the moment to develop 
relationships with the consultants”. Pharmacist 6 
“It’s really really variable depending on what hospital you’re in. I 
really don’t see a lot of them here [referring to day-to-day 
interactions with pharmacists]”. Physician 3 
“…I suppose there is that thing there’s so few of us, many of them 
[physicians]  won’t even know that we’re around…” Pharmacist 4 
 
GP: General practitioner        CHA₂DS₂-VASc: a scoring system to calculate stroke risk in non-valvular atrial fibrillation patients based on 
Congestive heart failure, Hypertension, Age ≥75, Diabetes mellitus, history of Stroke or transient ischemic attack, Vascular disease, Age 
65-74, and Sex category.        PPI: Proton pump inhibitor        SHO: Senior house officer        FYI: For your information  
